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 Abstract 
 
Engineering Artificial Metalloenzymes Based on Biotin-Streptavidin Technology for DNA 
Recognition and Asymmetric Transfer Hydrogenation Catalysis 
 
Malcolm Jeremy ZIMBRON 
 
Metalloproteins occupy a central place among all proteins since they represent nearly half of 
all proteins in nature. Metalloenzymes catalyze important biological processes 
(photosynthesis, respiration, water oxidation) and other chemical reactions (oxidoreduction 
reactions). Artificial metalloenzymes, which can be created from insertion of a metal-
containing moiety within a protein scaffold, combine the attractive properties of 
organometallic chemistry (activity provided by accurate chemical cofactor design) and 
enzymatic mean (fine-tuning of second coordination sphere to afford high substrate 
specificity, activity and selectivity) to provide a powerful tool with a great optimization 
potential.  
The biotin-streptavidin technology represents a versatile tool to create artificial 
metalloenzymes and other supramolecular assemblies, due to i) the exceptionally strong and 
precise anchoring ability; ii) the range of possibilities of chemical derivatization of the 
biotinylated compounds and iii) genetic optimization of the host protein.  
In the spirit of surface borrowing, i.e. modulating ligand-affinity by harnessing existing protein 
surfaces, the biotin-streptavidin assembly was exploited to create a metallodrug-presenter 
protein assembly. With the aim of investigating the mechanisms by which such assembly 
could deliver small molecules to preferred macromolecular targets in vitro, a biotinylated 
piano stool ruthenium complex was synthesized and incorporated into streptavidin. The 
metallodrug-protein assembly was constructed to provide non-covalent interactions that 
modulated binding of the organometallic moiety to specific DNA targets. Guided by the X-ray 
 structure of the drug embedded within the Sav protein, we explored the formation of 
metallodrug-mediated ternary complexes between the presenter protein and DNA. The study 
suggests that rational targeting of metallodrugs via presenter proteins could be exploited to 
improve selectivity of small molecules for G-quadruplex DNA over double-stranded DNA. 
In addition to target-selectivity for binding, we also investigated catalytically-active 
supramolecular complexes. With the aim of improving the screening efficiency of 
metalloenzymes in catalytic reactions, a new synthetic platform for fast chemical optimization 
of biotinylated catalysts was implemented. Incorporation of various d6-transition metal 
(rhodium and iridium) piano stool complexes, containing a tetramethylcyclopentadienyl 
(C5Me4) tethered to biotin into streptavidin provided a fast and convenient means of 
screening and optimizing of hybrid catalysts that affords new catalytically active artificial 
metalloenzymes in ATH of cyclic imines (production of salsolidine). Furthermore, in silico 
investigations allowed the use of the new synthetic platform in the design of a novel type of 
metal catalyst/protein assembly. Combination of rational ligand design and genetic 
optimization of the biomolecular host resulted in the creation of the first biotin/streptavidin-
based metalloenzyme using a dually anchored (supramolecular and dative anchoring) metal 
capable of performing enantioselective transfer hydrogenation reactions. Finally, the two 
strategies developed above were transposed to the less explored reductive amination of α-
keto acids. These studies provide the first example of synthetic enantioselective reductive 
amination for the preparation of a range of unprotected chiral α-amino acids in water, thus 
demonstrating the great potential of artificial metalloenzyme technology. 
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1. General Introduction 
 
1.1. Preamble 
 
This thesis describes the potential of hybrid supramolecular systems consisting of 
streptavidin and biotinylated piano stool complexes either as anticancer drugs or as well as 
transfer hydrogenation catalysts. For that purpose, a brief overview of piano stool complexes 
i) as anticancer metallodrugs, ii) as valuable catalysts in asymmetric transfer hydrogenation 
reactions and iii) as suitable scaffolds for the creation of novel artificial metalloproteins is 
presented below. 
i) The organometallic ruthenium half-sandwich complexes are described as promising 
anticancer drugs and their potential to preferentially interact with DNA is highlighted. In 
addition, telomeric DNA is also presented as new target for such metal-based drugs.  
ii) Piano stool complexes are further described as efficient transfer-hydrogenation catalysts, 
with a focus on ketone and imine reduction. 
iii) Finally, different strategies to design new artificial metalloenzymes are described with a 
focus on the biotin-streptavidin technology.  
 
1.2. Organometallic Half-Sandwich Complexes 
 
1.2.1. Piano Stool Complexes: Structure and Activity 
 
Organometallic chemistry has received increased attention in the last decades and provided 
great potential for the development of innovative complexes that find application in a wide 
range of domains.[1] Chiral-at-metal half-sandwich compounds, which are important 
representatives of the field, have been the subject of extensive research since the very early 
stage of transition metal chemistry.[2] Brunner and Ganter were very active in this chemistry 
and meticulously described the strategies to prepare chiral-at-metal compounds and their 
configurational stability.[3] After initial theoretical research, chiral metal complexes received a 
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growing interest that culminated with the Nobel prize awarded jointly to Knowles, Noyori and 
Sharpless in 2001 for their outstanding contributions in this field.[4] The half-sandwich 
complexes of d6-transition metals (see Figure 1a) have found a privileged place in 
organometallic chemistry. Piano stool ruthenium, rhodium and iridium complexes display 
interesting features such as air- and water-stability that explain their central role in the 
development of green chemistry.[5] They have found wide applications in catalysis and, more 
recently, in inorganic medicinal chemistry for their properties as anticancer agents.[6]  
 
Figure 1 a) Typical organometallic half-sandwich ruthenium, rhodium and iridium d
6
-complexes, b) 
Noyori’s Ru
II
-TsDPEN 1. 
 
The discovery by Noyori and coworkers of the highly active RuII-N-(p-toluenesulfonyl)-1,2-
diphenylethylenediamine complex 1 (see Figure 1b) as catalyst for the asymmetric transfer 
hydrogenation (ATH) brought to light the organometallic chemistry involving half-sandwich 
complexes.[7] Since then, η6-arene ruthenium complexes have been the subject of numerous 
studies in ATH.[8] Chiral piano stool scaffolds containing rhodium and iridium metals have 
been less investigated than the ruthenium counterpart. However, half-sandwich complexes 
bearing rhodium and iridium have found important applications in asymmetric reduction 
reactions.[9] Although the Cp*-rhodium complexes have been primarily described in the 
context of transfer hydrogenation, the Cp*-iridium catalysts have also been employed in a 
wide variety of different reactions, including numerous reports on amine alkylation with 
alcohols,[10] water oxidation[11] and oxidation of alcohol.[12] 
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It is interesting to note that many of the typical classes of organometallics,  such as 
metallocenes, half-sandwich complexes, carbene-, CO-, or π-ligands containing complexes 
that have been widely used in catalysis or biosensing, have now also found applications in 
medicinal chemistry.[6] In this context, the efforts of Sadler and Dyson have provided 
significant advances in the area of bioorganometallic chemistry. They developed half-
sandwich ruthenium metallodrugs that exhibit promising anticancer activity.[13] In parallel to 
this, monofunctional organometallic half-sandwich IrIII-complexes bearing 
pentamethylcyclopentadienyl ligands have also recently emerged as promising anticancer 
compounds.[14]  
The attractive features of piano stool complexes have also been extended to create new 
classes of catalysts: artificial metalloenzymes. The latter metal cofactor/protein assemblies 
have been shown to catalyze challenging processes in water.[15]  
 
1.2.2. Metallodrugs in Anticancer Therapy 
 
1.2.2.1. Organometallic Ruthenium Half-Sandwich Complexes  
 
Ruthenium metallodrugs have attracted considerable attention since the successful 
completion of phase I clinical trials of the compounds NAMI-A and KP1019 (see Figure 2).[16]  
 
Figure 2 Structures of widely-researched metal-based anticancer compounds. 
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Anticancer drugs containing this metal represent an interesting alternative to the widely-used 
metallodrug cisplatin (see Figure 2) with possible different modes of action and with a 
supposed reduced potential to develop tumor resistance.[17] Consequently, the last three 
decades have seen the development of an important number of ruthenium compounds that 
have been investigated for potential anticancer activity.[18]  
The idea of using ruthenium-containing organometallics as anticancer agents was first 
developed by Tochter and coworkers[19] before being intensively investigated in the groups of 
Sadler and Dyson.[20] They based their research on ruthenium piano stool complexes 
inspired by the “activation by reduction” hypothesis.[21] Indeed, it was expected that active 
RuII species may be formed in vivo from RuIII precursors such as NAMI-A or KP1019. To 
date, these novel piano stool complexes represent the most numerous group of cytotoxic 
ruthenium-based agents with promising anticancer activity in vitro and in vivo.[20] 
Representative examples of such organometallic RuII-arene compounds are RAPTA-C[22] and 
RM175 (see Figure 3).[23] A rapid glance at the Sadler and Dyson anticancer complexes 
might suggest that such similar structures would result in comparable mechanism of action. 
However, it appears that they exhibit different anticancer activity. 
 
Figure 3 Representative examples of ruthenium half-sandwich complexes developed by Sadler and 
Dyson. 
 
Sadler and coworkers have extensively investigated ruthenium half-sandwich compounds of 
the type [(η6-arene)Ru(chel)X], where chel is a neutral or mono-anionic N,N-, N,O-, or O,O-
chelating ligand (e.g., ethylenediamine, bipyridine, picolinate, 8-hydroxyquinolate, 
acetylacetonate, maltolate) and X is typically a halide (see Figure 3).[20b] These half-sandwich 
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compounds are either neutral or positively charged (typically isolated as PF6 salts), 
depending on the nature of the chelating ligand.  
Among the different organometallic half-sandwich complexes that displayed interesting 
anticancer activity in vitro and in vivo,[21a, 23-24] extensive structure-activity relationship 
investigations demonstrated that the ruthenium compounds containing ethylenediamine (en, 
Y and Z = N, see Figure 3) and extended polycyclic arenes were the most active toward 
A2780 human ovarian cancer cells.[25] The mechanism of action of such metallodrugs has 
many of analogies to that of cisplatin. Like for cisplatin, rapid hydrolysis of the Ru-Cl bond 
occurs, thereby generating an active monofunctional Ru-OH2 metabolite. The chloride 
ligands are believed to be stable at extracellular chloride concentration (about 0.1 M) 
enabling cell penetration but rapidly hydrolyzed where the chloride concentration is much 
lower (4-25 mM, corresponding to intracellular conditions). The kinetics of aquation and 
cellular uptake of such complexes can be fine-tuned by the nature of the metal center, the 
arene or the chelating ligands.[24c, 25-26] It was proposed that the cytotoxicity of such ruthenium 
organometallic compounds is related to the ability of aquated products to bind to nuclear 
DNA.[20b] It was also demonstrated that ruthenium-arene complexes preferentially form 
monofunctional adducts via the N7 atom of guanine residues.[23, 27] Such strong preference for 
G bases may allow ruthenium complexes to selectively target G-rich regions of DNA. In this 
context, telomeres which are guanine-rich DNA sequence overhanging at the ends of 
eukaryotic chromosomes could represent and interesting target.[28] Furthermore, interactions 
between aromatic arenes (like the biphenyl RM175, see Figure 3) of the ruthenium 
complexes and nucleobase can be stabilized by π-π stacking.[23] Different studies carried out 
with human ovarian cancer cells A2780 revealed that cytotoxicity increases with the 
hydrophobicity of the arene ligands: ruthenium compounds bearing arene of the type 
biphenyl (RM175, see Figure 3) display similar activity than the antitumor drug carboplatin, 
whereas compounds with bulkier tetrahydronaphthalene arene are equipotent with 
cisplatin.[29] 
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Studies on the interactions between ruthenium arene complexes and several biologically 
relevant molecules such as cytochrome c, histidine, cysteine, methionine and glutathione 
were conducted.[20b, 21a, 24b, 30] Overall, they reveal that the ruthenium complexes exhibit higher 
reactivity towards DNA than with amino acids and proteins, thus explaining the low toxic side 
effects exhibited by these metallodrugs.[29] Moreover, the relatively weak binding of amino 
acids and proteins is suspected to help the transport and delivery to cancer cells. Similarly to 
cisplatin, some amino acids, peptides and proteins could serve as drug reservoirs for DNA 
ruthenation.[31] Although DNA is believed to be the main target of these metal-based 
drugs,[24a] the exact mechanism of action is still matter of debate. 
Sadler and coworkers have recently moved towards new metals as possible anticancer 
compounds (Os and Ir).[14] Furthermore, new bifunctional neutral half-sandwich cis-dichlorido 
RuII-amine complexes ([(η6-arene)Ru(NH3)Cl2], where arene is biphenyl or p-cymene) are 
also under investigation.[32] 
 
The RAPTA piano-stool-derivatives developed by Dyson and coworkers are typically 
characterized by a monodentate 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane (pta) ligand 
that were originally designed to improve the metallodrug aqueous solubility (see Figure 3). 
Similarly to cisplatin and Sadler’s complexes, RAPTA compounds have chloride ligands that 
are kinetically labile and may undergo rapid hydrolysis. It was then first anticipated that 
RAPTA complexes had DNA as primary target.[33] However, in vitro studies demonstrated 
that generally RAPTA complexes only exhibit modest cytotoxicities.[26b] In contrast, the 
RAPTA complexes exhibit high affinity for extracellular targets without prior aquation. Such 
interactions seem to be favored over DNA binding due to the presence of the hydrophobic 
arene moiety. These extracellular targets are strongly implicated in the ability of RAPTA 
metallodrugs to prevent metastasis: RAPTA-C and RAPTA-T (see Figure 3) demonstrated 
interesting antimetastatic activity.[26b, 34] For example, protein-RAPTA-C adducts were 
characterized by ESI-MS: reaction of RAPTA-C with horse heart cytochrome c and with hen 
egg white lysozyme revealed stable metalloadducts.[35] RAPTA compounds were also found 
General Introduction   13 
to be potent inhibitors of cathepsin B and weak inhibitors of thioredoxin reductase.[36] It was 
also demonstrated that RAPTA-C induces apoptosis and slows down cell division in cancer 
cells.[37]  
Beyond the conventional approach of drug discovery and with the aim to improve drug 
efficiency targeted drug design strategy has become a field of increasing interest. In this 
context, RAPTA derivatives and analogues were designed to have multiple modes of action 
and functionalized to achieve specific outcomes.[6, 38] This tailoring of functionality is well 
exemplified by the tethered RAPTA-human serum albumin (RAPTA-HSA), which was found 
to cause a twenty-fold increase of the cytoxicity compared to RAPTA-C.[39] The RAPTA 
complexes were the subject of detailed structure-activity investigations, where the arene cap, 
pta and the anionic ligands were systematically derivatized or substituted.[38] For example, 
Dyson and coworkers recently prepared RAPTA carboxylato derivatives.[40] This work was 
inspired by the structures of carboplatin and oxaliplatin. It was assumed that the carboxylato 
ligands may hydrolyze more slowly and in a more controllable way than the chloride ligands 
in the original RAPTA-C compound.  
It is clear that RAPTA compounds have multiple modes of action and that a target validation 
has yet to be achieved. However, RAPTA complexes exhibit promising antitumor properties 
and represent ideal templates for the design and development of tailored therapeutic drug. 
Surprisingly, given their structural similarities, Sadler and Dyson anticancer compounds 
displayed different modes of actions on tumor cells. 
 
1.2.2.2. DNA-Targeting Strategies for Metal-Based Therapeutics  
 
1.2.2.2.1. Targeting Double-Stranded DNA with Metallointercalators 
 
An increasing number of therapeutic agents designed to target nucleic acids has recently 
emerged.[41] The most effective metallodrug in anticancer therapy, cisplatin and its 
derivatives is thought to have DNA as a main target: DNA-metallodrug adducts generate 
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lesions which ultimately trigger cell death. However, platinum-based drugs often suffer from 
high systemic toxicity, inherent or acquired resistance, which is a main problem that limits 
their clinical use. Consequently, much effort was devoted in designing more selective drug 
delivery systems and/or activation of cisplatin-related prodrugs.[24a] The specific recognition of 
DNA by therapeutic agents has received increasing interest and metal-based drugs are 
viewed as playing an important role in the field. Metal complexes traditionally interact with 
DNA in one of the three ways, leading to the following classification: metallointercalators,[42] 
groove binders[43] and the more novel metalloinserters.[44] Perhaps the most commonly 
encountered type, the metallointercalators are made of organic intercalators covalently 
attached to transition metal complexes that offer new DNA interactions opportunities, which 
can ultimately influence the biological activity. Intercalative binding refers to the non-covalent 
stacking interaction between a planar heterocyclic aromatic ring belonging to the metal-
based molecule and the base pairs of the DNA double helix. Metallointercalators can bind 
specifically to sequences in the major groove of the DNA double helix. Such intercalations 
can stabilize, lengthen, stiffen or unwind DNA by acting as a kind of “new base pair”. 
Modulation of the aromatic side chain of the metal complex opens the way to fine-tune the 
DNA binding and allows the introduction of new modes of metallodrug-biomolecule 
interaction. 
This strategy has been investigated by Sadler and coworkers with the RuII-piano stool 
complexes bearing polycyclic arene ligands such as RM175 (see Figure 3). Such complexes 
were found to be more potent toward cancer cells than their non-intercalating analogs (e.g., 
ruthenium bearing η6-p-cymene or η6-benzene).[23] This design concept can be applied to 
structure activity relationships for other organometallic anticancer complexes, including 
cyclopentadienyl complexes.[14] In this context, Liu et al. reported that the hydrophobicity and 
intercalative ability of IrIII-half-sandwich complexes make a major contribution to the 
anticancer potency. 
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1.2.2.2.2. Targeting Telomeric DNA  
 
As mentioned above, ruthenium complexes preferentially interact with guanine bases and, 
consequently, bind mostly to guanine-rich DNA sequences. Telomeres, which are structures 
found at the ends of eukaryotic chromosomes,[45] consist of highly conserved and repeated 
G-rich sequences and can be considered as a privileged target. Telomeric DNA consisting of 
(TTAGGG)n repeats in humans, protects the very end of linear chromosomes and thus 
preserves the stability and the structural integrity of chromosomes[46] particularly during 
mitotic cell division.[47] Telomeres are also important because they preserve the genome 
integrity by protecting chromosomes from a loss of genetic information. However, in normal 
cells the chromosomes are progressively shortened over rounds of cell replication until a 
length-limit (Hayflick limit) that induces a signal in the cell, leading to senescence.[48] The 
telomere dysfunction can lead to chromosome instability and abnormalities, senescence or 
apoptosis, and represents potentially the most widespread cause of genome instability in 
cancer.[49] The enzyme telomerase, which counteracts this shortening by adding base pair 
repeats to the 3’ end of DNA strands, is largely absent in healthy cells, but is expressed in 
85-90% of tumor cells.[50] A particularity of cancer cells is their unlimited proliferative capacity, 
which is at least in part sustained by the activation of a telomere maintenance mechanism 
(TMM). Disruption of the TMM, facilitates rapid and infinite proliferation of the tumor cells. 
The 3′-G-overhang of the telomere, (TTAGGG)n is able to fold in a G-quadruplex structure 
that consists of a planar arrangement of tetrads of guanine bases associated by Hoogsteen-
type hydrogen bonds. The G-quadruplex structures can be classified depending on the 
orientation of the DNA:[51] parallel,[52] antiparallel[53] and two mixed-hybrid structures (see 
Figure 4).[54] In most cases, the structures are determined in the presence of a monovalent 
cation (mostly Na+ or K+)[55] which plays an important role in the stabilization of tetrad 
structure due to electrostatic interactions engaged with the guanine carbonyl groups of two 
adjacent G-quartets (see Figure 4).[56]  
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Figure 4 G-quartets and G4 DNA. a) G-quadruplex, a planar ring of four guanines, with a monovalent 
central metal cation. b) G4 DNA. Strands may be parallel (left), antiparallel (center) or mixed (right). 
The latter stabilization was found to be of major interest.  
 
Telomerase exclusively recognizes the extremity of the 3’-G-overhang of telomeric DNA. 
Consequently, the formation of G-quadruplex structures may hinder telomeric recognition by 
telomerase and may interfere with telomere elongation.[57] Therefore, the stabilization of G-
quadruplex DNA structures by chemotherapeutics has been proposed as a new anticancer 
strategy.[58]  
 
1.2.3. Piano-Stool Complexes in Transfer Hydrogenation Reactions 
 
1.2.3.1. Asymmetric Transfer Hydrogenation of Ketones 
 
The catalytic asymmetric transfer hydrogenation (ATH) has emerged as a practical 
alternative to hydrogenation processes (no use of hazardous H2). ATH has demonstrated to 
be particularly suitable for the preparation of optically active secondary alcohols which are 
important intermediates in the synthesis of various high value-added chemicals.[59]  
Discovered in 1925, the Meerwein-Ponndorf-Verley (MPV) reduction was the first example of 
transfer hydrogenation of carbonyl groups.[60] Since then, the majority of the research carried 
out in this area has relied on piano stool complexes involving RuII-arene or IrIII/RhIII-
cyclopentadienyl moieties and bearing optically active phosphine and amino/sulfonamide 
ba
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ligands.[61] Perhaps the most important advance in such catalytic systems employed in ATH 
of ketones was the discovery by Noyori and coworkers of the RuII-TsDPEN catalyst 1 (see 
Figure 1),[7a] which displays broad substrate scope and provides optically active alcohols at 
high enantiomeric purity and yield.  
The most common sources of hydrogen for ATH of ketones are isopropanol, azeotropic 
mixtures of isopronapol with triethylamine, formic acid or formate salts. However, mixtures of 
formate salts or formic acid and triethylamine are increasingly used since the irreversible 
formation of CO2 (g) with generation of the metal hydride favors an irreversible reaction.
[7a] 
One limitation of the process is the decomposition of the catalyst in contact with high 
concentrations of formic acid.[61b] 
The advantage of using transition metal catalysts for asymmetric transformations is the 
possibility of catalyst improvement by easy modification of the ligands. Most of the metal 
complexes bear bi-, tri-, or tetradentate ligands containing nitrogen, oxygen or phosphorus as 
coordinating atoms.[61b, 61e, 62] Water-soluble ligands and addition of surfactants have 
contributed to the development aqueous transfer hydrogenation reactions.[62-63] Finally, the 
reduction rates were considerably faster using HCOONa than the HCOOH/Et3N azeotrope or 
iPrOH.[64] In this context, Xiao has shown that both the reaction rate and the 
enantioselectivity of aqueous transfer hydrogenation reactions critically depend on the pH.[65] 
The mechanisms by which hydrogen is transferred from a donor to an acceptor can proceed 
in different manners depending on the metal, ligand and hydrogen donor used (see Figure 
5). 
 
Figure 5 Postulated transition states for the mechanism of hydrogen transfer to a ketone. 
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The “direct hydrogen transfer” usually occurs with main group metals, while transition metal 
catalysts follow the “hydridic route”, in which a mono- or a dihydride metal species is 
involved.[61c, 66] The monohydridic transfer can either occur via ketone coordination to the 
metal, or via an outer sphere mechanism. Finally, when no substrate-metal interaction is 
involved, the mechanism can be concerted or stepwise.[61c]The currently accepted 
mechanism for the Noyori-type transfer hydrogenation catalyzed by Ru-, Rh- or Ir-complexes 
proceeds via an outer sphere concerted hydride transfer and relies on metal-ligand 
cooperation.[66b, 67] Both the metal and the ligand participate to the bond-breaking and forming 
process and the transition state does not involve direct coordination of the substrate to the 
metal (see Figure 5). Ligands possessing acidic protons (i.e. metal-coordinated primary or 
secondary amines), facilitate the hydride delivery to the carbonyl (see Scheme 1). 
 
Scheme 1 Postulated catalytic cycle for the transfer hydrogenation of an aromatic ketone using [Ru(p-
cymene)(R,R-TsDPEN)Cl] and iPrOH as hydrogen donor. 
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The true catalytic species is the 16 e- Ru-complex A formed from the catalyst precursor B by 
elimination of HCl in the presence of a base. The protonation of the amide leads to the 18 e- 
Ru-hydride complex C. The hydride and the axial NH proton are transferred simultaneously 
from the 18 e- Ru-complex to the substrate via a six membered ring transition state, to 
regenerate the 16 e- complex A.[68] 
 
1.2.3.2. Asymmetric Transfer Hydrogenation of Imines 
 
Optically active amines are highly valuable products in industry[69] and intermediates of great 
importance in chemical synthesis as chiral ligands, auxiliaries or catalysts.[70] In 1981, Grigg 
and coworkers reported the first example of transfer hydrogenation of imines.[71] In this work, 
Wilkinson’s catalyst, [RhCl(Ph3P)3] was used for the reduction of aldimines by isopropanol in 
the presence of sodium carbonate. Later on, Brune et al. attempted to elucidate the 
mechanism of proton and hydride transfer from 2-propanol to imines in the presence of 
Wilkinson’s catalyst.[72] Since the pioneering use of the Wilkinson’s catalyst, an increasing 
number of catalytic systems, including chiral variants, have been developed. Among them, 
the most studied and most successful ones are those employing half-sandwich complexes as 
catalysts. In 2001, Casey studied one of the most famous catalysts for the stoichiometric TH 
of imines: the bifunctional Shvo catalyst 2 (see Figure 6).[73] Bäckvall and coworkers 
subsequently reported the catalytic reduction of imines with the Shvo catalyst using 2-
propanol as the hydrogen source with benzene as a co-solvent.[74] In solution, the Shvo pre-
catalyst dissociates into species 3 and 4; the 18 e- catalyst 3 effects the hydrogenation, 
turning into complex 4 which dehydrogenates isopropanol to regenerate the specie 3 (see 
Figure 6). 
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Figure 6 Reduction of imines with Shvo’s catalyst 2. 
 
In 1996, Noyori and coworkers described the first chiral RuII-TsDPEN 1 complex that 
efficiently catalyzed the ATH of cyclic and acylic imines under mild conditions using formic 
acid-triethylamine as the hydrogen source (see Scheme 2).[75] Since these pioneering 
studies, ATH has become a powerful tool for the reduction of imines.[76] Moreover, these 
studies on cyclic imines led to consider tetrahydroisoquinoline-based scaffolds as substrates 
of choice for the implementation of new reactions. The synthesis of salsolidine 5 was 
considered to be a model reaction in ATH. 
 
Scheme 2 Noyori’s chiral Ru-precatalyst for ATH of cyclic imines: preparation of salsolidine. 
 
The increasing demand for efficient and environmentally friendly chemistry resulted in the 
development of catalysts that are water-compatible with particular emphasis on the 
development of water-soluble catalysts. In such media RuII, RhIII and IrIII are quite effective 
metal cations in ATH reactions. In 2006, Wu et al. reported the first ATH of cyclic imines and 
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iminiums using a water soluble catalyst.[77] Deng and coworkers reported yield up to 99% and 
enantioselectivities up to 99% when enantiopure o,o’-disulfonated N-tosyl-1,2-
diphenylethylene diamine was combined with [Ru(p-cymene)Cl2]2 using HCOONa as the 
hydrogen source and CTAB (cetyltrimethylammonium bromide) as a surfactant (see Scheme 
3). 
 
Scheme 3 Asymmetric transfer hydrogenation of cyclic imine in water. 
 
Later, Süss-Fink and coworkers reported cationic arene ruthenium aquo complexes 
containing enantiopure chiral monosulfonated diamine ligands that performed ATH of 
aromatic ketones and imines in aqueous solution using sodium formate without any 
additional surfactant.[78] The investigations conducted by Xiao and coworkers on ATH 
reactions in water highlighted the determinant role of pH in the reaction rate.[9a, 65, 79] 
Compared to the extensively studied mechanism for the transfer hydrogenation of ketones, 
the mechanism by which imines are hydrogenated is still matter of debate.[80] The first 
mechanistic studies conducted by Bäckvall and coworkers proposed an inner sphere 
mechanism in which the addition of acid is necessary to pre-activate the substrate by 
protonation prior to hydrogen transfer.[80a] In contrast, based on DFT calculations using  
Shvo’s catalyst, Casey found the transition state to be a concerted outer sphere mechanism, 
comparable to the ketone reduction mechanism.[80b] Since then, various lines of evidence 
appear to favor an ionic mechanism[66a, 81] where the metal-hydride transfers to a protonated 
and hence activated imine, involving no coordination of the imine to the metal centre during 
the hydride transfer. This is in contrast to the well-established metal-ligand bifunctional 
pathway for ketone reductions.[67, 82] Further evidence for the ionic pathway is found in the TH 
of quinolines, where acidic conditions are required.[79] In addition, Xiao and coworkers 
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developed cyclometalated iridium catalyst with no free NH allowing metal-ligand bifunctional 
action that would also follow the same ionic mechanism.[83] 
Practical studies on the ATH of cyclic imines revealed that the mechanism of ketone 
reduction cannot be transposed to isoquinoline-type imines since the opposite enantiomer is 
observed compared to the enantiomer produced in ATH of ketones with the same catalyst. 
With the aim to better understand the system, Martins et al. proposed two alternative 
mechanisms (see Figure 7).[84] The first mechanism depicted the reduction of imine via a six-
membered transition state (see Figure 7b). The orientation of the alkyl and the aryl groups 
are inverted thus avoiding the CH/π interaction proposed in Noyori’s mechanism (see Figure 
7a). The second proposed mechanism is an ionic mechanism in which Wills proposed the 
formation of an iminium cation that would be oriented away from the NH of the ligand amine 
(see Figure 7c). The latter mechanism proceeds without the formation of a concerted six-
membered transition state but would allow the CH/π interaction to afford the right 
enantiomer.  
 
Figure 7 Possible mode of reduction in ATH of cyclic isoquinoline-type imines with Noyori’s (R,R)-
TsDPEN catalyst 1.
[84]
 
 
Although the investigations of Bäckvall and Wills tend to support an ionic mechanism, the 
pathway of the transfer hydrogenation of imines is not yet completely understood and the 
possibility of a substrate-specific mechanism cannot be excluded. 
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1.2.3.3. Asymmetric Reductive Amination to Prepare Optically Pure Amino Acids  
 
Optically pure amino acids are important chiral building blocks[85] that are widely present in 
many natural bio-active molecules,[86] chiral synthons for the manufacturing of fine 
chemicals,[87] the design of chiral ligands and in total synthesis.[88] The synthesis of α-amino 
acids is an area of research that has gained a lot of attention in recent years.[89] However, no 
single methodology has yet emerged for the asymmetric synthesis of all natural and 
unnatural amino acids.[69a] The different approaches to obtain α-amino acids are summarized 
in Scheme 4. These methods can also be applied for the synthesis of unnatural α-amino 
acids which are now finding widespread application in the pharmaceutical, agrochemical, 
food additives and cosmetic industry.[90] Among the different methodologies to synthesize 
proteinogenic and non-proteinogenic α-amino acids, one of the most interesting is the 
asymmetric reductive amination of α-keto acids.[91] 
 
Scheme 4 Different approaches for the synthesis of natural and unnatural amino acids.
[89]
 
 
The resolution approach is depicted in method a. This method includes the separation of 
racemic mixture into single enantiomers or dynamic resolutions where the undesired 
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enantiomer is isomerized to allow a single product enantiomer to be formed. The second 
approach (b) involves the introduction of the side-chain for example through alkylation 
reaction using benzyl halides. Method c involves the chemical modifications of the side-chain 
to prepare the desired product. For example the synthesis of (L)-homoserine from 
methionine.[92] Amino acids can be obtained by introduction of either the nitrogen moiety (see 
method d) or the carboxylic acid group (see method e). In the first method the electrophilic 
introduction of azide with chiral imide enolates was used to prepare α-amino acids with high 
diastereoselection (the azide is further reduced to an amine)[93] Most of the methods involving 
the introduction of carboxylic acid group use the Strecker reaction where a nitrile is used as a 
masked carboxylic acid. Indeed, the Strecker reaction combines these last two approaches 
(method f).[94] In the classical Strecker reaction an aldehyde is condensed with ammonium 
chloride in the presence of potassium cyanide. The resulting α-aminonitrile is subsequently 
hydrolyzed to give the desired α-amino acid. Hydrogenation is depicted in method g: an 
example is the asymmetric reduction of the enamide with chiral rhodium catalysts.[4c]. Method 
h introduces the nitrogen group to unsaturation and this can be performed by an enzyme. 
Method i describes either a transamination or reductive amination approach, usually 
achieved by enzymes. 
The explosive growth of synthesis of α-AAs has been achieved as a result of the enormous 
effort in creating asymmetric catalysts.[95] Most enantioselective catalysts are either metal 
complexes with chiral organic ligands or chiral organic molecules, so-called 
organocatalysts.[96] However, asymmetric synthesis of pure α-amino acids often suffers from 
a lack of environmental awareness, since some of the most widely employed methods use 
organic solvents and highly toxic agents such as cyanides.[97] Moving towards a greener 
synthesis, the direct reductive amination (DRA) of α-keto acids may offer an attractive 
alternative. DRA transforms prochiral carbonyls into amines through the in situ generation of 
imine in the presence of a reducing agent.[98] Despite its long history and common use of the 
term reductive amination[99] only a few studies on the homogeneous direct reductive 
amination of carbonyls have been reported.[76d] Perhaps the best known example of 
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enantioselective reductive amination is that reported by Blaser and co-workers for the 
synthesis of the herbicide (S)-metolachlor (see Scheme 5).[61e, 100] 
 
Scheme 5 Enantioselective synthesis of Metolachlor by reductive amination of a prochiral ketone.
[101]
 
 
In 2003, Zhang studied the reductive amination of aryl alkyl ketones with p-anisidine using an 
Ir-f-Binaphane complex as the catalyst.[102] Full conversions (TON of 100) and high 
enantioselectivies (up to 96% ee) were achieved in asymmetric reductive amination in the 
presence of Ti(OiPr)4 and I2. The combined efforts of Kadyrov and Börner led to important 
advances in the field of chiral amine synthesis.[103] In 2009, Xiao exploited different Cp*IrIII-
TsDPEN complexes in combination with a BINOL-based chiral phosphate counter-anion 
(TRIP anion) to perform reductive amination of 46 ketones derivatives (see Scheme 6).[104] 
 
Scheme 6 DRA of a wide range of ketones by the cooperative catalysis of an Ir
III
-aminosulfonamide 
complex and an enantiopure phosphoric acid or its conjugate base.
[104]
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Direct reductive amination has been less investigated for the synthesis of α-AAs from α-keto 
acids.[105] The first catalytic enantioselective reductive amination using rhodium was reported 
by Tararov et al. (see Scheme 7).[106]  
 
Scheme 7 First catalytic enantioselective reductive amination of α-keto acids.
[106]
 
 
Fukuzumi and co-workers reported the first non-enzymatic highly chemoselective synthesis 
of α-amino acids by the reductive amination α-keto acids using HCOONH4 in water.
[107] They 
employed an acid-stable mononuclear iridium hydride complex and succeeded in the 
synthesis of all major types of α-AAs by controlling pH (see Scheme 8). The major advance 
of this work was the simplicity of performing reductive amination while using ammonium as a 
nitrogen source to produce α-AAs in water and formate as hydride source. 
 
Scheme 8 Synthesis of α-amino acids by reductive amination of α-keto acids with ammonia in 
water.
[107]
 
 
Selective reduction of the imine is critical because reduction of the carbonyl compounds 
results in undesired alcohol formation. Rhodium-, iridium- and ruthenium-based catalysts are 
useful in this respect because they are known to be more efficient at hydrogenating C=N 
bonds over carbonyls.[61b, 75] Several important factors contribute to the efficiency of catalytic 
direct reductive amination, including possible interactions between the resulting amine, which 
could readily coordinate to the unsaturated metal complex; and interactions between the 
transition metal catalyst and the starting material or the hydroxy acid, which could lead to 
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reaction inhibition. The DRA approach is useful in the cases where unstable intermediates 
are encountered during the reductive amination of α-keto acids. 
 
1.3. Artificial Metalloenzymes  
 
1.3.1. Designing Artificial Metalloenzymes 
 
Artificial metalloenzymes attempt to take advantage of the best of both homogeneous and 
enzymatic catalysts. Indeed, artificial metalloenzymes are created by incorporating a 
catalytically active transition metal complex within a biomacromolecule, typically a protein[108] 
or DNA.[109] The resulting hybrid can thus potentially give access to the best features from the 
mentioned fields of catalysis. In transition metal-mediated catalysis the first coordination 
sphere is provided by a ligand, thus influencing both activity and selectivity. In contrast, 
enzymes are able to provide, through hydrogen bonding and hydrophobic interactions, both 
first and second coordination sphere interactions responsible for the high activity, selectivity 
and efficiency. Inspired by these features, artificial metalloenzymes aim at harnessing 
second coordination sphere interactions to create transition metal-biomolecular assemblies 
that display enzyme-like activities and selectivities. For that purpose, different approaches 
make use of ligand-functionalized peptide chains, DNA, RNA and proteins.[110] One of the 
most challenging approaches is the de novo design of enzymes. This de novo strategy 
involves constructing a polypeptide sequence that is not directly related to any natural protein 
and that folds precisely into a defined three dimensional structure, providing the required 
second coordination sphere to the metal ion.[111] Designing metalloproteins using de novo-
designed scaffolds is extremely challenging since the protein’s structure and metal-binding 
properties must be designed. Unfortunately, the limited knowledge of the precise rules of 
protein folding limits the growth of the field. Only a few de novo-designed scaffolds have 
emerged, such as the α-helical bundles.[111] For this reason, the design of metalloproteins 
has focused on the creation of active sites within existing, native, biomolecular scaffolds, 
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such as proteins and DNA. The design of active sites into native scaffolds encounters some 
advantages, such as abundant scaffold choices from the Protein Database (PDB) and the 
finding that most of the natural protein scaffolds are thermodynamically stable and tolerate 
mutagenesis.[112] When designing an artificial metalloenzyme, it is also important to ensure 
that the catalytic moiety is localized within or close to the biomolecular scaffold, because only 
close contact to the second coordination sphere can eventually lead to selectivity for a given 
transformation. With this aim in mind, three different anchoring strategies have been 
pursued: supramolecular anchoring, dative anchoring and covalent anchoring. 
 
1.3.1.1. Supramolecular anchoring 
 
Supramolecular anchoring is based on strong and highly specific non-covalent interactions 
between the biomolecular scaffold and a specific moiety acting as an anchor. A perfect 
example of supramolecular anchoring is represented by biotin-streptavidin technology. 
Indeed, the strength of biotin/streptavidin interaction is so strong that it ensures precise 
biotinylated catalyst localization, which can be characterized structurally.[113] 
 
1.3.1.2. Dative anchoring 
 
Dative anchoring allows localization of the catalytically active metal through coordination to 
the biomolecular scaffold via dative bonds. Such coordinative bonds are created between the 
catalytic metal ion and functionalities presented by the biomolecular scaffold. Examples 
include artificial metalloenzymes made by incorporation of Mn-salen complexes in apo-
myoglobin and Fe and Mn corroles in serum albumins which have been used in catalytic 
enantioselective sulfoxidation reactions.[114] Another interesting example involves the metal-
substitution in carbonic anhydrase exploited independently by Kazlauskas and Soumillon.[115] 
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1.3.1.3. Covalent anchoring 
 
In covalent anchoring, a covalent bond is formed between the transition metal complex and 
the biomolecular scaffold. The covalent anchoring approach is based on the pioneering work 
of Kaiser.[116] Most often, a cysteine residue is used as the anchoring site which allows for 
site-selective anchoring of the catalytic moiety. Although the covalent strategy guarantees 
control over the structure and geometry of the catalytic site, this anchoring method involves 
chemical modifications and non-trivial purification steps, which limit the number of mutants 
which can easily be studied. 
 
1.3.1.4. Combining Different Anchoring Strategies 
 
Particular attention has to be devoted to the “dual” anchoring strategies. For example, Lu et 
al. used a “dual” covalent anchoring strategy to introduce an achiral manganese salen 
complex, into apo-sperm whale myoglobin.[117] This dual anchoring approach was shown to 
affect the catalytic sulfoxidation of thioanisole providing higher ee and rate than either non-
covalent or single-point covalent attachment strategies. In the same spirit, Watanabe and 
coworkers also exploited the exceptional properties of myoglobin in a “dual” anchoring 
approach to build artificial peroxidases: combination of supramolecular (hydrophobic 
interactions between the ligand [salen, salophen and porphycene] and the protein) and 
dative (metal-proximal histidine) interactions.[114a, 118] 
 
1.3.2. The Biotin-Streptavidin Technology  
 
1.3.2.1. Structural Considerations 
 
Designing new artificial metalloenzymes using supramolecular anchoring strategy relies on 
the accurate choice of the guest/host couple. As mentioned before, the supramolecular 
anchoring strategy takes advantage of the strong specific interactions between a biomolecule 
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and its substrate. For that purpose, the biotin-streptavidin system appears to be a perfect 
system to build artificial metalloenzymes.[119] Many reasons can explain the success of the 
biotin-streptavidin couple:  
i) The affinity of biotin for (strept)avidin is among the strongest known for a cofactor-protein 
assembly (Ka ≈ 10
13 M-1).[120] The affinity is so strong that the position of the metal complex in 
the protein is unambiguous, which allows improving the catalytic performances of 
metalloenzymes. Furthermore, derivatization of the valeric chain of biotin by introduction of 
linkers or modulation of the chelators does not cause dramatic changes in affinity.[120-121] 
ii) Streptavidin has an exceptional stability towards environment changes which allows the 
creation of a large repertoire of reactions: a fully biotin loaded streptavidin is stable at 110°C 
for several minutes, the protein is not fully denatured under extreme pH conditions (6 M 
guanidinium chloride at pH 1.5), streptavidin tolerates high concentrations of organic solvent 
(50% EtOH) and the presence of surfactants (such as sodium dodecyl sulphate, SDS).[122]  
iii) The biotin-(strept)avidin technology allows for a modular approach of optimization: protein 
and cofactor can be modified separately, by genetic and by chemical means, respectively. In 
addition, no chemical modification is needed after the incorporation of the catalyst precursor, 
ensuring the integrity of the catalytic moiety. 
iv) The easy access to a biomolecular host is an important parameter in the creation of 
metalloenzymes. From this point of view, streptavidin which is secreted by Streptomyces 
bacteria,[120] can be expressed from E. coli culture and produced as recombinant protein with 
high yields (about 200 mg per liter of E.coli culture).[123] In addition, streptavidin is easy to 
purify by affinity chromatography using immobilized iminobiotin. 
 
1.3.2.2. Optimization of the Catalytic Activity of Artificial Metalloenzymes  
 
In addition to traditional synthetic tools for optimization of the cofactor (ligand, spacer, 
counterion for example), the structure of the protein scaffold can be optimized. This strategy 
was coined by Distefano and Häring the “chemogenetic approach”.[124] In principle this 
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approach allows fine-tuning of the first and second coordination sphere, leading to hybrid 
catalyst library that can be screened for a specific reaction. For that purpose, the studies of 
Ward and Reetz on the biotin-strep(avidin) system highlighted the potential of evolving 
systems by the combinatorial screening of large numbers of mutant proteins.[125] Reetz and 
coworkers reported a “directed evolution” strategy.[126] This Darwinian approach, which 
involves repeated cycles of random mutagenesis coupled with an efficient high throughput 
screening (HTS) system for evaluating enantioselectivity, allows the generation of a large 
library of different enzymes.[127] Although direct evolution is a powerful tool to improve 
enzyme and protein performance,[128] the screening of large mutant libraries is time-
consuming and labor-intensive. To reduce the screening effort, a new methodology coined 
“Combinatorial Active-Site Saturation Test” (CAST),[129] was introduced by Reetz et al.[130] In 
contrast to directed evolution, Ward and coworkers implemented a strategy coined “designed 
evolution”,[131] where chemogenetic optimization is guided by rational decisions on sites of 
mutation. Structural information obtained either by crystallographic[113] or computational[132] 
means leads to site-directed mutagenesis of selected amino acids to tune the second 
coordination sphere around the metal catalyst. 
 
1.3. Aim of Thesis 
 
Engineered artificial metalloenzymes attempt to take advantage of the attractive properties 
both of homogeneous catalysis and biocatalysis, for example to perform important catalytic 
processes such as transfer hydrogenations. However, two of the main challenges in the field 
are i) the development of artificial enzymes for novel reactions and ii) increased mechanistic 
understanding, so that new features can be engineered “bottom-up”. This thesis contributes 
toward solving these challenges, by setting up synthetic tools and methodologies to expand 
the biotin-avidin technology for new applications, in particular for specific DNA targeting for 
improved delivery of anticancer metallodrugs and for new reactions, including reductive 
amination.  
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Throughout the thesis, the methods rely on synthesis and incorporation of biotinylated piano 
stool complexes into host streptavidin protein. In the first part of the thesis, the aim is to 
rationally design a metallodrug-presenter protein to improve selectivity of a ruthenium-based 
drug for G-quadruplex DNA over double-stranded DNA.  
The second part of this thesis deals with the development of artificial metalloenzymes by two 
different approaches:  
i) Setting up a new synthetic platform for accelerated chemical optimization of biotinylated 
catalysts; using d6-piano stool rhodium and iridium complexes with a tethered-
tetramethylcyclopentadienyl moitey directly attached to biotin. 
ii) Exploiting the versatility of the biotin-streptavidin technology to create new artificial 
metalloenzymes consisting of rational ligand design combined with genetic optimization of 
the biomolecular host. 
The two implemented strategies were investigated in asymmetric transfer hydrogenation 
reactions: the well established reduction of cyclic imines and the less explored reductive 
amination. 
In summary, this thesis describes studies of hybrid supramolecular constructs of streptavidin 
and biotinylated piano stools, with a focus on developing new methods and novel 
applications, leading to increased mechanistic understanding of this technology.
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2. Chemo-Genetic Optimization of DNA Recognition by Metallodrugs Using a 
Presenter Protein Strategy 
 
2.1. Introduction 
 
In this chapter, I describe mechanisms by which a presenter protein could be exploited to 
deliver small molecules like metallodrugs to preferred macromolecular targets in vitro. A 
ruthenium metallodrug-protein assembly based on the biotin-streptavidin technology was 
constructed to provide non-covalent interactions that modulate binding of the organometallic 
moiety to specific DNA targets. Guided by the X-ray structure of the drug embedded within 
the Sav protein, we explored the formation of metallodrug-mediated ternary complexes 
between the presenter protein and DNA.  
The assemblies bound more strongly to telomere G-quadruplexes than to double-stranded 
DNA; chemo-genetic modifications (varying the complex or mutating the protein) modulated 
binding to these targets. We suggest that rational targeting of metallodrugs via presenter 
proteins could be exploited to improve selectivity of small molecules to preferred 
macromolecular targets. 
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Figure 8 Presenter protein strategy for targeting DNA with ruthenium metallodrugs. The ruthenium 
drug embedded into tetrameric WT Sav in a 2 : 1 molar ratio forms a supramolecular complex that 
may allow extensive interactions with DNA. Chemo-genetic optimization, i.e. mutations of defined Sav 
residues (e.g. K121 and S112) or modifying the arene cap of the biotinylated ruthenium piano stool 
complex can modulate the affinity of the assembly for the DNA target. Compound 6 = [(η
6
-p-
cymene)Ru(Biot-L)Cl]CF3SO3 and 7 = [(η
6
-biphenyl)Ru(Biot-L)Cl]CF3SO3; Biot-L = Biotin-N-(R,R)-3,4-
diaminopyrrolidine.  
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2.2. Construction of the Presenter Protein and Metallodrug-Assembly: 6 ⊂ WT Sav 
 
2.2.1. Choice of the Organometallic Drug 
 
Organometallic drugs have received increasing attention spurred by their non cross-
resistance with Pt-based drugs. In specific, the study of ruthenium piano stool complexes as 
potential anti-tumor drugs has begun to establish structure-activity relationships.[133]  
 
Figure 9 Ruthenium piano stool metallodrug complexes developed by a) and b) Sadler
[133a]
 and by c) 
Dyson.
[133b]
 
 
These studies also highlighted the importance of non-covalent interactions in the second 
coordination sphere, such as hydrophobic interactions:  
i) The arene cap stabilizes RuII and provides also a hydrophobic face for the complex, which 
might improve biomolecular recognition processes.[24c, 134]  
ii) The transport of ruthenium through cell membranes can also be enhanced by such 
hydrophobic ligands.  
ii) Intercalation of the phenyl moiety of the biphenyl arene cap involving π stacking and DNA 
bases provides also further interaction that help to improve selectivity between the 
metallodrug and the target (see Figure 9a).  
Recently, the nature of the second coordination sphere has also been shown to influence 
both kinetic- and thermodynamic properties of binding to proteins, which constitute 
alternative macromolecular targets of anticancer drugs.[135]  
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2.2.2. Ruthenium Piano Stool Complexes as a Model for Metallodrugs 
 
Inspired by promising anticancer RuII-piano stool complexes developed by Sadler et al.[24a, 
133a] (see Figure 9a and b), we set-off to modify the second coordination sphere around the 
metal by embedding the piano stool inside a protein scaffold. Such metallodrug presenter 
protein will be chemogenetically engineered to target DNA. With the hope of increasing the 
specificity of metallodrugs towards DNA and as proof-of-concept that target selectivity can be 
engineered into a supramolecular assembly of drug and presenter protein, biotinylated 
ruthenium piano stool complexes [(η6-p-cymene)Ru(Biot-L)Cl]CF3SO3 6 and [(η
6-
biphenyl)Ru(Biot-L)Cl]CF3SO3 7 where Biot-L = Biotin-N-(R,R)-3,4-diaminopyrrolidine were 
synthesized (see Figure 10). These complexes were designed to be incorporated into a 
streptavidin host protein to build the supramolecular assembly. 
 
Figure 10 Biotinylated ruthenium piano stool complexes [(η
6
-p-cymene)Ru(Biot-L)Cl]CF3SO3 6 and 
[(η
6
-biphenyl)Ru(Biot-L)Cl]CF3SO3 7 where Biot-L = Biotin-N-(R,R)-3,4-diaminopyrrolidine. 
 
2.2.3. Synthesis of Biotinylated Metallodrugs 
 
In order to connect the ethylenediamine-type ligand to biotin, a pyrrolidine moiety was 
selected. The synthesis of the diaminopyrrolidine scaffold was achieved by using the protocol 
of Löwik et al.,[136] who used (L)-tartric acid as a starting material for the preparation of (R,R)-
3,4-diaminopyrrolidine (see Scheme 9). 
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Scheme 9 Synthesis of (S,S)-N-benzyl-3,4-dihydropyrrolidine 9. 
 
Benzylamine and (L)-tartaric acid were azeotropically dehydrated with boiling xylene in a 
Dean-Stark trap. After cooling, the crystalline product (with a yellowish color) was filtered, 
washed with acetone and recrystallized in EtOH. Compound 8 was obtained as a white solid 
(80% yield). Subsequently, reduction of the carbonyl group was performed by treating 8 with 
NaBH4/BF3 in dimethylester diglycol (diglyme) to yield 9 (71% yield). The resulting dihydroxy 
compound was reacted with methanesulfonylchloride to yield 10. The resulting crude product 
was directly used for the next step without additional purification. Addition of NaN3 to 10, 
through nucleophilic attack, yielded the diazide 11 in almost quantitative amounts (93% yield, 
see Scheme 10). The latter reaction step allowed to obtain the (R,R)-diaminopyrrolidine 
moiety. 
 
Scheme 10 Synthesis of (3R,4R)-N-benzyl-pyrrolidine-3,4-diazide 11. 
 
Compound 11 was then reduced with Pd/C to yield (3R,4R)-N-benzyl-3,4-diaminopyrrolidine 
12 (74% yield). The resulting amino groups were protected with tert-butyloxycarbonyl 
protective groups. Compound 13 was obtained in quantitative yield (see Scheme 11). 
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Scheme 11 Synthesis of (3R,4R)-N-benzyl-3,4-di(N,N-tert-butyloxycarbonyl)aminopyrrolidine 13. 
 
Subsequent hydrogenolysis of the benzyl group on Pd(OH)2/C afforded (3R,4R)-3,4-di(N,N-
tert-butyloxycarbonyl)aminopyrrolidine 14 in quantitative yield (see Scheme 12). 
 
Scheme 12 Synthesis of (3R,4R)-3,4-di(N,N-tert-butyloxycarbonyl)aminopyrrolidine 14. 
 
The next reaction consisted of coupling 14 with biotin. For that purpose, an activated biotin 
was used. One common activated form of biotin used in the Ward group is the N-
hydroxysuccinimide ester of biotin (BNHS).[137] Compound 14 was mixed with BNHS in the 
presence of Et3N as a base in DMF (see Scheme 13). The reaction was stirred overnight to 
afford 15. The reaction necessitated a further step of purification because of the presence of 
free biotin in the crude reaction mixture.  
 
Scheme 13 Synthesis of biotinylated (3R,4R)-3,4-di(N,N-tert-butyloxycarbonyl)aminopyrrolidine 15. 
 
The presence of free biotin may be due to the degradation of the activated biotin during the 
reaction. The resulting product was purified by column chromatography on silica gel yielding 
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15 as a white solid in excellent yield (95%). In order to cleave the Boc protective groups, 
acidic conditions (trifuoroacetic acid, TFA) were used: Compound 15 was dissolved in CH2Cl2 
and TFA was added to the solution. The reaction was stirred at RT until completion of the 
reaction as revealed by thin layer chromatography. The crude product was purified by 
column chromatography to afford 16 as a white solid (57% yield, see Scheme 14). 
 
Scheme 14 Synthesis of biotinylated (3R,4R)-3,4-diaminopyrrolidine 16. 
 
With the biotinylated diaminopyrrolidine ligand in hand, complexation with ruthenium was 
performed. Two different ruthenium complexes were envisaged: the first complex bears a p-
cymene arene cap (complex 6) while the second one possesses a biphenyl cap (complex 7, 
see Figure 10). To synthesize complex 6, the commercially available dimer [(η6-p-
cymene)RuCl2]2 was used as a precursor (see Scheme 15). 
 
Scheme 15 Synthesis of [(η
6
-p-cymene)Ru(Biotin-N-(3R,4R)-3,4-diaminopyrrolidine-N,N)Cl]CF3SO3 6. 
 
The dimer [(η6-p-cymene)RuCl2]2 was dissolved in MeOH and treated with 2 equivalents of 
AgCF3SO3 in order to precipitate the chlorides. The reaction mixture was then stirred in the 
dark for 2 h at RT. The resulting AgCl salts were filtered off and biotinylated ligand 16 was 
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added to the solution. The mixture was stirred for another 2 h. The solvent was evaporated 
and the residue was washed with CHCl3, precipitated and filtered to afford complex 6 as a 
yellow solid (95% yield, see Scheme 15). The same protocol was applied to afford 
biotinylated piano stool complex 7. However, since the dimeric biphenyl ruthenium complex 
precursor [(η6-biphenyl)RuCl2]2 was not commercially available, its synthesis was performed 
according to the protocol of Bennett et al.[138] For that purpose, biphenyl was first subjected to 
a Birch reduction (see Scheme 16).[139] This reaction allows the transformation of aromatic 
cyclic compounds into 1,4-cyclohexadiene products. The Birch reduction of aromatic rings 
generally proceeds in liquid ammonia with sodium, lithium or potassium solid and an alcohol, 
such as EtOH or tert-butanol. In our case we used EtOH and sodium in liquid ammonia. (see 
Scheme 16). The crude material was used directly in the next step without further 
purification. 
 
Scheme 16 Birch reduction for the synthesis of 3-phenyl-1,4-cyclohexadiene.
[139]
 
 
With the 3-phenyl-1,4-cyclohexadiene in hand, dimeric biphenyl ruthenium complex was 
prepared applying the protocol of Bennett et al.[138] Reaction of 3-phenyl-1,4-cyclohexadiene 
with ethanolic RuIII-trichloride provided [(η6-biphenyl)RuCl2]2 in 44% yield (see Scheme 17). 
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Scheme 17 Synthesis of [(η
6
-biphenyl)RuCl2]2.
[138]
 
 
Having obtained the dimeric biphenyl ruthenium complex, the synthesis of biotinylated piano 
stool complex 7 was carried out using the same protocol as for the synthesis of complex 6. 
Thus, biotinylated piano stool complex 7 was obtained in 55% yield (see Scheme 18). 
 
Scheme 18 Synthesis of [(η
6
-biphenyl)Ru(Biotin-N-(3R,4R)-3,4-diaminopyrrolidine-N,N)Cl]CF3SO3 7. 
 
2.3. Presenter Protein and Metallodrug-Assembly: 6 ⊂ WT Sav 
 
2.3.1. Isothermal Titration Calorimetry Titrations 
 
Telomeric DNA recognition by 6 ⊂ WT Sav was first investigated. For that purpose 
incorporation of biotinylated piano stool complex 6 into WT Sav was primarily studied by 
isothermal titration calorimetry (ITC). These ITC experiments demonstrated the strong 
binding affinity of biotinylated piano stool complex 6 for WT Sav with a calculated Kd < 60 nM 
(see Figure 11). 
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Figure 11 ITC profile for the binding of 6 to WT Sav. Titration was carried out at 25°C in MOPS buffer 
(75 mM) at pH 6.5 with 10 mM of KOH. The upper panel displays the raw titration data plotted as heat 
versus time. The lower panel displays the integrated heat measurements plotted as a function of 6 to 
WT Sav molar ratio. The heat values are plotted as a function of 6 to WT Sav molar ratio, to give the 
corresponding binding isotherms. The resulting isotherms were then fitted to a two set binding sites 
model. 
 
2.3.2. X-ray Crystal Structure of 6 ⊂ WT Sav 
 
The crystal structure of the metallodrug-presenter protein assembly 6 ⊂ WT Sav was 
obtained by soaking crystals of WT Sav with an aqueous solution of complex 6 (see Figure 
12). The structure was solved at 2.0 Å resolution by Tillmann Heinisch. The X-ray data 
demonstrates that the four biotin-binding sites are fully occupied with the metallodrug.  
6
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Figure 12 Crystal structure of biotinylated piano stool complex 6 embedded into the WT Sav presenter 
protein (6 ⊂ WT Sav). a) Close-up view of 6 bound to a WT Sav monomer (orange) also showing the 
cis-related ruthenium moiety (upper-left corner) that is bound to the symmetry-related WT Sav 
monomer (aquamarine). Selected Sav residues are shown in full and are labeled. Primed residues 
belong to the symmetry-related monomer. The 2 Fo-Fc electron density map of 6 is contoured at 1.0 
ζ. The ruthenium atom is tetrahedrally coordinated by two amino groups of the diaminopyrrolidine, the 
p-cymene and a putative chloride ion (shown in green). b) Molecular surface representation of the WT 
Sav tetramer showing two cis-related ruthenium moieties. The WT Sav surface is colored according to 
amino acid, with blue = basic residues, red = acidic residues, green = polar residues, grey = 
hydrophobic residues.  
 
Ruthenium is coordinated by four ligands, two amino groups of the (3R,4R)-
diaminopyrrolidine, a chloride molecule and the aromatic ring of the p-cymene (see Figure 
12). The metal complex has a distorted-tetrahedral “piano stool”-like conformation. In 
addition to the well documented biotin-Sav interactions,[140] other interactions between 6 and 
WT Sav found in the crystal structure enforce the localization of the piano stool moiety within 
the biotin binding pocket (see Figure 12): 
i) H-bonding of diaminopyrrolidine nitrogen to the side-chain of S112. 
ii) Apolar interactions of p-cymene with T114 (see Figure 13)  
ba
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iii) Indirect binding of the labile chloride (or water) ligand to the backbone carbonyl of S122 
via a well-ordered water molecule.  
 
Figure 13 Stereoview on the binding site between WT Sav and the head group of biotinylated piano 
stool complex 6. 
 
The diaminopyrrolidine S112H-bond is reminiscent of a critical interaction between a Pt 
ligand N-H group and the phosphate backbone of dsDNA identified by Lippard et al. in both 
cisplatin and oxaliplatin X-ray structures.[141] In the latter work they reported the 2.4-Å 
resolution X-ray crystal structure of the major adduct between a platinum complex 
[Pt(ammine)(cyclohexylamine)]2+ and a DNA dodecamer. They concluded that hydrogen 
bonding, hydrophobic, and other major groove interactions between protein, DNA, and the 
ligands on the platinum may affect drug activity.  
In the crystal structure, symmetry related cis-Ru atoms are 10.4 Å apart. In the absence of a 
neighboring biotinylated piano stool complex 6 in cis (see Figure 14), the size and charge of 
the pocket would allow multiple interactions with an incoming DNA molecule (see Figure 15). 
The orientation of the labile Ru-Cl bond is compatible with coordination to electron-rich N7 
atoms of purines[134] in an endo-base of single-stranded DNA (ssDNA). 
 
ba
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Figure 14 Model of the metallodrug-presenter protein assembly from crystal structure with vacated 
neighboring biotin-binding site in cis. 
 
Figure 15 Assembly of biotinylated piano stool complex 6  WT Sav with modeled incoming DNA. 
The biotinylated piano stool complex 6 (yellow) is shown for illustration purposes in only one of the two 
cis biotin-binding sites, reflecting experimental conditions The vacated biotin-binding site is large 
enough to accommodate a trinucleotide sequence AGT (shown in green).  
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2.4. DNA Recognition by the Presenter Protein: 6  WT 
 
2.4.1. Investigation on Telomeric G-quadruplex DNA Binding by 6  WT 
 
Having established the structure of the metallodrug-presenter protein assembly, we next 
investigated the binding of 6  WT Sav to a model G-quadruplex telomeric DNA consisting of 
39 bases (G4A).[142] The assembly was constructed by mixing two equivalents of biotinylated 
piano stool complex 6 with one equivalent of tetrameric WT Sav. The ability of 6  WT Sav to 
bind G-quadruplex was first investigated by ITC (see Figure 16). 
 
Figure 16 Binding of biotinylated piano stool drug-presenter protein assembly 6 ⊂ WT Sav to G4A 
monitored by ITC. Titration was carried out at 25°C in MOPS buffer (75 mM) at pH 6.5 with 10 mM of 
KOH. The upper panel displays the raw titration data plotted as heat versus time. The lower panel 
displays the integrated heat measurements plotted as a function of 6  WT Sav to G4A molar ratio, to 
give the corresponding binding isotherms: A single set of identical sites model provided a dissociation 
constant of (0.74 ± 0.28)·10
-6
 M, enthalpy of (1.23 ± 0.355)·10
4
 kcal/mol, and stoichiometry of 0.90 ± 
0.02. 
 
6
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ITC titration presented in Figure 16 suggested the formation of a ternary complex between 
the drug-presenter protein assembly 6  WT Sav and G4A, with sub-micromolar affinity (Kd = 
0.74 μM). The integrated heat measurements were fitted as a single-binding model providing 
a stoichiometry approaching one quadruplex bound per WT Sav tetramer (molar ratio = 
0.90). The enthalpy of binding at 25C was endothermic (H = 1.23·104 kcal/mol), and 
therefore the strong affinity implies a favorable entropic component upon binding 6  WT Sav 
to G4A. Binding capacity of 6  WT Sav for G4A was also determined by electrophoretic 
mobility-shift assays (EMSA, see Figure 17). 
 
Figure 17 Binding of assembly of metallodrug and presenter protein (6 ⊂ WT Sav) to G4A monitored 
by EMSA on agarose-gels. Lane 1: DNA Marker. Lane 2: G4A. Lane 3: G4A (3.3 μM) + WT Sav (39.6 
μM); Lane 4: G4A (3.3 μM) + 6 (85.7 μM). Lanes 5-10: G4A (3.3 μM) + 6 ⊂ WT WT Sav at increasing 
concentrations: 0.8 μM, 1.6 μM, 3.9 μM, 7.9 μM, 19.8 μM, 39.6 μM, representing a 6 ⊂ WT Sav : G4A 
ratio from 0.2 to 12. In all cases 500 ng of DNA was loaded onto the gel. 
 
The supramolecular assembly of WT Sav with the biotinylated ruthenium drug produced a 
concentration-dependent change in migration of G4A DNA in EMSA, leading to a single slow 
migrating species that was also consistent with the formation of a ternary complex with a 
defined 1 : 1 stoichiometry (DNA : 6  WT Sav, see Figure 17). This ternary complex 6  WT 
Sav-G4A DNA displayed a Kd  2 µM as extrapolated from EMSA analyses, a value in 
agreement with the affinity data found by ITC (Kd = 0.74 µM). Thus, whether measured 
accurately in solution by ITC or more conservatively in EMSA, both these studies supported 
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the conclusion that the presenter protein contributed to the binding and to the formation of a 
defined ternary complex with quadruplex DNA.  
 
The affinity of WT Sav alone for DNA was also investigated. In comparison, the binding of 
the protein alone with quadruplex DNA was markedly weaker (Kd = 15.2 µM) in the absence 
of biotinylated piano stool complex 6 (see Figure 18).  
 
Figure 18 Binding of WT Sav to G4A monitored by ITC. Titration was carried out at 25°C in MOPS 
buffer (75 mM) at pH 6.5 with 10 mM of KOH. The upper panel displays the raw titration data plotted 
as heat versus time. The lower panel displays the integrated heat measurements plotted as a function 
of Sav to G4A molar ratio, to give the corresponding binding isotherms: A single set of identical sites 
model give a dissociation constant of (15.20 ± 2.35)·10
-3
 M, enthalpy of (1.055 ± 0.124)·10
3
 kcal/mol, 
and stoichiometry of 1.81 ± 0.09. 
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The weak affinity of WT Sav for DNA (theoretical WT Sav pI  7) was one of the reasons for 
using Sav for biotechnology applications involving biotinylated DNA (rather than the related, 
but very basic protein avidin, pI  10.4).[143] The binding affinity of the protein alone was more 
than ten times weaker than in the presence of biotinylated piano stool complex 6. Lack of 
detectable binding of WT Sav in the absence of biotinylated piano stool complex 6 for DNA 
was also confirmed by EMSA gels (see Figure 17, Lane 3) 
 
EMSA gels and ITC using G4A as target were also carried out with biotinylated piano stool 
complex 6 alone (in absence of Sav). These data revealed the formation of a mixture of fast 
migrating species that cannot be resolved by EMSA (see Figure 17, Lane 4). ITC analysis 
revealed multiple binding equilibria with a large enthalpic contribution (see Figure 19).  
 
Figure 19 Binding of biotinylated piano stool complex 6 to G-quadruplex DNA monitored by ITC. 
Titration was carried out at 25°C in 75 mM MOPS (pH 6.5) with 10 mM KOH. The upper panel 
displays the raw titration data plotted as heat versus time. The lower panel displays the integrated heat 
measurements plotted as kcal/mol of drug injected into telomeric DNA. The resulting isotherms could 
not be fitted to a one-site binding model. 
6
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These experiments supported the expected multiple strong binding events to the DNA. 
Similar multiple binding events of piano stool complexes to oligonucleotides have been 
described before and support the notion that metallodrugs exhibit little DNA-sequence 
selectivity.[144] There is ample experimental evidence for related ruthenium piano stool 
complexes that display preferential binding to N7 guanine in DNA;[134] a QM-MM calculation 
predicts a Kd of 0.1 μM for a related Ru piano stool.
[145] 
Both ITC and EMSA analyses demonstrated that binding of biotinylated piano stool complex 
6 to DNA in the absence or presence of the presenter protein assembly is very different, 
indicating that the protein influenced the mode of binding of biotinylated piano stool complex 
6 and helped to form a defined ternary complex with quadruplex DNA. The binding of a 
single drug-protein to a G4A DNA containing 39 nucleotides intimated the existence of an 
extended contact between both macromolecules. This large contact between WT Sav and 
G4A DNA, both of comparable size, would suggest that such drug-presenter protein can be 
engineered to display selectivity towards the DNA sequence. 
 
Figure 20 Binding of assembly of metallodrug and presenter protein (6 ⊂ Sav), at 1 or 4 equivalents of 
Ru metallodrug per tetramer, to G4A DNA monitored by EMSA on agarose-gels. Lane 1: Marker (M). 
Lane 2: G4A, Lane 3: G4A (3.3 μM) + Sav (39.6 μM). Lane 4: G4A (3.3 μM) + complex 6 (43 μM for 1 
Ru/Sav and 160 μM for 4 Ru/Sav, respectively). Lane 5-10: G4A (3.3 μM) + 6 ⊂ Sav at increasing 
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concentrations: 0.8 μM, 1.6 μM, 3.9 μM, 7.9 μM, 19.8 μM, 39.6 μM, representing a 6 ⊂ Sav : G4A ratio 
from 0.2 to 12. In all cases 500 ng of DNA was loaded onto the gel. Lane 11: 1 ⊂ Sav : G4A ratio of 
1.2, with 1 equivalent of ruthenium per tetramer. Lane 12: 1 ⊂ Sav : G4A ratio of 1.2, with 2 
equivalents of ruthenium per tetramer. Lane 13: 1 ⊂ Sav : G4A ratio of 1.2, with 4 equivalent of 
ruthenium per tetramer. 
 
Affinities obtained by varying the ratio of 6 : Sav from 1 : 1 to 4 : 1 are comparable (see 
Figure 20). The 2 : 1 ratio was selected for all subsequent studies as it yielded a well defined 
1 : 1  stoichiometry (6 ⊂ Sav : G4A) by ITC (see Figure 16) and EMSA (see Figure 17). 
 
2.4.2. Selectivity for Single Stranded DNA (ssDNA) 
 
2.4.2.1. Binding of 6  Sav to Unstructured G-quadruplex DNA 
 
We also investigated the selectivity of interaction of 6  Sav for different DNA targets. DNA 
quadruplexes are known to be greatly stabilized by potassium ions. Accordingly, by carrying 
out binding assays in Li+ salts instead of K+, the formation of quadruplex DNA by G4A can be 
prevented.[146] Affinity binding between 6  Sav and unstructured DNA (G4A in presence of 
LiOH) were investigated (see Figure 21). 
 
Figure 21 EMSA gel for the titration of 6  Sav into G4A in MOPS (75mM) with LiOH (140mM). Lane 
1: Marker, Lane 2: G4A, Lane 3-11: concentration increase of 6  Sav: 1.8 μM, 2.65 μM, 3.5 5μM, 7 
μM, 14.5 μM, 18 μM, 35.5 μM, 89 μM, 178.5 μM with a 6  Sav:G4A ratio from 0.1 to 12.5.  
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The experiment monitored in EMSA gels with 6  Sav and “lithiated” G4A DNA demonstrated 
that under these conditions, the resulting presumably unstructured ssDNA oligonucleotide 
bound to the metallodrug-protein assembly with a similar apparent affinity to that of its more 
structured G-quadruplex form (estimated Kd < 1.6 μM, see Figure 21).  
ITC titrations of 6  Sav with this unstructured lithiated G4A were also performed. These 
experiments support the notion that 6  Sav displays comparable affinities for both 
unstructured ssDNA and folded G4A, albeit with different forms of binding (see Figure 22).  
 
Figure 22 Binding of 6 ⊂ Sav to G-quadruplex DNA with LiOH monitored by ITC. Titration was carried 
out at 25°C in 75 mM MOPS (pH 6.5) with 140 mM LiOH. The upper panel displays the raw titration 
data plotted as heat versus time. The lower panel displays the integrated heat measurements plotted 
as kcal/mol of 6 ⊂ Sav injected into G4A DNA. The data could not be fitted to a one-site binding 
model. 
 
Comparison of the ITC experiment displayed in Figure 16 and 22 suggests that the binding-
modes of 6  Sav folded G-quadruplex and its unstructured form are different. Although 
EMSA gels established comparable apparent affinities, ITC data did not yield unambiguous 
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and interpretable binding isotherms. Consequently this titration suggests that a complicated 
binding mechanism occurs when 6  Sav and unstructured G4A are mixed together. 
 
2.4.2.2. Binding of 6  Sav to Scrambled Telomeric DNA 
 
To test whether 6 ⊂ Sav recognized structural features of G4A or simply its nucleotide 
content, we used a “scrambled” telomeric sequence (scG4A) that could not form a G-
quadruplex structure (see Figure 23). 
 
Figure 23 EMSA gel for the titration of 6  Sav into scG4A in MOPS (75mM) with KOH (135 mM). 
Lane 1: Marker, Lane 2: scrambled G4A, Lane 3-11: concentration increase of 1  Sav: 1.8 μM, 2.65 
μM, 3.55 μM, 7 μM, 14.5 μM, 18 μM, 35.5 μM, 89 μM, 178.5 μM with a 1  Sav : ScG4A ratio from 0.1 
to 12.5.  
 
As displayed in Figure 23 the binding of 6 ⊂ Sav to this control oligonucleotide (scG4A) was 
measurably weaker than for G4A (Kd = 2.3 μM, see Figure 23), which was bound 
stoichiometrically in our EMSA assay (Kd < 1.6 μM, see Figure 17). Scrambled G4A had the 
same sequence than G4A and was designed to be unable to form quadruplexes even in the 
presence of K+. The metalloprotein 6 ⊂ Sav formed a ternary complex in the presence of 
scG4A as determined by EMSA, suggesting that the metallodrug-presenter protein could 
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also interact with other ssDNA, with little sequence selectivity. Titration experiments of 
scG4A with 6 ⊂ Sav were carried out (see Figure 24).  
 
Figure 24 Binding of 6 ⊂ Sav to a “scrambled” telomeric DNA (scG4A) monitored by ITC. Titration 
was carried out at 25°C in 75 mM MOPS (pH 6.5) with 10 mM KOH. The upper panel displays the raw 
titration data plotted as heat versus time. The lower panel displays the integrated heat measurements 
plotted as kcal/mol of 6 ⊂ Sav injected into scG4A DNA. The resulting isotherms gave markedly 
different and more complicated than the one-site-model binding to G-quadruplex G4A, but is very 
reminiscent of binding of 6 ⊂ Sav to unstructured G4A with LiOH (see Figure 22).  
 
The binding of 6  Sav to this control oligonucleotide gave a similar ITC titration curve to that 
of unstructured G4A (Figure 22), which could not be fitted to a one-site binding model. 
Therefore, under these conditions, 6 ⊂ Sav binds strongly to the G-quadruplex in a defined 1 
: 1 stoichiometry that fits a single-binding site mechanism and also binds to other ssDNA, 
whether scrambled ssDNA or unstructured G4A with LiOH, with marginally less affinity and in 
a more complicated manner. Similar binding flexibility has been observed in nucleotide 
shuffling experiments of natural ssDNA binding proteins.[147] It is noteworthy that, although 
many ssDNA binding-proteins are unable to recognize G-quadruplexes,[146] the 
1

S
a
v
6
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bioengineered 6  Sav assembly described here can bind to both unstructured ssDNA and 
to a G4A telomeric quadruplex with similar affinity. 
 
2.4.3. Competitive Binding 
 
2.4.3.1. Glutathione 
 
To test the selectivity of a ternary complex with DNA, experiments in the presence of 
potentially interfering molecules were carried out. The first competition studies were 
performed with glutathione (GSH). Glutathione has been shown to coordinate anticancer Ru 
complexes in vitro[24b, 148] and has also been implicated in metallodrug inactivation in vivo.[149]. 
It has also been demonstrated that GSH plays a key role in the regulation of cisplatin 
resistance in cancer chemotherapy.[150] Interactions between biotinylated piano stool complex 
6 and GSH were investigated by mixing both species in water at 25°C. Mass spectrometry 
measurements demonstrated that biotinylated piano stool complex 6 reacted rapidly with 
glutathione presumably through the thiol group, which is a highly abundant intracellular form, 
giving rise to GSH adducts (see Figure 25).  
 
Figure 25 Mass spectrum of biotinylated piano stool complex 6-GSH adduct, prepared by adding an 
excess of GSH (83 μM) compared to the biotinylated piano stool complex 6 (12 μM) in H2O. The mass 
spectrum was recorded after only 5 min at 25°C.  
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Table 1 Main peaks identified in the mass spectrum of biotinylated piano stool complex 6 
with GSH in H2O at 25°C. 
Entry Reaction and observed ions m/z (measured) m/z (theoretica) 
1 [Glutathione + H]+ 308.0 307.1 
2 [6 - Cl]+ 561.9 562.7 
3 [6]+ 597.9 598.2 
4 [GSSG]+ 614.9 612.6 
5 [6 + Na]+ 621.9 621.1 
6 [6-(GS)]
+ 868.8 869.1 
 
Mass spectrometry experiments displayed in Figure 25 suggest the presence of GSH (Table 
1, entry 1), biotinylated piano stool complex 6 alone (Table 1, entries 2 and 3) and GSH 
dimer (Table 1,entry 4). The mass of 868.8 corresponding to the biotinylated piano stool 
complex 6-GSH adduct was visible with the expected isotopic distribution (see Figure 25 and 
Table 1). 
 
These experiments confirmed that biotinylated ruthenium piano stool complex 6 can easily 
bind to GSH. Binding affinities between our metallodrug-presenter protein and G4A DNA in 
the presence of interfering GSH was investigated by EMSA gels (see Figure 26). 
 
Figure 26 Binding of assembly of 6 ⊂ WT Sav to G4A monitored by EMSA on agarose-gels in the 
presence of 1 mM GSH. Lane 1: DNA Marker. Lane 2: G4A. Lane 3: G4A (3.3 μM) + WT Sav (39.6 
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μM); Lane 4: G4A (3.3 μM) + 6 (85.7 μM). Lanes 5-10: G4A (3.3 μM) + 6 ⊂ Sav at increasing 
concentrations: 0.8 μM, 1.6 μM, 3.9 μM, 7.9 μM, 19.8 μM, 39.6 μM, representing a 6 ⊂ WT Sav : G4A 
ratio from 0.2 to 12. In all cases 500 ng of DNA was loaded onto the gel. 
 
These experiments were carried out in the presence of 300-fold excess GSH compared to 
G4A (final concentration of glutathione = 1 mM; i.e. within the physiological range). The 
presence of such high concentration of GSH did not appreciably affect the formation of the 
complex with G4A as evidenced by EMSA (estimated Kd < 1.6 μM, see Figure 26). In 
analogy, the anticancer-drug picoplatin was rationally designed to provide steric bulk around 
the metal centre, reducing its inactivation by species like GSH.[149a, 151] We hypothesize that 
the protein also offers steric and electronic shielding from competing species, such as GSH 
or other macromolecules. 
 
2.4.3.2. Competing ssDNA 
 
Interactions of our assembly with single stranded DNA were investigated by EMSA gels (see 
Figure 27). A 12mer ssDNA and a trinucleotide GGG were selected for the study. 
 
Figure 27 Binding of 6  WT Sav to G-quadruplex DNA in the presence of competing DNA substrates, 
monitored by EMSA on agarose-gels. Lane 1: Marker (M). Lane 2: G4A. Lane 3: G4A (3 μM) + GGG 
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trinucleotide (206.5 μM) or 12mer ssDNA (462 μM) respectively. Lane 4: G4A (3 μM) + GGG (206.5 
μM) or 12mer (462 μM) respectively + complex 6 (76.5 μM). Lane 5-10: GGG (206.5 μM) or 12mer 
(462 μM) were co-incubated with G4A (3 μM) and the 6  WT Sav assembly at increasing 
concentrations: 0.7 μM, 1.4 μM, 3.5 μM, 7 μM, 17.7 μM, 35.3 μM; under these conditions, the molar 
ratio 6  WT Sav : G4A ranges from 0.2 to 12, while GGG : G4A and 12mer : G4A ratio is 69 and 154, 
respectively. Lane 11: G4A (3 μM) and 6  WT Sav assembly (35.3 μM). Lane 12: GGG (206.5 μM) or 
12mer (462 μM) in the presence of 6  WT Sav assembly (35.3 μM); GGG or 12mer are barely visible 
by ethidium bromide staining due to lack of intercalation of the dye in ssDNA. 
 
An excess of competing ssDNA co-incubated with G4A (up to 157 equivalents of competing 
ssDNA compared to G4A) lowered binding of the metallodrug-protein assembly as 
determined by EMSA, but only marginally. The 12mer ssDNA was better at inhibiting G4A-
binding (estimated Kd = 5.4 μM) than GGG (estimated Kd = 2 μM), which may intimate the 
existence of a more extended interaction with the 6 ⊂ WT Sav assembly compared with the 
smaller GGG-trinucleotide. These results supported the notion that G4A is a privileged target 
for the 6 ⊂ WT Sav assembly. 
 
2.4.4. Genetic Control of the 2nd Coordination Sphere 
 
Next, we investigated the influence of the second-coordination sphere on G4A binding 
through site-directed mutagenesis. The crystal structure revealed two lysines (K121 of the 
two adjacent monomers) within 10 Å of the ruthenium, at the entrance of the largely 
hydrophobic biotin-binding pocket (see Figure 12). Binding affinities of 6 ⊂ K121A for G4A 
DNA were investigated by EMSA gels (see Figure 28). 
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Figure 28 Binding of assembly of metallodrug and presenter protein (6 ⊂ K121A) to G4A monitored by 
EMSA on agarose-gels. Lane 1: DNA Marker. Lane 2: G4A. Lane 3: G4A (3.3 μM) + K121A (39.6 μM); 
Lane 4: G4A (3.3 μM) + 6 (85.7 μM). Lanes 5-10: G4A (3.3 μM) + 6 ⊂ K121A at increasing 
concentrations: 0.8 μM, 1.6 μM, 3.9 μM, 7.9 μM, 19.8 μM, 39.6 μM, representing a 6 ⊂ K121A : G4A 
ratio from 0.2 to 12. In all cases 500 ng of DNA was loaded onto the gel. 
 
These experiments demonstrated that mutation of this positively-charged residue (K121A) 
decreased affinity greatly (estimated Kd = 28.8 μM), such as also seen in other nucleic acid-
binding proteins.[146, 152] These experiments suggested that the lysines might form a salt-
bridge with the phosphate backbone. Similarly, the introduction of a negative charge in the 
vicinity of the ruthenium (S112D) also reduced binding-affinity (see Figure 29). This is 
probably caused by charge-repulsion between the overall negatively charged DNA and the 
deprotonated aspartic acid in position 112 (estimated Kd = 12.2 μM).  
 
Figure 29 Binding of assembly of metallodrug and presenter protein (6 ⊂ S112D) to G4A monitored 
by EMSA on agarose-gels. Lane 1: DNA Marker. Lane 2: G4A. Lane 3: G4A (3.3 μM) + S112D (39.6 
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μM); Lane 4: G4A (3.3 μM) + 6 (85.7 μM). Lanes 5-10: G4A (3.3 μM) + 6 ⊂ S112D at increasing 
concentrations: 0.8 μM, 1.6 μM, 3.9 μM, 7.9 μM, 19.8 μM, 39.6 μM, representing a 6 ⊂ S112D : G4A 
ratio from 0.2 to 12. In all cases 500 ng of DNA was loaded onto the gel. 
 
The influence of a bulky hydrophobic residue on DNA binding was also investigated. EMSA 
on agarose-gels were carried out with a mutated presenter protein bearing a phenylalanine in 
position 112 (S112F, see Figure 30). 
 
Figure 30 Binding of assembly of metallodrug and presenter protein (6 ⊂ S112F) to G4A monitored by 
EMSA on agarose-gels. Lane 1: DNA Marker. Lane 2: G4A. Lane 3: G4A (3.3 μM) + S112F (39.6 μM); 
Lane 4: G4A (3.3 μM) + 6 (85.7 μM). Lanes 5-10: G4A (3.3 μM) + 6 ⊂ S112D at increasing 
concentrations: 0.8 μM, 1.6 μM, 3.9 μM, 7.9 μM, 19.8 μM, 39.6 μM, representing a 6 ⊂ S112F : G4A 
ratio from 0.2 to 12. In all cases 500 ng of DNA was loaded onto the gel. 
 
Compared to the other two mutated Sav tested (K121A and S112D), introduction of an 
aromatic residue in position 112 did not appreciably change the affinity for G4A (estimated Kd 
< 1.6 μM). These results demonstrated that DNA binding of the cationic Ru complex 6 is 
influenced by the second coordination sphere provided by the presenter protein, particularly 
by charged residues in the vicinity of Ru. These data support the notion that optimized 
genetic screening could be carried out to improve the affinity of binding of a ternary complex. 
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2.4.5. Chemo-Genetic Optimization for Improved Binding to dsDNA 
 
We also explored whether Sav could present the metallodrug 6 to dsDNA. For this purpose, 
we used an 18 base pair dsDNA that includes the sequence of the common Braf V599E 
oncogenic mutation (dsOnc).[153] It has been argued that recognition of ssDNA and dsDNA by 
proteins are fundamentally different. For example, Theobald et al. explored the mechanisms 
of sequence-specific ssDNA recognition.[147] They determined the crystal structures of 10 
different non-cognate ssDNAs complexed with the Oxytricha nova telomere end-binding 
protein and evaluated their corresponding binding affinities. Their investigations highlighted a 
fundamental difference between protein recognition of ssDNA versus dsDNA. Consequently, 
we decided to extend our EMSA experiments to investigate the binding ability of 6 ⊂ WT Sav 
for dsOnc DNA (see Figure 31). 
 
Figure 31 Binding of assembly of metallodrug and presenter protein (6 ⊂ WT Sav) to dsOnc 
monitored by EMSA on agarose-gels. Lane 1: Marker (M). Lane 2: dsOnc. Lanes 3-11: dsOnc (3.12 
μM) + concentration increase of 6 ⊂ WT Sav: 0.4 μM, 0.6 μM, 0.8 μM, 1.6 μM, 3.2 μM, 3.9 μM, 7.9 
μM, 19.8 μM, 39.6 μM with a 6 ⊂ WT Sav : dsOnc ratio from about 0.1 to 13. In all cases 500 ng of 
DNA was loaded onto the gel. 
 
Compared to the affinity for G4A (Kd < 1.6 μM as estimated by EMSA; Figure 17), the affinity 
for dsOnc was significantly lower, with Kd ≈ 37.9 μM (see Figure 31). We hypothesize that a 
different organization of functional groups as well as the reduced flexibility of dsDNA 
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hampered efficient interaction between the ruthenium and nucleophilic sites on the bases. 
With the aim of improving binding to dsDNA, chemical optimization by modifying the 2nd 
coordination sphere of the complex was investigated. It has been reported that η6-biphenyl 
piano stool complexes can improve binding between ruthenium and dsDNA through 
intercalation.[153] In analogy, we synthesized the biphenyl derivative [(η6-biphenyl)Ru(Biot-
L)Cl]CF3SO3 7 (see Figure 10). Combination of WT Sav with this chemical variation was 
investigated in DNA binding (see Figure 32). 
 
Figure 32 Binding of assembly of metallodrug and presenter protein (7 ⊂ WT Sav) to dsOnc 
monitored by EMSA on agarose-gels. Lane 1: Marker (M). Lane 2: dsOnc. Lanes 3-11: dsOnc (3.12 
μM) + concentration increase of 7 ⊂ WT Sav: 0.4 μM, 0.6 μM, 0.8 μM, 1.6 μM, 3.2 μM, 3.9 μM, 7.9 
μM, 19.8 μM, 39.6 μM with a 7 ⊂ WT Sav : dsOnc ratio from about 0.1 to 13. In all cases 500 ng of 
DNA was loaded onto the gel. 
 
Experiments presented in Figure 32 demonstrated that the introduction of an intercalator 
such as biphenyl did not improve the binding affinity when such complex was combined with 
WT Sav. The assembly 7 ⊂ WT Sav was found to bind to dsOnc with an estimated Kd of 37.9 
μM, which is the same affinity displayed by 6 ⊂ WT Sav (estimated by EMSA, see Figure 
31). 
To further demonstrate that DNA binding can be fine-tuned using an assembly of drug and 
presenter protein, we thought to improve binding to dsDNA chemo-genetically by using the 
complex 7 combined with a genetic mutated protein. For example by introducing an aromatic 
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residue in the position closest to Ru metal (S112). Subsequently, binding of 7 ⊂ S112F to 
dsOnc was investigated and monitored by EMSA gels (see Figure 33).  
  
Figure 33 Binding of assembly of metallodrug and presenter protein (7 ⊂ S112F) to dsOnc monitored 
by EMSA on agarose-gels. Lane 1: Marker (M). Lane 2: dsOnc. Lanes 3-11: dsOnc (3.12 μM) + 
concentration increase of 7 ⊂ S112F: 0.4 μM, 0.6 μM, 0.8 μM, 1.6 μM, 3.2 μM, 3.9 μM, 7.9 μM, 19.8 
μM, 39.6 μM with a 7 ⊂ S112F: dsOnc ratio from about 0.1 to 13. In all cases 500 ng of DNA was 
loaded onto the gel. 
 
Experiments presented in Figure 33 demonstrated that the biphenyl-containing S112F 
variant (7 ⊂ S112F) increased the affinity to dsOnc (Kd = 18.2 μM as estimated by EMSA). 
Indeed, the latter metallodrug-presenter protein was found to bind to dsOnc with an 
improvement of at least a factor of 2 when compared with 6 ⊂ WT Sav, 6 ⊂ S112F or 7 ⊂ 
WT Sav (Kd = 37.9 μM for every assembly). Both the molecular weight and the estimated size 
of G-quadruplex-forming G4A (39 bases) and of this dsDNA (18 base pair) are similar and in 
both cases a single slow-mobility species was found. Moreover, the value of 18bp in a 1 : 1 
stoichiometry with Sav is consistent with the experimentally-derived spacing of avidin onto 
plasmid DNA.[143]  Importantly, the finding that the metalloprotein 7  S112F improved the 
affinity for dsDNA suggested that modulation of non-covalent interactions in complexes of 
metallodrugs and presenter proteins can be engineered chemo-genetically to afford more 
specialized binders, with increased target-selectivity. 
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2.4.6. Summary 
 
Table 2 Summary of dissociation constants (Kd) of Ru  Sav assemblies for various DNA 
targets, as estimated from EMSA. 
Entry DNA Target Metal complex Ratio Ru/Sav Sav Kd (μM) 
1 G4A none - WT > 145[a] 
2 G4A 6 2 WT < 1.6[b], [c] 
3 G4A 6 2 S112F < 1.6[c] 
4 G4A 6 2 S112D 12.2 
5 G4A 6 2 K121A 28.8 
6 G4A (GSH)[d] 6 2 WT < 1.6[c] 
7 dsOnc 6 2 WT 37.9 
8 dsOnc 6 2 S112F 37.9 
9 dsOnc 7 2 WT 37.9 
10 dsOnc 7 2 S112F 18.2 
11 scG4A[e] 6 2 WT 2.3 
12 G4A (LiOH)[f] 6 2 WT < 1.6[c] 
13 G4A (GGG)[d] 6 2 WT 2 
14 G4A (12mer)[d] 6 2 WT 5.4 
15 G4A 6 1 WT 2.3 
16 G4A 6 4 WT < 1.6[c] 
[a]
 Kd determined by ITC: 15.2 μM (from Kd determined in Figure 18); 
[b]
 Kd determined by ITC: 0.74 
mM; 
[c]
 Binding was stoichiometric and probably beyond the sensitivity of these EMSA; 
[d]
 In brackets 
competing species: glutathione (GSH), trinucleotide GGG (GGG) and ssDNA 12mer (12mer); 
[e]
 
“Scrambled” G4A has identical nucleotide content to G4A but with a different sequence and structure.
 
[f]
 Experiment performed with LiOH instead of KOH: similar to unstructured G4A.  
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Our investigations are a proof-of-concept for a possible rational drug-design: binding a drug 
to a host presenter protein can be used both to protect a drug from unwanted interactions 
and to provide additional surface contacts (“surface borrowing”)[154] for a more specific 
recognition of the desired macromolecular target. The importance of the extended second 
coordination sphere that is provided by the presenter protein for selective binding of a small 
molecule to a macromolecular target is shown by:  
i) The different modes of binding of cationic biotinylated ruthenium piano stool complex 6 to 
G4A in presence or absence of Sav. 
ii) The influence of chemogenetic modifications on DNA binding: for example decreasing 
binding to G4A using a K121A mutant or by increasing the affinity for dsDNA by a judicious 
combination of genetic variant (S112F) and biotinylated piano stool complex 7 (containing a 
biphenyl arene-cap). 
In contrast, selective DNA binding is difficult to achieve with small metallodrugs, such as 
cationic biotinylated ruthenium piano stool complex 6 alone, because there are only limited 
interactions available for recognition of the target. 
 
2.5. Conclusion 
 
In this chapter we demonstrated that a supramolecular assembly consisting of a metallodrug 
(i.e., biotinylated ruthenium piano stool) combined with a presenter protein (i.e., streptavidin) 
modulated the recognition profile in vitro through the provision of additional non-covalent 
interactions. Such extended contacts, which are not typically available to small molecule 
drugs, allowed modulation of affinity and selectivity towards DNA telomeres, even in the 
presence of competing targets (such as glutathione and dsDNA).  
In the present form such assemblies cannot be delivered easily into cells, thus hampering in 
vivo studies. To overcome this challenge, our current alternative efforts include the following: 
i) Appending cell penetrating peptide sequences to the presenter protein. 
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ii) Exploring non-DNA,[135a] extracellular targets, which circumvents the need for intracellular 
delivery. 
ii) Exploiting endogenous species as presenter proteins, such as those overexpressed in 
cancer cells. The latter would thus only require cell penetration of the metallo-prodrug.  
The ultimate aim of these experiments is to use such tethered or cross-linking drugs[155] in 
which an initial kinetic binder[31, 156] does not merely act as a “carrier”[157] or “reservoir”[158] but 
also chaperones the drug selectively to a macromolecular target in vivo, contributing 
ultimately to the inhibitory (bioactive) species. 
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3. Streptavidin as Host Protein for Asymmetric Transfer Hydrogenation of Imines  
 
3.1. Introduction 
 
Within this chapter I present the synthesis and reactivity of a new generation of biotinylated 
half-sandwich complexes that potentially give access to high chemo-diversity and thus faster 
chemical screening of artificial metalloenzymes. The new scaffold involves d6-transition metal 
(rhodium and iridium) piano stool complexes that contain a pentamethylcyclopentadienyl 
moiety (Cp*) tethered to biotin for incorporation into a host protein, streptavidin. Two different 
strategies were pursued:  
i) The functionalized piano stool complexes were associated with a variety of bidentate 
ligands (N-N, N-O…) potentially giving rise to high chemical diversity of biotinylated catalysts. 
ii) The biotinylated piano stool moiety was found to fit into the host protein containing a 
histidine residue and could act as a ligand, thereby creating a supramolecular (biotin-
streptavidin) and dative (metal-histidine) anchoring to the host protein. This approach 
constituted a novel metalloprotein design in which the host protein provided simultaneously 
the first and the second coordination sphere. 
The reduction of cyclic imines by ATH was selected as the model reaction to screen the 
potential of these metalloenzymes in enantioselective catalysis. 
 
3.2. New Generation of Biotinylated Complexes Displaying High Chemo-Diversity 
 
3.2.1. First Generation of Biotinylated Complexes Developed for ATH Reactions 
 
Since the development, by Letondor et al. of highly active and selective biotinylated catalysts 
[η6-(arene)Ru(Biot–q–L)Cl], all the complexes that have been used for asymmetric transfer 
hydrogenation in the Ward group shared this scaffold (Figure 34).[159]  
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Figure 34 Biotinylated complexes designed by Ward and coworkers for ATH of ketones and 
imines.
[159-160]
 
 
During the development of the first generation of Cp* iridium catalysts, I supervised a Master 
student, Annette Mutschler for the synthesis of [Cp*Ir(Biot–p–L)Cl]. Although this ligand 
approach has been successively applied in enantioselective reduction of both ketones and 
cyclic imines,[160] this method offered relatively limited chemical diversity. Diversification of 
the bidentate ligand and/or the spacer was time consuming. 
 
3.2.2. Second Generation of Biotinylated Complexes Offering High Chemo-Diversity 
 
To create organometallic complexes with high chemo-diversity potential, direct attachment of 
biotin to the arene cap was envisioned (see Figure 35).  
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Figure 35 Design principle of a new generation of biotinylated piano stool complexes affording high 
chemo-diversity. 
 
This strategy gave a straightforward access to a new generation of biotinylated Cp* moiety 
and allowed the introduction of potentially high chemo-diversity through variation of the 
bidentate ligand bound to the metal (N-N, N-O, P-N, P-P): X, Y. Furthermore, chemical 
diversity can also be achieved in a similar fashion to the first generation of biotinylated piano 
stool complexes (see Figure 34): 
i) Introduction of a spacer between the biotin anchor and the Cp* moiety: Spacer. 
ii) Variation of the metal IrIII, RhIII and RuII: M. 
iii) Modification of the length of the arm on the functionalized tethered Cp* (n = 1 or 2): ( )n. 
 
These biotinylated complexes can subsequently be incorporated into streptavidin as host 
protein for the construction of a variety of chemogenetically engineered metalloenzymes. 
Based on the work of Reiner et al.[161] and van Leusen et al.,[162] we synthesized tethered 
complexes with an ethylene spacer (n = 1, see Figure 35).[162] The biotinylated dimeric 
complexes [(η5-Me4Cp-(CH2)2-N-Biot)MCl2]2 (where M = Rh or Ir, see Figure 36) were 
selected for the creation of artificial metalloenzymes: 
i) The dimers were used as staring material for the synthesis of diverse mononuclear 
biotinylated piano stool complexes bearing an additional bidentate ligand. 
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ii) Combination of the dimers with Sav mutants bearing a suitably positioned histidine residue 
allowed the creation of dually anchored artificial metalloenzymes. 
 
Figure 36 Biotinylated dimeric rhodium 17 and iridium 18 complexes. 
 
3.2.3. Synthesis of Biotinylated Complexes 17 and 18 
 
For the synthesis of the dimeric complexes 17 and 18, the procedure by van Leusen et al. 
was slightly modified.[162] To accomplish the synthesis of various ethylene-bridged 
tetramethylcyclopentadienylamines, van Leusen et al. used the commercially available 
2,3,4,5-tetramethylcyclopent-2-enone 19 as starting material (see Scheme 19).  
 
Scheme 19 Synthesis of ethylaminocyclopentene precursor 21.
[162]
 
 
Treatment of 2,3,4,5-tetramethylcyclopent-2-enone 19 with deprotonated acetonitrile in THF 
at -80°C afforded the hydroxy intermediate which, upon acidic treatment, underwent 
dehydration to yield the corresponding nitrile 20 (90% yield). The resulting nitrile 20 could not 
be reduced using the van Leusen protocol. Instead, the procedure published by McCalmont 
et al.[163] using activated (AlCl3)•LiAlH4 in dry THF was employed and yielded the 
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corresponding amine 21 as a mixture of isomers. The crude amine was directly used as a 
starting material for the next step as it was found to be unstable. The dimeric rhodium 
complex 22 was prepared from 21 following the protocol of Reiner et al. (see Scheme 20).[161] 
While Reiner et al. performed the reaction in EtOH to afford 22 in 72% yield, MeOH proved to 
be a better solvent in our hands: the dimer 22 was obtained in higher yield (85%). 
 
Scheme 20 Synthesis of the dimeric rhodium complex [(η
5
-Me4Cp-(CH2)2NH3)RhCl2]2(Cl)2 22.
[161]
 
 
The coupling of biotin to 22 proved challenging. One common activated form of biotin used in 
the Ward group is the N-hydroxysuccinimide ester of biotin (BNHS).[137] The dimeric rhodium 
complex was mixed with BNHS in the presence of Et3N as a base in DMF. The reaction was 
stirred overnight to afford the biotinylated rhodium dimer 17 (80% yield, see Scheme 21). 
However, 1H NMR spectrum revealed the presence of biotin impurities. The reaction with 
BNHS was incomplete due to biotin N-hydroxysuccinimide degradation during the reaction 
which liberated biotin. To overcome this problem, biotin pentafluorophenyl ester was used 
(see Scheme 21).[164] 
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Scheme 21 Synthesis of [(η
5
-Me4Cp-(CH2)2-N-Biot)MCl2]2 (M = Rh, 17 and M = Ir, 18). 
 
The complex 17 was obtained as a pure solid in good yield (85%). It was found to be 
particularly stable and could be stored under air without significant degradation. The 
successful synthesis of 17 through this route was applied to the synthesis of the biotinylated 
iridium dimer [(η5-Me4Cp-(CH2)2-N-Biot)IrCl2]2 18 (see Scheme 21). Unfortunately, synthesis 
of the analog dimeric iridium complex 18 displayed distinct differences. Reiner et al. 
described the reaction affording the μ-chloro bridged η5-cyclopentadienyl iridium homolog 
complex in poor yield (16 %, see Scheme 22).[161] They found the iridium dimer 23 had 
increased solubility in EtOH compared to the rhodium dimer 22 analog. Consequently the 
dimer 22 remained dissolved, leading to limited product recovery. 
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Scheme 22 Alternative synthesis for the preparation of [(η
5
-Me4Cp-(CH2)2NH3)IrCl2]2(Cl)2 23. 
 
An alternative synthesis to yield dimeric iridium complex 23 was developed, based on the 
work of Jaouen et al.[165] They described an efficient synthesis of [Cp*MCl2]2 complexes (M = 
Rh or Ir) in high yield (90%) involving the oxidation of MI to MIII with concentrated HCl. This 
method allowed the transformation of dimeric complex [IrCl(COD)]2 (COD = 1,5-
cyclooctadiene) in to [Cp*IrCl2]2. The protocol of Jaouen et al. was then adapted to perform 
the synthesis of dimer 23. To prevent coordination of the amine to the metal, the 
cyclopentadienyl precursor 21 was first protonated. Then [IrCl(COD)]2  was used instead of 
IrCl3•nH2O, in the presence of concentrated HCl. The presence of HCl was essential 
because the oxidation of the starting IrI proceeded by oxidative addition to give the 
intermediate [IrIIIHCl2(COD)]2. The iridium hydride generated in situ was allowed to react with 
the protonated amine derived from 21 to produce the iridium dimer 23 as a yellowish solid in 
60% yield (see Scheme 22). The dimeric iridium 23 was subjected to the same biotinylation 
protocol as the rhodium analog 22. The coupling reaction between the dimer 23 and BPFP 
yielded biotinylated iridium dimer 18 as a yellowish powder in 80% yield (see Scheme 21). 
The biotinylated complex was found to be highly stable against air.  
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3.3. Designing New Metalloenzymes  
 
3.3.1. Incorporation of Biotinylated Bidentate Catalysts into Streptavidin for the ATH of 
Imines 
 
3.3.1.1. Chemical Optimization 
 
With the dimeric biotinylated tethered-Cp* rhodium and iridium complexes 17 and 18 in hand, 
various bidentate chelating ligands were added to generate a small library of catalysts for 
further incorporation into Sav (see Figure 37). This new synthetic platform allowed fast 
chemical optimization to design artificial metalloenzymes that were tested in the transfer 
hydrogenation reaction.  
 
Figure 37 Biotinylated tethered-Cp* catalyst: a new synthetic platform for the generation of chemical 
diversity. 
 
Inspired by the work of Ogo et al. on the transfer hydrogenation using piano stool complexes 
bearing 2,2’-bipyridine bidentate ligands,[166] the biotinylated rhodium and iridium dimers 17 
and 18 were tested as precursors for the preparation of piano stool complexes bearing 
diimine ligands (see Scheme 23).[167]  
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Scheme 23 Synthesis of diverse biotinylated N,N-bidentate rhodium and iridium complexes 24-29. 
 
The biotinylated piano stool complexes 24-29 bearing diimine ligands were synthesized, 
isolated and characterized. The resulting biotinylated catalysts were incorporated into WT 
Sav and tested in the ATH of imines using the catalytic conditions described by Ogo et al. 
(see Scheme 24 and Table 3).[166] The reduction of 6,7-dimethoxy-1-methyl-3,4-
dihydroisoquinoline, the precursor of salsolidine 5, was selected as a model system (Scheme 
24). 
 
Scheme 24 Asymmetric transfer hydrogenation of imines for the production of salsolidine 5. 
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Table 3 Results for the production of salsolidine 5 using biotinylated piano stool complexes 
bearing diimine ligands.[a] 
Entry Complex Protein Conversion (%) ee (%) 
1 24 no quant. rac. 
2 25 no quant. rac. 
3 26 no quant. rac. 
4 27 no quant. rac. 
5 28 no quant. rac. 
6 29 no 52 rac. 
7 17 no 32 rac. 
8 18 no 43 rac. 
9 24 WT Sav -[b] n.d. 
10 25 WT Sav -[b] n.d. 
11 26 WT Sav 74 rac. 
12 27 WT Sav -[b] n.d. 
13 28 WT Sav 35 rac. 
14 29 WT Sav 23 rac. 
15 17 WT Sav -[b] n.d. 
16 18 WT Sav -[b] n.d. 
[a]
 Reactions were carried out at 25°C for 12 h using 1 mol% complex vs. substrate (680 μM final metal 
concentration, 68 mM substrate) and 0.33 mol% tetrameric WT Sav (corresponding to 916 μM biotin 
binding sites) at pH 5.0 containing 3.88 M of HCOONa in a total reaction volume of 200 μL. 
[b] 
Peaks 
were too small to determine conversion. 
 
The results demonstrated the high activity of the bipyridine-type complexes in the absence of 
protein: full conversion was observed after 12 h at 25°C. Interestingly, some catalysis 
experiments were inhibited in the presence of WT Sav (see Table 3, entries 9, 10, 12, 15 and 
16). Only the bulkier diimine catalysts exhibited promising activity when combined with WT 
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Sav (see Table 3, entries 11, 13 and 14). The best candidate was found to be the rhodium-
based catalyst 26 which bears 4,4’-dimethoxybipyridine ligand (74% yield, see Table 3, entry 
11). However, only racemic product was obtained in the presence of WT Sav.  
Encouraged by these results, we screened different complexes. For that purpose, the in situ 
preparation of biotinylated catalysts was tested. This method was exploited by Parekh et al. 
in ATH of quinolines using tethered RuII catalysts.[168] In order to verify the reliability of the 
method, parallel reactions were performed with biotinylated complex 26 and the in situ 
prepared catalyst 26-is (is = in situ formed, see Scheme 25 and Table 4). In parallel, a 
complex bearing N-tosylethylenediamine ligand (TsEN, catalyst 30, see Scheme 25 and 
Table 4) was also tested. Indeed, this ligand on the rhodium scaffold exhibits high conversion 
and ee for the enantioselective preparation of salsolidine by ATH.[160] The in situ method of 
preparation was the following: the precatalyst was generated in situ by reacting the bidentate 
ligand (from a stock solution in DMSO) with rhodium dimer 17 (from a stock solution in 
DMSO) at RT for 30 minutes. This in situ prepared catalyst was added to the protein, which 
was previously dissolved in a solution containing the hydride source, and stirred for 15 min. 
The ATH was initiated by adding the substrate. 
 
Scheme 25 In situ preparation of [(η
5
-Me4Cp-(CH2)2-N-Biot)Rh(4,4’-diMeObpy)Cl]Cl 26-is and [(η
5
-
Me4Cp-(CH2)2-N-Biot)Rh(TsEN)Cl] 30. 
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Table 4 Results for the production of salsolidine 5 using preformed and in situ prepared 
biotinylated piano stool complexes.[a] 
Entry Complex Protein Conversion (%) ee (%) 
1 26 no quant. rac. 
2 26-is no quant. rac. 
3 30[c] no 65 rac. 
4 17 no 32 rac. 
5 26 WT Sav 74 rac. 
6 26-is WT Sav 68 rac. 
7 30[c] WT Sav 70 rac. 
8 17 WT Sav -[b] n.d. 
[a]
 Reactions were carried out at 25°C for 12 h using 1 mol% complex vs. substrate (680 μM final metal 
concentration, 68 mM substrate) and 0.33 mol% tetrameric WT Sav (corresponding to 916 μM biotin 
binding sites) at pH 5.0 containing 3.88 M of HCOONa in a total reaction volume of 200 μL. 
[b] 
Peaks 
were too small to determine conversion. 
[c] 
pH 6.5 with MOPS buffer (3.1 M) and 3.88 M HCOONa 
were used for catalysis carried out with complex 30.
[160]
 
 
As expected, both preformed 26 and in situ prepared 26-is provided similar results (see 
Table 4, entries 1, 2, 5 and 6). These results constituted a first proof of principle: bidentate 
complexes formed in situ display comparable activity to that of pure isolated analogues. The 
metalloenzyme 30  WT Sav exhibited good activity but no enantioselectivity (70% yield, see 
Table 4, entry 7). The dimer 17 displayed modest activity alone (32% yield) and was inactive 
in the presence of WT Sav (see Table 4, entries 4 and 8). 
 
3.3.1.2. Genetic Optimization 
 
Encouraged by the results obtained with the catalysts prepared in situ, a genetic optimization 
was carried out. The complex 30 was selected as catalyst (see Table 5).  
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Table 5 Results for the production of salsolidine 5 using Sav-incorporated biotinylated piano 
stool complex 30.[a] 
Entry Complex Protein Conversion (%) ee (%) 
1 30 S112G 75 rac. 
2 30 S112A 28 rac. 
3 30 S112F 94 rac. 
4 30 S112K 70 rac. 
5 30 S112E 26 rac. 
6 30 S112R 42 rac. 
7 30 S112Y 95 rac. 
8 30 S112W quant. rac. 
9 30 S112H quant. 48 (S) 
10 30 P64G quant. rac. 
11 30 L124Y quant. rac. 
12 30 L124G quant. rac. 
13 30 L124H quant. rac. 
14 30 K121H quant. 65 (R) 
15 30 K121G 66 rac. 
16 30 K121N quant. rac. 
17 30 H87A 58 rac. 
18 30 H127A 54 rac. 
19 30 no 95 rac. 
20 17 no 18 rac. 
21 17 S112H 95 41 (S) 
22 17 K121H 95 60 (R) 
[a]
 Reactions were carried out at 55°C for 12 h using 1 mol% complex vs. substrate (680 μM final metal 
concentration, 68 mM substrate) and 0.33 mol% tetrameric Sav isoforms (corresponding to 916 μM 
biotin binding sites) at pH 6.5 (MOPS buffer 3.1 M) containing 3.88 M HCOONa in a total reaction 
volume of 200 μL. 
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Having identified a catalytically active hybrid catalyst 30  WT Sav (see Table 4, entry 7), we 
proceeded to optimize its performance by screening various Sav single point mutants. 
Aminosulfonamide-piano stool complex 30 was screened for the synthesis of salsolidine 5. In 
previous studies, positions S112, K121, P64 and L124 were identified as residues lying close 
to the organometallic moiety.[159, 169] 
We initially screened a focused library of Sav mutants S112X (X = A, G, F, K, E, R, Y, H and 
W, see Table 5, entries 1-9). In most cases, the conversions were good. Concerning 
enantioselectivity, salsolidine 5 was obtained in racemic form except for the S112H mutant 
that yielded (S)-salsolidine in 48% ee (see Table 5, entry 9). This fascinating result suggests 
that histidine at this position plays a critical role in enantioselection. Next, mutants at 
positions P64, K121 and L124 were tested in the presence of complex 30. Of all this second 
round of screening with Sav mutants, only K121H yielded significant levels of 
enantioselectivity (65% ee for the (R)-enantiomer of salsolidine 5, see Table 5, entry 14). To 
our delight 30  S112H and 30  K121H yielded opposite enantiomers. In contrast, 
introduction of a histidine residue at position 124 (L124H) afforded racemic material (see 
Table 4, entry 13). WT Sav possesses two solvent exposed histidine residues: H87 and 
H127. To test their potential influence on catalysis, both single point mutants H127A and 
H87A were tested in catalysis. These mutants produced racemic material but with a reduced 
conversion (see Table 5, entries 17 and 18). This result may suggest that these residues 
may bind to complex 30 albeit with a dangling biotin anchor. The Lewis basic properties of 
these His residues have been illustrated in the group in various X-ray characterizations: 
anomalous X-ray scattering, diagnostic of the presence of precious metals has been 
detected with Os,[170] Ir[160] as well as with Ru (unpublished). To test their involvement, it 
would be interesting to produce triple mutants Sav H87A-S112H-H127A and Sav H87A-
K121H-H127A. This would ensure that none of the biotinylated complex 30 is interacting with 
these surface exposed residues. Due to the difficulty of refolding the single point mutant 
H87A, these experiments remain to be performed. 
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As amply demonstrated, imine reduction by piano stool complexes proceeds without 
coordination of the substrate to the d6-transition metal: A single free coordination site at the 
metal is required for hydride generation (from formate) and delivery to one prochiral face of 
the imine. Considering that, the three-legged piano stool complex 30 bears a bidentate 
ligand, we speculated that, upon coordination of a histidine side-chain to the metal would 
create a catalytically inactive, coordinatively saturated, piano stool complex. To rationalize 
the observed results, we envisaged two possible mechanisms:  
i) The histidine does not bind to the piano stool complex, instead it interacts with the 
substrate, thus leaving a free coordination site available for catalysis.  
ii) Alternatively, the proximity of the histidine residue to the Rh center leads to a very high 
effective molarity of the Lewis basic residue, eventually displacing the bidentate 
aminosulfonamide ligand. 
To distinguish between these two alternative mechanisms, the dinuclear rhodium catalyst 
precursor 17 was tested in the presence of both histidine containing mutants Sav S112H and 
Sav K121H (see Table 5, entries 21 and 22). The results obtained with the catalyst derived 
from dinuclear complex 17 (which is expected to break down in solution to yield the 
corresponding solvated mononuclear complex) were very similar to those obtained with 
complex 30: Compare 65 % ee (R) and 48 % ee (S) for 30  K121H and 30  S112H with 60 
% ee (R) and 41 % ee (S) for 17  K121H and 17  S112H respectively. These results 
suggest that the bidentate ligand may indeed be displaced by the close-lying histidine 
residue. 
Overall, the mutants S112H and K121H provided a suitable chiral environment to rhodium 
catalysts which lead to enantioselective reduction of the salsolidine precursor. Next, the 
metalloenzymes consisting of the incorporation of biotinylated Rh-complexes with bidentate 
ligands into Sav isoforms were screened against more challenging enantioselective 
reactions, such as reductive amination for the preparation of unprotected chiral α-amino 
acids (see Chapter 4). 
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3.3.2. Towards New Artificial Transfer Hydrogenases: Dual Anchoring Strategy 
 
3.3.2.1. Incorporation of the Rhodium Dimer 17 into S112H and K121H: Docking 
Studies 
 
We have highlighted that combination of dimer 17 and proteins bearing histidine mutants at 
position 112 and 121 may form active artificial metalloenzymes in ATH. In order to obtain a 
qualitative model of these hybrid catalysts, in silico studies were carried out. The combination 
of dimer 17 with selected host proteins and its capacity to form dually-anchored (dative and 
supramolecular) artificial metalloenzymes was then tested. Docking experiments were 
carried out by Maurus Schmid using the VMD program: the biotinylated rhodium monomer 
[η5-Me4Cp-(CH2)2-N-Biot)RhCl2(H2O)] 17’ embedded into S112H (see Scheme 26 and Figure 
38) and K121H (see Scheme 26 and Figure 39). 
 
Scheme 26 Anticipated biotinylated rhodium monomer (17’ derived from 17) embedded into S112H or 
K121H host proteins. 
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Figure 38 Docking simulation of biotinylated complex 17’ in S112H host protein. 
 
Figure 39 Docking simulation of biotinylated complex 17’ in K121H host protein. 
 
Docking experiments suggested an ideal spacer length for the incorporation of biotinylated 
complex 17’ into S112H and K121H Sav mutants. The ethylene spacer between the biotin 
S112H
K121
S112
K121H
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anchor and the Cp*, places the metal in close proximity to histidines either at position 112 or 
121 in mutants S112H or K121H respectively. 
 
3.3.2.2. Artificial Metalloenzymes 17’  S112H and 17’  K121H for ATH of Imines  
 
3.3.2.2.1 Chemo-Genetic Optimization 
 
In order to confirm the importance of histidines residues at position 112 and 121 in the 
formation of metalloenzymes, 17’  S112H and 17’  K121H, catalysis experiments were 
performed using proteins bearing a possible dative anchoring site (Lewis basic residues, see 
Table 6). 
 
Table 6 Results for the production of salsolidine 5 using biotinylated piano stool rhodium 
complex 17’ and proteins with a possible dative anchor.[a] 
Entry Complex Protein Conversion (%) ee (%) 
1 17 no 31 rac. 
2 17’ WT Sav 15 rac. 
3 17’ S112H 95 41 (S) 
4 17’ K121H 95 60 (R) 
5 17’ L124H 67 rac. 
6 17’ S112C 12 rac. 
[a]
 Reactions were carried out at 55°C for 12 h using 2 mol% complex vs. substrate (680 μM final metal 
concentration, 34 mM substrate) and 0.66 mol% tetrameric Sav isoforms (corresponding to 916 μM 
biotin binding sites) at pH 6.5 (MOPS buffer 3.1 M) with 3.88 M HCOONa in a total reaction volume of 
200 μL. 
 
The catalysis experiments carried out with WT Sav, L124H and S112C as hosts exhibited 
modest activity and no enantioselectivity (see Table 6, entries 2, 5 and 6). As expected, the 
catalysis experiments carried out with rhodium dimer 17 in the absence of protein provided 
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racemic product, in low yield (see Table 6, entry 1). The latter result highlighted the 
importance of metal/imidazole coordination in the activation of the catalyst. The study 
corroborated the docking experiments and supported the crucial role of bound histidines in 
ATH of imines: the protein scaffold simultaneously provided the first and second coordination 
sphere contacts to the catalyst affording new active and enantioselective artificial 
metalloenzymes. 
 
3.3.2.2.1.1. pH Optimization 
 
The influence of pH was tested using hybrid catalysts 17’  S112H and 17’  K121H; 
reactions were performed with HCOONa in non-buffered solutions (see Figure 40).  
  
Figure 40 Influence of pH on ee and conversion using hybrid catalysts a) 17’  S112H and b) 17’  
K121H. For experimental details, see experimental part on Table 6. 
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As expected, the pH influenced the reaction outcome: increasing the pH from 5.0 to 8.0 
resulted in a decrease of both the conversion and the enantioselectivity. The best results in 
terms of activity and enantioselectivity were obtained when catalysis experiments were 
carried out at pH 5.0, in unbuffered solutions: the metalloenzyme 17’  S112H yielded (S)-
salsolidine in 86% yield with 45% ee (see Figure 40a) and 17’  K121H afforded (R)-
salsolidine in 98% yield with 66% ee (see Figure 40b). 
 
3.3.2.2.1.2. Buffer Optimization  
 
In order to further examine the pH influence during the reaction, different buffers were tested 
at pH 5.0 and 5.5 (acetate, citric acid, MES, MOPS, see Table 7). 
 
Table 7 Influence of buffer composition on ee and conversion using hybrid catalysts 17’  
S112H and 17’  K121H at pH 5.0 and 5.5.[a] 
Entry Complexes Buffer pH Protein Conversion (%) ee (%) 
1 17’ acetate 5.0 S112H 36 32 (S) 
2 17’ acetate 5.5 S112H 32 28 (S) 
3 17’ citric acid 5.0 S112H 60 40 (S) 
4 17’ citric acid 5.5 S112H 60 38 (S) 
5 17’ MES 5.0 S112H 83 38 (S) 
6 17’ MES 5.5 S112H 86 40 (S) 
7 17’ MOPS 5.0 S112H quant. 55 (S) 
8 17’ MOPS 5.5 S112H quant. 53 (S) 
9 17’ acetate 5.0 K121H 37 50 (R) 
10 17’ acetate 5.5 K121H 37 50 (R) 
11 17’ citric acid 5.0 K121H quant. 65 (R) 
12 17’ citric acid 5.5 K121H quant. 64 (R) 
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13 17’ MES 5.0 K121H quant. 69 (R) 
14 17’ MES 5.5 K121H quant. 67 (R) 
15 17’ MOPS 5.0 K121H quant. 72 (R) 
16 17’ MOPS 5.5 K121H quant. 70 (R) 
[a] 
Reactions were carried out at 55°C for 12 h using 2 mol% complex vs. substrate (680 μM final metal 
concentration, 34 mM substrate) and 0.66 mol % tetrameric Sav (corresponding to 916 μM biotin 
binding sites) with 3.88 M HCOONa in a total reaction volume of 200 μL. Reactions were carried out 
with acetate, citric acid, MES and MOPS (2 M). 
 
The catalysis experiments carried out with MOPS as a buffer provided the best results 
regarding conversion and enantioselectivity: (S)-salsolidine was produced quantitatively in 
55% ee with 17’  S112H while 17’  K121H quantitatively yielded the (R)-enantiomer in 
72% ee (see Table 7, entries 7 and 15). The results suggested that MOPS played an 
important role in determining the enantioselectivity. Recently, Chan et al. reported the 
participation of the sulfonic group of TfO- via a possible 10-membered transition state during 
the enantioselective hydrogenation of quinolines.[171] In a similar fashion, the sulfonic group of 
MOPS could be involved in the transition state of the proton transfer to the amine of 
salsolidine: MOPS could provide the proton to the amine and form the iminium intermediate 
prior to transfer hydrogenation (see the mechanism proposed by Wills on Figure 7c).[84] 
In order to further study the influence of MOPS, catalysis experiments with varying 
concentrations of buffer were run at pH 5.0. For that purpose, the concentration of formate 
was kept constant while MOPS concentration was varied from 0.36 M to 2.9 M (see Figure 
41). 
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Figure 41 Influence of MOPS-concentration at pH 5.0 on ee and conversion using hybrid catalysts a) 
17’  S112H and b) 17’  K121H. For experimental details, see experimental part on Table 7. 
 
The variation in buffer concentration experiments demonstrated that MOPS has a greater 
influence on hybrid catalyst 17’  S112H than on metalloenzyme 17’  K121H. The hybrid 
catalyst 17’  S112H displayed a dramatic decrease in activity and selectivity at MOPS 
concentrations lower than 1.55 M and 0.78 M respectively (see Figure 41a). In contrast the 
metalloenzyme 17’  K121H exhibited high activity and constant enantioselectivity in all 
reactions performed (see Figure 41b). In order to avoid any deleterious influence of MOPS 
during catalysis experiments, reactions were carried out with a concentrated MOPS solution 
(3.10 M). 
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3.3.2.2.1.3. Temperature Optimization 
 
The influence of temperature on catalytic performance of the artificial metalloenzymes was 
tested. Reactions were carried out at different temperatures (5°C, 25°C, 37°C and 55°C) for 
a period of 12 h using the previously optimized catalytic conditions (see Table 8). 
 
Table 8 Temperature optimization using hybrid catalysts 17’  S112H and 17’  K121H.[a] 
Entry Complexes Temperature (°C) Protein Conversion (%) ee (%) 
1 17’ 5 S112H 5 45 (S) 
2 17’ 25 S112H 85 52 (S) 
3 17’ 37 S112H 90 53 (S) 
4 17’ 55 S112H quant. 55 (S) 
5 17’ 5 K121H 5 50 (R) 
6 17’ 25 K121H 25 50 (R) 
7 17’ 37 K121H 50 48 (R) 
8 17’ 55 K121H quant. 67 (R) 
[a]
 Reactions were carried out for 12 h at pH 5.0 using 2 mol% complex vs. substrate (680 μM final 
metal concentration, 34 mM substrate) and 0.66 mol % tetrameric Sav (corresponding to 916 μM 
biotin binding sites) with 3.88 M HCOONa and 3.1 M MOPS in a total reaction volume of 200 μL. 
 
Temperature is known to play a major role in the reaction outcome and particularly in the 
enantioselectivity. Previous work in the Ward group confirmed that selectivity could be 
increased in imine reduction by lowering the temperature from 55°C to 5°C.[160] 
Unexpectedly, a drop in ee was observed at lower temperatures, accompanied by a 
decrease in catalytic capacity (see Table 8, entries 1 and 5). These unexpected results 
suggested that there is a pre-equilibrium between the substrate and the catalyst (second 
coordination sphere provided by the protein), also called "Curtin-Hammet conditions". In our 
case decreasing the temperature would mean that the equilibrium will be pushed further 
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towards the less stable diastereomer which reacts faster with the hydridic metal. After 12 
hours, both metalloenzymes 17’  S112H and 17’  K121H displayed the best results for 
reactions carried out at 55°C (see Table 8, entries 4 and 8). Consequently, 55°C was 
selected in subsequent investigations. 
 
3.3.2.2.1.4. Metal/Active Site Ratio Investigations 
 
Previous investigations demonstrated that histidine was able to activate the catalyst 
presumably via dative anchoring of the biotinylated complex. In order to confirm this trend, 
increasing amounts of biotinylated catalyst 17’ were added to the host protein (see Figure 
42).  
  
Figure 42 Metal/active site ratio using hybrid catalysts a) 17’  S112H and b) 17’  K121H. For 
experimental details see experimental part on Table 8. 
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The best metal/active site ratio for the hybrid catalyst 17’  S112H was observed at 0.75: 
quantitative production of (S)-salsolidine with 60% ee. On the other hand, the metalloenzyme 
17’  K121H exhibited the highest conversions and enantioselectivities when the 
metal/active site ratio was at 0.50 equivalent: full conversion and 79% ee in favor of the (R)-
enantiomer were obtained. Previous work conducted in the Ward group concerning 
metal/active site ratios demonstrated that an excess of metal vs. biotin binding site led to a 
decrease in enantioselectivity.[160] Interestingly, the experiments performed with the new 
artificial metalloenzymes did not exhibit such a trend. The fact that the rhodium dimer 17 
displayed remarkably low activity in ATH of imine (see Table 6, entry 1) may account for this 
result. This study reinforced the hypothesis that the catalyst is activated by the protein (dative 
anchoring with histidine residues) to successfully perform imine reduction. The same trend 
was observed by Roelfes et al. in the DNA-based catalytic enantioselective Michael addition 
and Friedel-Crafts alkylation reaction.[172]  
These results augur well for the implementation of direct evolution protocols with artificial 
metalloenzymes. Indeed, the phenomenon of protein accelerated catalysis highlighted herein 
may allow a more straightforward screening, as the amount of protein will not have to be 
determined precisely.  
 
3.3.2.2.1.5. Loading Optimization  
 
In order to study the catalyst performance of both metalloenzymes 17’  S112H and 17’  
K121H, loading of the metal complex was varied by keeping the concentration of salsolidine 
precursor constant. Reactions were carried out with the best metal/active site ratios of each 
protein (see Table 9). 
  
Asymmetric Transfer Hydrogenation of Imines           92 
Table 9 Loading optimization using hybrid catalysts 17’  S112H and 17’  K121H keeping 
the substrate concentration constant[a] 
Entry Complexes Loading 
(%) 
Complex concentration 
(mM) 
Protein Conversion 
(%) 
ee (%) 
1 17’ 1 0.68 S112H quant. 59 (S) 
2 17’ 0.1 0.068 S112H 17 56 (S) 
3 17’ 0.01 0.0068 S112H 2 42 (S) 
4 17’ 1 0.458 K121H quant. 79 (R) 
5 17’ 0.1 0.0458 K121H 24 77 (R) 
6 17’ 0.01 0.00458 K121H 4 56 (R) 
[a] 
Reactions were carried out at 55°C for 12 h at pH 5.0 using a fixed salsolidine precursor 
concentration (68 mM with 17’  S112H and 45.8 mM with 17’  K121H) with MOPS buffer (3.1 M) 
containing 3.88 M HCOONa in a total reaction volume of 200 μL. 
 
The study allowed to determine the TON and TOF of artificial metalloenzymes. The hybrid 
catalyst 17’  S112H yielded (S)-enantiomer with up to 170 TONs and 56% ee while the 
metalloenzyme 17’  K121H provided the (R)-enantiomer with up to 240 TONs and 77% ee. 
However, low TOFs were observed: the catalyst 17’  K121H exhibited TOFs of 20 h-1 and 
the metalloenzyme 17’  S112H demonstrated TOFs of 14 h-1. 
 
3.4. Conclusion 
 
In summary, a new synthetic platform for fast chemical optimization of biotinylated catalysts 
was implemented. Embedding of such metal cofactors within streptavidin mutants led to the 
creation of new active artificial metalloenzymes for the ATH of cyclic imines (production of 
salsolidine 5). Furthermore, in silico investigations allowed the design of a novel type of 
metal catalyst/protein assembly in which both supramolecular and dative anchoring are 
involved. Both (S)- and (R)-enantiomers could be obtained with the same metal complex 
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depending on the host protein employed. Indeed, the metalloenzyme consisting of the 
incorporation of dimer 17 into K121H provided (R)-salsolidine with up to 240 TONs and 
remarkable enantioselectivity (77% ee). The complementary metalloenzyme, 17’  S112H 
yielded (S)-product with up to 170 TONs, and promising enantioselectivity (56% ee). The 
importance of MOPS in ATH reactions was highlighted (see Table 7 and Figure 41).[171] A 
crystal structure of hybrid catalysts 17’  S112H and 17’  K121H would allow to rationalize 
the catalytic results and to provide clues for further sites of mutations to improve the 
performance of these artificial metalloenzymes. 
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4. Non-enzymatic Reductive Amination of α-Keto Acids for the Enantioselective 
Synthesis of Unprotected α-Amino Acids in Water  
 
4.1. Introduction 
 
The aim of this chapter is to test the two different approaches to create new artificial 
metalloenzymes in the challenging reductive amination of α-keto acids. Reductive amination 
has recently emerged as an interesting water compatible process for the straightforward 
synthesis of unprotected α-amino acids. Indeed, in 2004 Fukuzumi and coworkers reported 
on the synthesis of α-amino acids catalyzed by bipyridine iridium complexes using 
NH4COOH as an amine and hydrogen source (see Scheme 27). This pioneering work forms 
the basis of this project.[173]  
 
Scheme 27 Reductive amination of α-keto acids for the synthesis of racemic α-amino acids. 
The two promising artificial metalloenzymes consisting of i) combination of functionalized 
piano stool complexes associated with bidentate ligands (see Figure 43a) or ii) hybrid 
catalysts 17’  Sav S112H and 17’  Sav K121H (see Figure 43b) were investigated as 
catalysts for the synthesis of natural (phenylalanine) and unnatural (phenylglycine) α-amino 
acids. 
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Figure 43 Artificial Metalloenzymes used for the reductive amination of α-keto acids. 
 
4.2. New Artificial Metalloenzymes for the Enantioselective Synthesis of α-Amino 
Acids in Water 
 
4.2.1. Dually-Anchored Rhodium Complex 17’ into Streptavidin for the Production of α-
Amino Acids 
 
The metalloenzymes resulting from the incorporation of dimer 17 either into S112H or K121H 
were investigated as catalysts in reductive amination reaction. For that purpose, the 
formation of phenylalanine 34 was selected as model (see Scheme 28).  
 
Scheme 28 Enantioselective synthesis of α-phenylalanine 34 via reductive amination. 
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Fukuzumi and coworkers developed acid-stable bipyridyl iridium complexes for the 
chemoselective preparation of α-AAs and reported that pH had a strong influence on the 
chemoselectivity of catalyst (see Scheme 27).[173] Therefore, the influence of pH on the 
metalloenzyme was investigated by performing the catalysis experiments with increasing pH 
(from 5.0 to 9.0). In this initial study, only chemoselectivity was investigated (see Figure 44). 
 
Figure 44 pH-dependent chemoselective formation of phenylalanine 34 with a) 17’  S112H and b) 
17’  K121H. Reactions were carried out at 55°C for 12 h with 1 mol% complex vs. substrate: 680 μM 
final metal concentration and 68 mM substrate with 0.33 mol% tetrameric S112H (corresponding to 
916 μM biotin binding sites) or 458 μM final metal concentration 45.8 mM substrate, with 0.50 mol% 
tetrameric K121H (corresponding to 916 μM biotin binding sites), with 4.90 M NH4COOH in a total 
reaction volume of 200 μL. 
 
Both metalloenzymes exhibited high conversion and chemoselectivity for the production of 
phenylalanine 34. In contrast to the work reported by Fukuzumi and coworkers,[173] the 
results highlighted the modest influence of pH on the outcome of the reaction. Encouraged 
by the catalytic activity demonstrated by artificial metalloenzymes 17’  S112H and 17’  
K121H, the enantioselective reductive amination of phenylpyruvic acid was investigated next. 
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4.2.2. Catalytic Activity of Artificial Metalloenzymes as Catalyst for the Synthesis of 
Enantiopure Phenylalanine 
 
4.2.2.1. pH Optimization 
 
The pH dependence of both artificial metalloenzymes 17’  S112H and 17’  K121H 
towards the synthesis of phenylalanine 34 was investigated and the results are summarized 
in Table 10.  
 
Table 10 Influence of pH on the synthesis of phenylalanine 34 with hybrid catalysts 17’  
S112H and 17’  K121H.[a] 
Entry Metalloenzyme pH Conversion (%) Yield (%) Selectivity (%) ee (%) 
1 17’  S112H 5 quant. 84 84 rac. 
2 17’  S112H 6 quant. 90 90 rac. 
3 17’  S112H 7 quant. 89 89 rac. 
4 17’  S112H 8 quant. 87 87 rac. 
5 17’  S112H 9 quant. 90 90 rac. 
6 17’  K121H 5 quant. 89 89 13 (S) 
7 17’  K121H 6 quant. 92 92 13 (S) 
8 17’  K121H 7 quant. 92 92 18 (S) 
9 17’  K121H 8 quant. 91 91 24 (S) 
10 17’  K121H 9 quant. 93 93 13 (S) 
[a] 
Reactions were carried out at 55°C for 12 h using 1 mol% complex vs. substrate: 680 μM final metal 
concentration, 68 mM substrate and 0.33 mol% tetrameric S112H (corresponding to 916 μM biotin 
binding sites) or 458 μM final metal concentration, 45.8 mM substrate and 0.50 mol% tetrameric 
K121H (corresponding to 916 μM biotin binding sites) with 4.90 M NH4COOH in a total reaction 
volume of 200 μL. 
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The results suggest that the pH does not influence either the activity or the selectivity of 
either 17’  S112H or 17’  K121H in the reductive amination of phenylpyruvic acid 33. 
However, the enantioselectivity of the reductive amination of 33 was found to be pH-
dependent: while hybrid catalyst 17’  S112H yielded racemic mixtures, the metalloenzyme 
17’  K121H yielded (S)-phenylalanine in modest enantioselectivity. Subsequently, further 
investigations were conducted with hybrid catalyst 17’  K121H. 
 
4.2.2.2. Temperature Optimization 
 
Our previous work demonstrated that temperature had a strong influence on the outcome of 
the ATH reaction: lowering the temperature lead to a decrease of the enantioselectivity of 
imine reduction. The results for the reductive amination using hybrid catalyst 17’  K121H at 
different temperatures (5°C, 25°C, 37°C and 55°C) are summarized in Table 11. 
 
Table 11 Temperature optimization with hybrid catalyst 17’  K121H.[a] 
Entry Temperature (°C) Conversion (%) Yield (%) Selectivity (%) ee (%) 
1 5 5 5 -[b] 32 (S) 
2 25 7 5 -[b] 21 (S) 
3 37 10 10 -[b] 18 (S) 
4 55 quant. 93 93 22 (S) 
[a]
 Reactions were carried out at pH 8.0 for 12 h with 1 mol% complex vs. substrate (458 μM final 
metal concentration, 45.8 mM substrate and 0.50 mol% tetrameric K121H (corresponding to 916 μM 
biotin binding sites) with 4.90 M NH4COOH in a total reaction volume of 200 μL. 
[b] 
Peaks were too 
small to determine selectivity. 
 
The temperature had a strong influence on the activity of the metalloenzyme 17’  K121H: a 
dramatic decrease in conversion was observed upon lowering the temperature (see Table 
11, entry 1). However, the enantioselectivity increased upon lowering the temperature to 5°C 
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(32% ee for (S)-Phe, see Table 11, entry 1). Unfortunately, prolonging the reaction time to 96 
h did not increase significantly the yield.  
 
4.2.2.3. Catalyst Loading 
 
In order to gain a better insight in the catalytic performance of 17’  K121H, loading of the 
metal complex was varied, keeping the concentration of phenylpyruvic acid 33 constant. The 
TON of the artificial metalloenzyme was then determined at two different temperatures (5°C 
see Table 12 and 55°C, see Table 13). 
 
Table 12 Results of loading investigation of the hybrid catalyst 17’  K121H at 5°C.[a] 
Entry Loading 
(%) 
Complex 
concentration (mM) 
Conversion 
(%) 
Yield 
(%) 
Selectivity 
(%) 
ee (%) 
1 2 0.916 28 28 quant. 43 (S) 
2 1 0.458 8 8 quant. 39 (S) 
3 0.5 0.229 2 2 -[b] 31 (S) 
4 0.1 0.0458 <1 <1 -
[b] 20 (S) 
[a] 
Reactions were carried out at 5°C for 96 h at pH 8.0 using fixed substrate concentration (45.8 mM 
with 0.50 mol% tetrameric K121H) with 4.90 M NH4COOH in a total reaction volume of 200 μL. 
[b] 
Peaks were too small to determine selectivity. 
 
The study clearly highlighted the modest catalytic performance of the artificial metalloenzyme 
17’  K121 in the reductive amination of phenylpyruvic acid 33 at 5°C: only 14 turnovers 
were achieved after 96 h of reaction with a substrate/metal ratio of 50/1 (see Table 12, entry 
1). 
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Table 13 Results of loading investigation of the hybrid catalyst 17’  K121H at 55°C.[a] 
Entry Loading 
(%) 
Complex 
concentration (mM) 
Conversion 
(%) 
Yield 
(%) 
Selectivity 
(%) 
ee (%) 
1 2 0.916 quant. 90 90 24 (S) 
2 1 0.458 quant. 92 92 19 (S) 
3 0.5 0.229 24 24 -[b] rac. 
4 0.1 0.0458 17 17 -[b] rac. 
[a]
 Reactions were carried out at pH 8.0 for 12 h using fixed substrate concentration (45.8 mM with 
0.50 mol% tetrameric K121H) with 4.90 M NH4COOH in a total reaction volume of 200 μL. 
[b] 
Peaks 
were too small to determine selectivity. 
 
The study demonstrated the promising activity for the production of phenylalanine 34 with the 
artificial metalloenzyme 17’  K121 at 55°C: the (S)-enantiomer was obtained with up to 45 
TONs and 24% ee. 
 
4.2.2.4. Genetic Optimization 
 
With the aim of gaining structural insight into the artificial transfer hydrogenases, in silico 
investigations were carried out by Maurus Schmid. Guided by previous docking experiments 
(see Chapter 3) and based on the work of Reetz et al. on directed evolution of 
enantioselective hybrid catalysts,[174] position 110 was selected for a second round of genetic 
optimization. Indeed, qualitative inspection of the docked complex 17’ inside K121H 
suggested that position 110 was close-lying to the metal center (see Figure 45). 
Subsequently, the double mutants, K121H-L110X were selected for production. The proteins 
were produced with the "small-scale purification” method (SSP, work carried out by Elisa 
Nogueira). The catalysis experiments performed with double mutants involving K121H-
L110X are summarized in Table 14. The double mutant K121H-S112H was also tested. 
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Figure 45 Model of the biotinylated rhodium catalyst 17’ embedded into K121H host protein. Residue 
110 is highlighted in red. 
 
Table 14 Results for the preparation of phenylalanine 34 using hybrid catalysts 17’  K121H-
L110X.[a], [b] 
Entry Protein[d] Protein 
concentration (μM) 
Conversion 
(%) 
Yield 
(%) 
Selectivity 
(%) 
ee (%) 
1 K121H-L110A 110 86 73 85 rac. 
2 K121H-L110E 180 83 68 82 rac. 
3 K121H-L110K 215 84 68 81 rac. 
4 K121H-L110D 50 60 44 74 rac. 
5 K121H-L110C 90 91 82 90 25 (S) 
6 K121H-S112H 105 quant. 82 82 rac. 
[a] 
Reactions were carried out at 55°C for 12 h at pH 8.0 with 2 mol% complex vs. substrate (1 mol% 
tetrameric Sav isoforms) with 4.90 M NH4COOH in a total reaction volume of 200 μL. 
[d] 
Proteins 
obtained from the SSP protocol. 
 
a
b
K121H
L110
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The catalysis experiments carried out with the different double mutants yielded modest to 
good conversions and only the hybrid catalyst 17’  K121H-L110C yielded (S)-phenylalanine 
with 25% ee (see Table 14, entry 5). Interestingly, the metalloenzyme 17’  K121H-S112H 
yielded racemic phenylananie 34 (see Table 14, entry 6). This result could be explained by 
the possible coordination of the metal by the two histidine residues.  
This screening effort led to the identification of a new active artificial metalloenzyme: 17’  
K121H-L110C. Subsequently, production and isolation of pure protein, K121H-L110C was 
performed by Elisa Nogueira. With large amounts of this double mutant, catalysis 
experiments were performed at two different temperatures (5°C and 55°C, see Table 15). 
 
Table 15 Comparison of hybrid catalysts bearing single and double mutants.[a], [c] 
Entry Protein Temperature 
(°C) 
Conversion 
(%) 
Yield (%) Selectivity 
(%) 
ee (%) 
1 K121H-L110C[d] 55[e] 91 82 90 25 (S) 
2 K121H-L110C 55[e] quant. 97 97 24 (S) 
3 K121H 55[e] quant. 90 90 24 (S) 
4 K121H-L110C 5[f] 74 74 quant. 30 (S) 
5 K121H 5[f] 28 28 quant. 43 (S) 
[a]
 Reactions were carried out at pH 8 with 2 mol% complex (458 μM final metal concentration, 1 mol% 
tetrameric Sav isoforms), with 4.90 M NH4COOH in a total reaction volume of 200 μL. 
[d] 
Proteins 
obtained from the SSP protocol. 
[e] 
Reactions were carried out for 12 h. 
[f] 
Reactions were carried out 
for 96h. 
 
The catalysis experiments using the pure protein K121H-L110C demonstrated that the 
metalloenzyme 17’  K121H-L110C was able to nearly quantitatively produce (S)-Phe in 
24% ee at 55°C (see Table 15, entry 2). The latter result confirmed the trend observed with 
K121H-L110C produced with the SSP method (see Table 15, entry 1), thus supporting the 
reliability of the method. Moreover, increased activity was observed with 17’  K121H-L110C 
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when compared to 17’  K121H (see Table 15, entries 2, 3, 4 and 5). However, 17’  K121H 
displayed better enantioselectivity at 5°C than the double mutant (see Table 15, entries 4 
and 5). Although the selectivity of the double mutant was slightly lower than that of single 
mutant, its activity at 5°C was markedly higher, thus highlighting the importance of both first 
and second coordination sphere contacts in determining both the activity and the selectivity 
of artificial metalloenzymes.  
 
4.2.2.5. Towards the Enantioselective Synthesis of Unnatural Amino Acid (uAA) 
Catalyzed by 17’  K121H 
 
The metalloenzyme 17’  K121H was investigated for its capacity to perform reductive 
amination of benzoylformic acid 36 to yield phenylglycine 37 (PhGly, see Scheme 29). This 
unnatural amino acid was selected because it represents an important component in 
marketed drugs.[175] 
 
Scheme 29 Reductive amination of benzoylformic acid 36. 
 
The hybrid catalyst 17’  K121H displayed low activity for the preparation of phenylglycine 
37 at 55°C (2% loading, 19% yield). However, interesting enantioselectivity was observed: 
the phenylglycine was formed with 25% ee in favor of the (R)-enantiomer. This result 
highlighted the versatility of catalyst 17’  K121H to transform different α-keto acid into non-
natural amino acids.  
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4.2.3. Incorporation of Biotinylated Bidentate Catalysts into Streptavidin for the 
Enantioselective Synthesis of α-Amino Acids 
 
4.2.3.1. Ethylenediamine Rhodium and Iridium Catalysts 
 
With the aim of creating novel active and enantioselective metalloenzymes in reductive 
amination, the incorporation of biotinylated catalyst bearing bidentate ligands into a Sav host 
protein was investigated. The catalysis experiments were carried out with in situ prepared 
rhodium 31 and iridium 32 complexes (see Figure 46) for the synthesis of phenylglycine. The 
resulting piano stool complexes were combined with Sav mutants (WT Sav, P64G-L124V, 
V47G, S112A) that were selected based on previous work in the Ward group (see Table 
16).[160, 169, 176] 
  
Figure 46 In situ prepared Rh and Ir biotinylated catalysts bearing ethylenediamine ligand 31 and 32. 
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Table 16 Results for the synthesis of phenylglycine 37 using hybrid catalyst involving in situ 
prepared rhodium 31 and iridium 32 complexes [a] 
Entry Complex Protein Conversion (%) Yield (%) Selectivity (%) ee (%) 
1 31 no 56 13 24 rac. 
2 31 WT Sav 8 1 14 rac. 
3 31 S112A 13 3 27 rac. 
4 31 V47G 5 5 -[b] rac. 
5 31 P64G-L124V quant. 24 24 26 (S) 
6 32 no 16 7 43 rac. 
7 32 WT Sav 6 2 34 rac. 
8 32 S112A 3 3 -[b] rac. 
9 32 V47G 12 12 -[b] rac. 
10 32 P64G-L124V 76 27 35 29 (S) 
[a]
 Reactions were carried out at 55°C for 12 h at pH 8.0 with 2 mol% complex vs. substrate: 458 μM 
final metal concentration, 22.9 mM substrate and 1 mol% tetrameric Sav (corresponding to 916 μM 
biotin binding sites), with 4.90 M NH4COOH in a total reaction volume of 200 μL. 
[b] 
Peaks were too 
small to determine selectivity. 
 
The screening of four Sav isoforms lead to the identification of P64G-L124V as a potential 
host protein for both ethylenediamine rhodium complex 31 (24% yield and 26% ee for the 
(S)-enantiomer) and iridium complex 32 (27% yield and 29% ee for the (S)-enantiomer). 
 
4.2.3.2. Chemical Optimization 
 
Encouraged by the results obtained with both metalloenzymes 31  P64G-L124V and 32  
P64G-L124V, different bidentate ligands (depicted in Figure 47) were screened. The results 
are summarized in Table 17. 
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Figure 47 Bidentate ligands selected for the chemical optimization. 
 
Table 17 Screening of bidentate ligands with 17 and 18 for the synthesis of phenylglycine 37 
in the presence of P64G-L124V.[a] 
Entry Complex Ligand Conversion (%) Yield (%) Selectivity (%) ee (%) 
1 17 Phen 4 4 quant. 16 (S) 
2 17 Bpy 3 3 quant. 9 (S) 
3 17 MeObpy 10 1 10 rac. 
4 17 Pycarb 25 9 38 rac. 
5 17 Pico quant. 17 17 16 (S) 
6 17 iPrEN 60 11 19 rac. 
7 17 GlyAm quant. 16 16 rac. 
8 17 AmOH quant. 17 17 10 (S) 
9 18 Phen 3 <1 31 6 (S) 
10 18 Bpy 5 1 24 10 (S) 
11 18 MeObpy 10 5 50 rac. 
12 18 Pycarb 25 9 38 rac. 
13 18 Pico quant. 7 7 15 (S) 
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14 18 iPrEN 2 <1 11 7 (S) 
15 18 GlyAm 54 6 10 rac. 
16 18 AmOH 37 3 7 rac 
[a]
 Reactions were carried out at 55°C for 12 h at pH 8.0 with 2 mol% complex: 458 μM final metal 
concentration, 22.9 mM substrate and 1 mol% tetrameric Sav (corresponding to 916 μM biotin binding 
sites), with 4.90 M NH4COOH in a total reaction volume of 200 μL. 
 
The results highlighted the poor performance of the artificial metalloenzymes towards the 
synthesis of phenylglycine 37. The best enantioselectivity was observed for catalysis 
experiments carried out with hybrid catalysts combining Phen-17, Pico-17 and Pico-18 (see 
Table 17, entries 1, 5 and 13). The rhodium complex 17 bearing the picolylamine ligand was 
found to be the only bidentate complex capable of both quantitatively transforming 
benzoylformic acid 36 and providing interesting enantioselectivity (see Table 17, entries 5). 
However, very low yield for the desired α-uAA was observed. Indeed, the major product 
obtained was the corresponding α-hydroxy acid (mandelic acid 38), suggesting that the 
ketone reduction is favored over the reductive amination for this substrate (see Scheme 30). 
 
Scheme 30 Ketone reduction faster than imine reduction for the reductive amination of benzoylformic 
acid 36. 
 
The results highlighted the importance of the first coordination sphere: only the smallest 
ligand ethylenediamine was able to provide interesting yield and ee. This focused chemical 
screening of ligand did not allow identification of an additional catalyst for the reductive 
amination reaction.  
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4.2.3.3. Genetic Optimization 
 
In order to improve the ee and the conversion in reductive amination of benzoylformic acid 
36, genetic optimization was performed using the rhodium complex bearing an additional 
bidentate ligand 31. To confirm that both mutations in P64G-L124V were important, catalysis 
experiments using single mutants P64G and L124V Sav were performed. In addition, single 
mutants bearing neutral alkyl side chain such as L124G, L124A and L124F were also 
investigated (see Table 18). 
 
Table 18 Influence of neutral alkyl side chain at position P64 and L124 for the synthesis of 
phenylglycine 37 using complex 31.[a] 
Entry Complex Protein Conversion (%) Yield (%) Selectivity (%) ee (%) 
1 31 P64G-L124V quant. 24 24 26 (S) 
2 31 P64G quant. 25 25 rac. 
3 31 L124V quant. 6 6 34 (S) 
4 31 L124G 59 9 16 8 (S) 
5 31 L124A quant. 15 15 8 (S) 
6 31 L124F quant. 17 17 21 (S) 
[a]
 Reactions were carried out at 55°C for 12 h at pH 8.0 with 2 mol% complex vs. substrate: 458 μM 
final metal concentration, 22.9 mM substrate and 1 mol% tetrameric P64G-124V (corresponding to 
916 μM biotin binding sites), with 4.90 M NH4COOH in a total reaction volume of 200 μL. 
 
This focused genetic screening highlighted that mutation at position P64G was not important 
for the enantioselection (see Table 18, entry 2). We conclude that in the double-mutant 
P64G-L124V, only the mutation L124V plays a key role in enantioselection (34% ee in favor 
of the (S)-enantiomer, see Table 18, entry 3). However, the double mutant P64G-L124V 
leads to better activity and selectivity than the single mutant L124V. It appears that small 
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variations at position 124 play a determinant role in enantioselectivity, thus suggesting the 
close contact between the catalyst and this side chain. 
 
4.2.3.4. Temperature Optimization  
 
The metalloenzyme 31  L124V was identified as the best catalyst in terms of 
enantioselectivity. In order to test the previously observed trend concerning the temperature, 
the reductive amination with 31  L124V was investigated at different temperatures (5°C, 
25°C, 37°C and 55°C, see Table 19). 
 
Table 19 Temperature optimization using 31  L124V for the enantioselective production of 
phenylglycine 37.[a] 
Entry Complex Temp. (°C) Conversion (%) Yield (%) Selectivity (%) ee (%) 
1 31 5 30 4 12 73 (S) 
2 31 25 50 8 15 56 (S) 
3 31 37 quant. 15 15 50 (S) 
4 31 55 quant. 6 6 34 (S) 
[a]
 Reactions were carried out for 12 h at pH 8.0 with 2 mol% complex vs. substrate: 458 μM final metal 
concentration, 22.9 mM substrate and 1 mol% tetrameric 124V (corresponding to 916 μM biotin 
binding sites), with 4.90 M NH4COOH in a total reaction volume of 200 μL.  
 
As expected, lowering the temperature lead to an increase in enantioselectivity for the 
metalloenzyme consisting of 31  L124V (up to 73% ee in favor of the (S)-enantiomer). 
Unfortunately, both the yield and the selectivity were very low (see Table 19, entry 1).  
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4.3. Conclusion 
 
In summary, we reported the first non-enzymatic enantioselective reductive amination for the 
preparation of unprotected natural (phenylalanine, 34) and non-natural (phenylglycine, 37) α-
amino acids by two different artificial metalloenzymes.  
We demonstrated the capacity of the metalloenzyme 17’  K121H to catalyze the reductive 
amination of phenylpyruvic acid 33 in water to afford (S)-phenylalanine (24% ee) with 
promising activity (TON = 45 at 55°C). The studies also highlighted an unexpected result: 
compared to the ATH reaction, hybrid catalyst 17’  S112H afforded racemic material in the 
reductive amination. We speculate that the ammonium group of the close-lying lysine in 
position 121 may interact differently depending on the substrate (salsolidine precursor or 
phenylpyruvic acid 33):  
Furthermore, we confirmed that low temperatures leads to increase enantioselectivity: up to 
43% ee was obtained with the hybrid catalyst 17’  K121H for the reductive amination of 
phenylpyruvic acid 33. However, the metalloenzyme suffers from low TONs (14 at 5°C vs. 45 
at 55°C) 
In order to increase the yield and the ee, genetic optimization was investigated using a small-
scale purification process, “SSP”. This strategy allowed the identification of K121H-L110C as 
attractive double mutant (TON = 49). The combination of the rhodium dimer 17 with pure 
K121H-L110C exhibited increased activity even at 5°C (TON = 37) when compared to the 
single-mutated metalloenzyme, 17’  K121H (TON = 14). These results confirmed the 
validity of the mutant production strategy as genetic screening combined with qualitative in 
silico investigations. Although precise information about the enantioselection mechanism is 
difficult to achieve with such method (which is also the case with X-ray structure), in silico 
studies have been found to be a useful tool in guiding the design of artificial metalloenzymes. 
We also identified additional metal complex/protein assemblies that were competent in the 
synthesis of the unnatural α-amino acid, phenylglycine 37. Indeed, rhodium piano stool 
complexes bearing an ethylenediamine ligand displayed promising properties with Sav 
Reductive Amination of α-Keto Acids for the Synthesis of α-Amino Acids      111 
mutants P64G-L124V, L124V and L124F: up to 73% ee for (S)-PhGly. Future efforts towards 
improving the yield and the selectivity are underway in the group. 
 
.  
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5. General Conclusion and Outlook 
 
5.1. General Conclusion 
 
The biotin-streptavidin technology has proven to be a remarkable tool for the design of 
effective artificial metalloenzymes. Two main properties contributing to the usefulness of the 
technology are: i) the exceptional strength and precision of the supramolecular anchoring 
and ii) the possibilities offered through chemical derivatization of the biotinylated cofactor 
with metal-complexes. These properties allow the resulting artificial metalloproteins to 
catalyze diverse processes (oxidation and reduction reactions). Furthermore, large 
organometallic guests can be effectively combined with a macromolecular host in order to 
also achieve unexplored processes (at least with metalloproteins) such as drug delivery. In 
addition, the nature of the host can also be fine-tuned by genetic modification, providing a 
very powerful chemo-genetic approach for optimization of catalytic or binding properties of 
the assembly. 
In the first chapter, we demonstrated that the combination of a metallodrug (i.e. biotinylated 
ruthenium piano stool) with a presenter protein (i.e. streptavidin) provided a supramolecular 
assembly able to modulate the affinity and selectivity towards DNA telomers in vitro. The 
recognition profile through the provision of additional non-covalent interactions was effective 
even in the presence of competing targets (such as glutathione and dsDNA).  
As concerns supramolecular assemblies with catalytic activity, as described in the second 
part of this thesis, in most cases the artificial metalloenzymes display low activity (few 
turnovers, see Table 20). In general, one challenge remains to develop highly active 
catalysts for specific embedding into host biomolecules. We addressed this challenge by 
implementing an effective synthetic platform for a straightforward chemical optimization of 
biotinylated complexes (see Table 20, blue row). 
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Table 20 Comparison of metalloenzymes in reduction reactions. 
Catalyzed 
reaction 
Anchoring Macromolecule Complex or ligand ee (%)  TON Group 
Transfer 
Hydrogenation 
Supramolecular 
Sav P64G-
L124V 
[η6-(p-cymene)Ru(Biot-
p-L)Cl] 
98 (R)  100 Ward[169] 
Sav S112A [Cp*Ir(Biot-p-L)Cl] 96 (R)  4000 Ward[160] 
Dative and 
Supramolecular 
Sav K121H 
[(η5-Me4Cp(CH2)2-N-
Biot)RhCl2]2 
77 (R)  240 this thesis 
 
Hydrogenation 
Supramolecular 
Sav S112W 
[Rh(Biot-(R)-Pro-amino- 
diphosphine)(COD)]BF4 
95 (S)  100 Ward[177] 
Sav N49V 
[Rh(Biot-amino- 
diphosphine)(COD)]BF4 
65 (R)  500 Reetz[178] 
Avidin 
[Rh(Biot-amino- 
diphosphine)(NBD)]Tf 
41 (S)  >500 Whitesides[179] 
[Rh-(S,S)-pyrphos 
(COD)]BF4 
48 (R)  32 Chan[180] 
Antibody 1G8 
[Rh(aminodiphosphine) 
(COD)]ClO4 
98 (S)  854 Yamaguchi[181] 
Dative 
Carbonic 
anhydrase 
[Rh(COD)2]BF4 20:1
[a]  100 
Kazlauskas[115
a] 
Covalent 
Papain [Rh(COD)2]BF4 
-  400 de Vries[182] 
-  800 de Vries[183] 
Photoactive 
Yellow Protein 
[Rh(COD)(MeCN)2]BF4 n.d.  n.d. Kamer
[184] 
[a]
 Selectivity for cis-stilbene over trans-stilbene 
 
In this thesis a d6-piano stool rhodium and iridium complexes with a tethered-Cp* directly 
attached to biotin for incorporation into streptavidin were designed. Combination of a 
chemically optimized cofactor (by varying the linker, the metal and/or its ligand for example) 
with fine-tuning of the second coordination sphere (designed evolution and directed evolution 
approaches) allowed us to identify a new generation of active biocatalysts, summarized as 
follows: 
i) Incorporation of biotinylated d6-piano stool (rhodium and iridium) complexes bearing 
bidentate ligands into L124 Sav mutants displayed promising activity in ATH. Particularly 
interesting was the hybrid catalyst consisting of L124V and rhodium-piano stool complexes 
bearing an ethylenediamine ligand, which was competent in the non-enzymatic 
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enantioselective synthesis of unprotected non-natural α-amino acids, with up to 73% ee for 
the (S)-enantiomer of phenylglycine. 
ii) Rational ligand design with genetic optimization of the biomolecular host allowed the 
design of the first active metalloenzyme based on the biotin-streptavidin technology using a 
dual anchoring strategy, with both supramolecular and dative anchoring. Both (S)- and (R)-
enantiomers could be obtained with the same metal complex depending on the host protein 
employed: incorporation of biotinylated piano stool rhodium complex 17 into K121H provided 
(R)-salsolidine with up to 240 TONs and remarkable enantioselectivity (77% ee); the 
complementary metalloenzyme, 17’  S112H yielded (S)-product with up to 170 TONs, and 
promising enantioselectivity (60% ee). We also demonstrated the capacity of metalloenzyme 
17’  K121H to catalyze the reductive amination of phenylpyruvic acid in water to afford (S)-
phenylalanine (24% ee) with promising activity (TON = 45 at 55°C). This is the first example 
of enantioselective synthesis of unprotected α-amino acids in water. 
In conclusion, the facile chemical optimization of these catalysts potentially allows to 
elaborate highly active and selective hybrid catalysts for a given reaction.  
 
5.2. Outlook 
 
5.2.1. Optimization of a Drug Delivery System 
 
In the present form, such assemblies cannot be delivered easily into cells, thus hampering in 
vivo studies. To overcome this challenge, current alternative strategies include the following:  
i) Appending cell penetrating peptide (CPP) sequences to the presenter protein. CPPs allow 
cell-impermeable compounds to reach intracellular targets. Recent advances in the field 
have demonstrated that some CPPs can exhibit cell specificity.[185] 
ii) Exploiting endogenous host proteins overexpressed in cancer cells as presenter proteins, 
such as lysozyme or carbonic anhydrase[186]. The latter would thus only require cell 
penetration of the metallo-prodrug.  
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5.2.2. Use of Artificial Metalloenzymes in Challenging Reactions 
 
Enantioselective transfer hydrogenation reactions (keto and imine reduction) have been 
effectively implemented in organic media. However, reactions involving hydride transfers 
remain challenging and enantioselective reductive amination of ketones and keto acids in 
aqueous media remain underdeveloped: Thus, the novel artificial enzymes described in this 
thesis have great potential in developing interesting enantioselective reductive amination 
reactions, for example for future effective synthesis of high-value enantiopure compounds 
including: 
i) Optically active amines yielded by enantioselective reduction of imines (see Figure 48). 
The asymmetric hydrogenation of acyclic imines in which R2 is distinct from methyl or both 
groups are alkyl is particularly challenging.[76c] There is an increasing demand for catalysts 
providing high enantioselectivities in the reduction of dialkyl imines or phenyl substituted 
quinolines. Moreover, in the hydrogenation of cyclic imines such as quinolines, isoquinolines, 
and quinoxalines the nature of the substituent R4 influences the efficiency of the reduction 
reaction. For example, when R4 is a bulky substituent such as aryl, the enantioselectivity 
dropped significantly. 
 
Figure 48 Interesting imine and enamide substrates for the ATH 
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An additional interesting scaffold is the enamide class: the ortho-substituted enamides are 
particularly difficult to reduce.[76d] This is exemplified by ortho-fluorophenyl enamide (when R7 
= F). The ortho-substituted-α-aryl enamide has been intermittently reported on but deserves 
attention because the products more closely mimic alkaloid or drug-like structures. 
The optically active (R)-2-methylpyrrolidine is useful as a chiral building block of H3 histamine 
receptor antagonist, ABT-239.[187] Consequently reduction of 2-methyl-1-pyrroline represents 
a relevant but challenging reaction. Finally, the chemistry of dibenzo[b,f][1,4]oxazepine 
derivatives has attracted much attention since they are found in many physiologically active 
compounds.[188] 
ii) Non-protected α- and ß-amino acids. Generally, α-amino acids are prepared under their 
protected form. The challenge remains to efficiently and enantioselectively produce natural 
and unnatural amino acids that would not require a further deprotection step. Among the 
unnatural amino acids, α-allylglycine is found in different bioactive molecules such as 
binaphthyl-supported macrocycles that display antibacterial activity.[189] In this particular case, 
α-allylglycine is involved in a ring-closing metathesis reaction. Furthermore, (S)-allylglycine 
and (R)-allylglycine were found inhibit proteinase K.[190] Additional interesting unnatural α-
amino acids are the substituted phenylalanine such as O-methyl-L-tyrosine (see Figure 49) 
which enters in the composition of Puromycin (PM).[191] PM is an aminoacyl nucleoside 
antibiotic is categorized as a mimic of aminoacyl-tRNA (aa-tRNA), acts as an inhibitor of 
protein synthesis.[192] 
 
Figure 49 Interesting unnatural α-amino acids. 
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Enantiomerically pure ß-amino acids are present in a number of natural products that 
possess a wide range of biological activities.[193] Thus, synthesis of ß-amino acids is a 
challenging target for organic chemists.[194] 
In summary, the studies described in this thesis provide the first example of synthetic 
enantioselective reductive amination for the preparation of a range of unprotected chiral α-
amino acids in water, thus demonstrating the great potential of artificial metalloenzymes to 
complement both homogeneous and enzymatic catalysts. 
.  
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List of Abbreviations 
 included in 
ACN acetonitrile 
AcOEt ethyl acetate 
Å Angström 
Ar arene 
Avi avidin 
ATH  Asymmetric Transfer Hydrogenation 
Biot biotin(yl) 
B4F  biotin-4-fluoresceine 
BNHS biotin N-hydroxysuccinimide ester 
Boc tert-butoxycarbonyl 
BPFP biotin pentafluorophenyl ester 
4,4’diMeObpy 4,4'-dimethoxy-2,2'-bipyridine 
bpy bipyridine 
Conv. conversion 
COD 1,5-cyclooctadiene 
Cp* pentamethylcyclopentadienyl 
DEA diethylamine 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
ds-DNA  double stranded DNA 
dsOnc double stranded oncogenic DNA 
ss-DNA single stranded DNA 
EDTA ethylenediaminetetraacetic acid 
ee enantiomeric excess 
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e. g. exempli gratia, for example 
EMSA Electrophoretic Mobility Shift Assay 
EN ethylendiamine 
eq. equivalent(s) 
ESI Electron Spray Ionisation 
Et ethyl 
EtOH ethanol 
Et2O diethyl ether 
Et3N  triethylamine 
G4A G-quadruplex telomeric DNA 
GSH glutathione 
HABA 4-hydroxyazobenzene-2-carboxylic acid 
HPLC High Performance Liquid Chromatography 
i. e. id est, that is 
ITC isothermal titration calorimetry 
M metal 
Me methyl 
Me4Cp tetratamethylcyclopentadienyl 
min. minute(s) 
MES 2-(N-morpholino)ethanesulfonic acid 
MOPS 3-(N-morpholino)propanesulfonic acid 
MS Mass Spectrometry 
NMR  Nuclear Magnetic Resonance 
NBD norbornadiene 
PDB  Protein Data Bank 
ppm parts-per-million 
iPr  isopropyl 
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iPrEN N-isopropylethylene diamine 
Sav streptavidin 
scG4A “scrambled” telomeric sequence 
R.T.  room temperature 
t1, t2  retention times (min.) 
Temp.  temperature 
THF  tetrahydrofuran 
TH  Transfer hydrogenation 
TFA trifuoroacetic acid 
TfO- trifluoromethanesulfonate 
TOF  turnover number 
TON  turnover frequency 
TS transition state 
TsEN N-tosylethylenediamine 
TsDPEN N-(p-toluenesulfony1)-1,2-diphenylethylenediamine 
vs.  versus 
VMD Visual Molecular Dynamics 
WT  wild-type 
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7. Experimental Section 
 
7.1. Chemical Synthesis 
 
7.1.1. Synthesis of Biotinylated Piano Stool Metallodrugs Used in DNA Recognition 
 
(3R,4R)-N-benzyl-3,4-dihydropyrrolidin-2,5-dione (8)[136] 
 
Benzylamine (125.25 ml, 1.309 mol) and (L)-tartaric acid (50 g, 333.13 mmol) were 
azeotropically dehydrated with boiling o-xylene (120 ml) in a Dean-Stark trap (until the 
formation of 4.95 ml of water). After cooling, the crystalline (yellowish color) precipitate was 
filtered, washed with acetone and recrystallized in EtOH to yield compound 8 as a white solid 
(58.9 g, 80% yield). The product was characterized according to the 1H NMR described in 
literature[136]: 
1H NMR (400 MHz, MeOD) δ 7.36-7.15 (m, 5H, Ar-1), 4.07-4.03 (m, 2H, 4.87 (s, 2H, H3), 
4.64 (s, 2H, H1, H2). 
 
(3S,4S)-N-benzyl-3,4-dihydropyrrolidine (9)[136] 
 
To a solution of compound 8 (10 g, 45.21 mmol) and the BF3/Et2O (22.51 ml, 177.66 mmol) 
in dimethylester diglycol (100 ml) was added NaBH4 (4.5 g, 118.89 mmol) in small portions 
during 1 h at 0°C. When the evolution of hydrogen had stopped, the mixture was allowed to 
come to RT followed by heating for 2 h at 70°C. After cooling to RT, HCl (6N, 60 ml) was 
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slowly added, then the reaction was heated again for 15 min at 70°C. NaF (27.71 g) was 
then added in one portion with vigorous stirring. The mixture was immediately acidified by 
adding HCl, 6N (45 ml) to pH 1.0 followed by heating for 30 min at 100°C. After cooling to RT 
NaOH, 20% (60 ml) was added (pH 9.0-10.0). The salts were removed by filtration and the 
organic and the aqueous phases were separated. The organic phase was concentrated to 
afford a colorless solid. This residue was dissolved H2O (35 ml) and extracted 10 times with 
Et2O. The combined organic phases were dried (Na2SO4) and concentrated to a pale yellow 
oil, which solidified upon standing. Recrystallization from AcOEt (35 ml) provided 9 as a 
crystalline powder. The water phase was extracted continuously for 8 h with Et2O. The 
organic phase was dried and concentrated to give a residue which was recrystallized from 
AcOEt (35 ml) to afford more 9 (6.20 g, 71% final yield). The product was characterized 
according to the 1H NMR described in literature:[136] 
1H NMR (400 MHz, MeOD) δ 7.52-7.28 (m, 5H, Ar-1), 4.07-4.03 (m, 2H, H1, H2), 3.70-3.54 
(m, 2H, H5), 2.94/2.48 (dd, J = 12.4, 3.4 Hz, 2H, H3, H4). 
 
(3S,4S)-benzyl-3,4-di(methylsulfonyloxy)pyrrolidine (10)[136] 
 
A solution of 9 (10 g, 51.75 mmol) in CH2Cl2 (40 ml) was treated with Et3N (14.42 ml, 103.49 
mmol) and stirred at 0°C. Then, methanesulfonylchloride (8.01 ml, 103.49 mmol) was added 
dropwise. After 30 min stirring at RT, the mixture was washed twice with water (30 ml) and 
the organic layers were treated with 1 M solution of HCl (190 ml). The aqueous layers 
formed, were treated with NaOH solution 20% (100 ml). The resulting oil was extracted twice 
with dichloromethane (2x60 ml). The organic phase was evaporated until dryness and the 
crude product was used without any further purification for the next step. 
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(3R,4R)-N-benzyl-pyrrolidine-3,4-diazide (11)[136] 
 
A stirred solution of compound 10 (10 g, 28.65 mmol) and NaN3 (4.84 g, 74.84 mmol) in dry 
DMF (150 ml) was heated at 100°C for 4 h. After cooling to room temperature, the white solid 
was filtered off and the residue (6.47 g) was purified by column chromatography using 
AcOEt/Heptane (1:1) to afford compound 11 as yellowish oil (6.48 g, 93% yield). The product 
was characterized according to the 1H NMR described in literature[136]: 
1H NMR (400 MHz, MeOD) δ 7.35-7.32 (m, 5H, Ar-1), 3.99-3.94 (m, 2H, H1, H2), 3.70-3.66 
(m, 2H, H5), 2.99/2.60 (dd, J = 12.4, 3.4 Hz, 2H, H3, H4). 
 
(3R,4R)-N-benzyl-3,4-diaminopyrrolidine (12)[136] 
 
To a solution of compound 12 (500 mg, 2.06 mmol) in degassed EtOH (10 ml) was added 
Pd/C (10%, 50 mg). The resulting mixture was hydrogenated during 4 h at 5 bar. The 
solution was then filtered and solvents were evaporated. The crude product was purified by a 
column chromatography (CH2Cl2) to yield compound 12 (292 mg, 74% yield). The product 
was characterized according to the 1H NMR described in literature[136]: 
1H NMR (400 MHz, MeOD) δ 7.35-7.32 (m, 5H, Ar-1), 3.65-3.60 (m, 2H, H1, H2), 3.05-3.82 
(m, 4H, H5, H3, H4), 2.94/2.38 (dd, J = 12.4, 3.4 Hz, 2H, H3, H4).  
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(3R,4R)-N-benzyl-3,4-di(N,N-tert-butyloxycarbonyl)aminopyrrolidine (13)[136] 
 
Compound 12 (1.37 g, 7.16 mmol) was dissolved in CH2Cl2 (30 ml) and the mixture was 
cooled to 0°C. Then (BOC)2O (3.75 g, 17.19 mmol) and Et3N (3.99 ml, 28.65 mmol) were 
added. The reaction was stirred overnight at RT. The resulting crude product was purified by 
column chromatography on silica gel (100% CH2Cl2 then CH2Cl2/MeOH : 10/1)) to yield 
compound 13 quantitatively (2.74, 98% yield). The product was characterized according to 
the 1H NMR described in literature[136]: 
1H NMR (400 MHz, MeOD) δ 7.33-7.25 (m, 5H, Ar-1), 3.87-3.83 (m, 2H, H1, H2), 3.60 (s, 2H, 
H5), 2.95/2.41 (dd, J = 12.4, 3.4 Hz, 2H, H3, H4), 1.44 (s, 18H, H7, H7’).  
 
(3R,4R)-3,4-di(N,N-tert-butyloxycarbonyl)aminopyrrolidine (14)[136] 
 
Compound 13 (910 mg, 2.32 mmol) was dissolved on a degassed mixture of 60 ml of 
AcOEt/EtOH (5 : 1). Pd/C (10 %) and PdOH2 (10 %) were added and the mixture was 
hydrogenated overnight at 5 bar. After the catalysis finished the crude precipitate was filtered 
and evaporated to afford compound 14 (678 mg, 97% yield). The product was characterized 
according to the 1H NMR described in literature[136]: 
1H NMR (400 MHz, MeOD) δ 3.91-3.83 (m, 2H, H1, H2), 3.15 (dd, J = 12.4, 3.4 Hz, 2H, H3, 
H4), 2.65 (dd, J = 12.3, 3.4 Hz, 2H, H3’, H4’), 1.42 (s, 18H, H7, H7’).  
 
Experimental Part             125 
(3R,4R)-1-biotinyl-3,4-di(N,N-tert-butyloxycarbonyl)aminopyrrolidine (15) 
 
Compound 14 (0.37 g, 1.21 mmol, 1 eq.) was dissolved in DMF (30 mL). Biotin N-
hydroxysuccinimide ester (0.39 g, 1.21 mmol, 1 eq.) and Et3N (0.51 mL, 3.63 mmol, 3 eq.) 
were then added and the mixture was heated at 80°C overnight. The solvent was removed 
and the product was then purified by column chromatography on silicagel (CH2Cl2/MeOH : 
10/1.5) to obtain compound 15 as a white solid (383 mg, 95.0% yield). 
1H NMR (400 MHz, MeOD): δ 4.49 (dd, J = 4.9, 7.6 Hz, 1H, H2), 4.31 (dd, J = 4.4, 7.7 Hz, 
1H, H2’), 4.10-3.92 (m, 2H, H11, H12), 3.86 (dd, J = 6.8, 12.2 Hz, 1H, H9), 3.77 (dd, J = 6.9, 
12.2 Hz, 1H, H10), 3.30-3.36 (m, 1H, H9’), 3.17-3.25 (m, 2H, H4, H10’), 2.93 (dd, J = 4.9, 12.0 
Hz, 1H, H3’), 2.70 (d, J = 12.0 Hz, 1H, H3), 2.33 (t, J = 7.4 Hz, 2H, H8), 1.82-1.40 (m, 6H, H5, 
H7, H6), 1.47 (s, 18H, H15, H15’). 13C NMR (101 MHz, MeOD): δ 173.71, 173.20, 164.85, 
157.84 (2C), 79.35 (2C), 62.06, 60.36, 55.70 (2C), 49.83, 39.77, 33.29, 28.57, 28.26, 27.42 
(6H), 25.00, 24.44. MS (ESI-MS, pos): m/z = 549.93 [M+Na]+; calcd. for C24H41N5O6S, 
527.68. See appendix. 
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(3R,4R)-1-biotinyl-3,4-diaminopyrrolidine (16) 
 
Compound 15 (0.20 g, 0.39 mmol, 1 eq.) was dissolved in CH2Cl2 (10 mL). TFA (2 mL, 26.09 
mmol, 67 eq.) was added and the mixture was stirred at RT until completion of the reaction 
as revealed by thin layer chromatography. After evaporation of the volatiles, the crude 
product was dissolved in water (20 mL), washed three times with CH2Cl2 (40 mL) and then 
the pH adjusted to 9.0. The product was extracted with CH2Cl2 (2x40 mL). The organic phase 
was dried and the crude product was purified by column chromatography (MeOH/CH2Cl2 : 
7/3) to afford 16 as white solid (34 mg, 57.0 % yield). 
1H NMR (400 MHz, MeOD): δ 4.49 (dd, J = 4.9, 7.8 Hz, 1H, H2), 4.31 (dd, J = 4.5, 7.8 Hz, 
1H, H2’), 3.90-3.71 (m, 2H, H9, H10), 3.27-3.03 (m, 5H, H4, H9’, H10’, H11, H12), 2.93 (dd, J = 
5.0, 12.0 HZ, 1H, H3’), 2.70 (d, J = 12.0 Hz, 1H, H3), 2.33 (t, J = 7.4 Hz, 2H, H8), 1.81-1.53 
(m, 4H, H5, H7), 1.47 (dd, J = 7.5, 15.1 Hz, 1H, H6). 13C NMR (101 MHz, MeOD): δ 173.39, 
166.13, 63.34, 61.63, 59.11, 57.80, 56.00, 54.81, 53.58, 41.04, 34.66, 29.89, 29.54, 25.76. 
HR-MS (ESI-MS, pos): m/z = 328.1793 [M+H]+; calcd. for C14H25N5O2S, 327.1728. See 
appendix. 
 
[(η6-p-cymene)Ru(biotin-N-(R,R)-3,4-diaminopyrrolidine-N,N)Cl]CF3SO3 (6) 
 
The dimer [(η6-p-cymene)RuCl2]2 (46.8 mg, 0.0736 mmol, 0.5 eq.) was dissolved in MeOH (5 
mL) and AgCF3SO3 (39.2 mg, 0.1527 mmol, 1 eq.) was added to the solution. The reaction 
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mixture was then stirred in the dark for 2 h at RT. The AgCl was filtered off and the resulting 
solution was added to the (3R,4R)-1-biotinyl-3,4-diaminopyrrolidine (50 mg, 0.1527 mmol, 1 
eq.). The mixture was stirred for 2 h and the solvent was evaporated to dryness. The residue 
was washed with CHCl3 (50 mL), the precipitate was filtered and dried to afford a yellow solid 
(87 mg, 95 % yield). 
1H NMR (400 MHz, MeOD): δ 5.67 (d, J = 5.4 Hz, 2H, Ar-1), 5.56 (dd, J = 5.4 Hz, 2H, Ar-1), 
4.50 (dd, J = 4.8, 7.7 Hz, 1H, H2), 4.29 (dd, J = 4.4, 7.8 Hz, 1H, H2’), 3.81-3.49 (m, 2H, H9, 
H10), 3.25-3.20 (m, 2H, H4, H9’), 3.09-2.90 (m, 5H, H10’, H11, H12, H3’, H16), 2.71 (d, J = 12.4, 
1H, H3), 2.27 (s, 3H, H15), 2.32-2.23 (m, 2H, H8), 1.74-1.35 (m, 6H, H7, H5, H6), 1.31 (dd, 6H, 
H17, H17’). 13C NMR (101 MHz, MeOD): δ 173.86, 165.09, 104.37, 97.96, 82.23, 80.73, 63.78, 
62.81, 62.34, 60.64, 59.12, 58.13, 56.03, 46.13, 45.30, 40.05, 32.90, 31.04, 28.71, 28.59, 
25.51, 22.23, 21.28, 17.21. (ESI-MS, pos): m/z = 598.1532 [M]+, 562.27 [M-Cl]+; calcd. for 
C24H39ClN5O2RuS, 598.19. See appendix. 
 
3-Phenyl-1,4-cyclohexadiene[139]  
Biphenyl (5 g, 32.42 mmol) was added to anhydrous EtOH (50 ml) in a 1 L three-necked 
flask equipped with loose cotton plugs in the side necks. After the biphenyl was dissolved, 
liquid ammonia (300 ml) was condensed into the stirred solution. Then sodium (2 g) was 
added in small pieces. When about 1/3 of the sodium has been added, the white sodium salt 
of the acid precipitated and there was strong foaming of the reaction mixture. After all the 
sodium has been consumed, as evidenced by the disappearance of the blue color, NH4Cl 
(5.7 g, 106.67 mmol) was added cautiously. The mixture was stirred for an additional hour 
and then allowed to stand at RT until the ammonia has evaporated. The resulting residue 
was dissolved in water (150 ml). The solution was poured onto ice (100 g) and acidified (pH 
4.0) by addition of 10% HCl (40 ml). The resulting mixture was extracted with portions of 
ether (4x50 ml), and the combined extracts were washed with saturated aqueous solution of 
NaCl (25 ml) and dried over MgSO4. The ether solution was separated from the drying agent 
and concentrated at RT under reduced pressure. The residual oil was distilled from a 25 ml 
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Claisen flask with an intended neck. The crude material was used directly in the next step 
without further purification. 
 
[(η6-biphenyl)RuCl2]2
[138] 
A mixture of 3-Phenyl-1,4-cyclohexadiene (4.28 g, 12.05 mmol) and RuCl3, x•H2O (0.25 g, 
1.205 mmol) in EtOH (25 ml) was refluxed for 4 h. The resulting precipitate was removed by 
filtration and washed with EtOH. The combined filtrate and washings were then concentrated 
to give [(η6-biphenyl)RuCl2]2.(379 mg, 44% yield). The product was characterized according 
to the 1H NMR described in literature. 
1H NMR (400 MHz, DMSO-d6) δ 7.85-7.76 (m, 2H), 7.52-7.45 (m, 3H), 6.45 -6.39 (m, 2H), 
6.10-6.00 (m, 3H).  
 
[(η6-biphenyl)Ru(biotin-N-(R,R)-3,4-diaminopyrrolidine-N,N)Cl]CF3SO3 (7) 
 
The dimer [(η6-biphenyl)RuCl2]2 (16 mg, 0.025 mmol 0.4 eq.) was dissolved in dry MeOH (5 
mL) and CF3SO3Ag (13.8 mg, 0.0626 mmol, 1 eq.) was added to the solution. Then the 
reaction mixture was stirred for 2 h at RT. The silver salts were filtered and the resulting 
solution was added to the (3R,4R)-1-biotinyl-3,4-diaminopyrrolidine (20.5 mg, 0.626 mmol, 1 
eq.). The mixture was stirred 4h and the solvent was evaporated. The residue was washed 
with CHCl3, the precipitate was filtered and then dried to yield a yellow solid (16 mg, 41% 
yield).  
1H NMR (500 MHz, MeOD): δ 7.70-7.69 (m, 2H, Ar-2), 7.43-7.40 (m, 3H, Ar-2), 6.12-6.05 
(m, 2H, Ar-1), 5.91-5.80 (m, 3H, Ar-1), 4.41-4.38 (m, 1H, H2), 4.24-4.14 (m, 1H, H2’), 3.62-
3.48 (m, 2H, H9, H10), 3.15-3.05 (m, 3H, H4, H9’, H10’), 2.87-2.76 (m, 3H, H3’, H11, H12), 2.60 
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(d, J = 12.7, 1H, H3), 2.12-2.08 (m, 2H, H8), 1.65-1.40 (m, 4H, H5, H7), 1.41-1.24 (m, 2H, H6). 
HR-MS (ESI-MS, pos): m/z = 618.1238 [M]+, 582.15 [M-Cl]+; calcd. for C26H35ClN5O2RuS, 
618.1243. The carbon 13C NMR could not be obtained since not enough material was 
available. See appendix 
 
7.1.2. Synthesis of Biotinylated Piano Stool Complexes Used in ATH 
 
(2,3,4,5-tetramethylcyclopentadienyl)acetonitrile (20)[162] 
 
To a solution of ACN (1.88 mL, 35.8 mmol) in THF (40 mL) cooled to -80°C was added n-
BuLi in hexane (14.3 mL of a 2.5 M solution, 35.88 mmol). After 15 min 2,3,4,5-
tetramethylcyclopent-2-enone 19 (4.85 mL, 4.5 g, 32.6 mmol) was added at -80°C over a 
period of 45 min. Over 3 h the temperature was allowed to rise to 0°C. Water (10 mL) was 
added, and the organic layer was washed with two portions of water (10 mL). Then, HCl (2N, 
10 mL) was added, the mixture was extracted, and after 16 h the layers were separated. The 
organic phase was washed with brine, dried over Na2SO4, and concentrated. The product 
was then purified by column chromatography (cyclohexane/AcOEt : 50/1) to yield a 
transparent oil (4.72 g, 90% yield). 
NMR data of the major isomer (2,3,4,5-tetramethylcyanomethylenecyclopent-2-ene): 1H NMR 
(400 MHz, CDCl3) δ 4.81 (d, J = 1.8 Hz,1H, H
1), 2.52 (br q, J = 7.2 Hz, 1H, H2), 2.19 (br q, J 
= 7.2 Hz, 1H, H3), 1.76 (br s, 3H, H4), 1.62 (br s, 3H, H5), 1.19 (d, J = 7.2 Hz, 3H, H6), 1.02 (d, 
J = 7.1 Hz, 3H, H7). 13C NMR (101 MHz, CDCl3) δ 177.13, 158.26, 131.43, 119.31, 82.20, 
52.03, 45.34, 19.94, 19.06, 14.22, 10.08. MS (ESI-MS, pos): m/z = 162.30 [M+H]+, 184.10 
[M+Na]+; calcd. for C11H15N, 161.28; (additional peak: 345.1, impurity from the instrument).  
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2-(2,3,4,5-tetramethylcyclopentadienyl)ethylamine (21)[162] 
 
Solid LiAlH4 (0.304 g, 8.02 mmol) was added to dry THF (5 mL). The reaction mixture was 
allowed to stir until a homogeneous slurry was formed. Solid AlCl3 (1.069 g, 8.02 mmol) was 
then added to the slurry. The reaction was then cooled to 0°C and a solution of 2-(2,3,4,5-
tetramethylcyclopentadienyl)ethylamine 20 (862 mg, 5.35 mmol) in THF was added dropwise 
to the reaction mixture. The reaction was allowed to warm to room temperature, and stirred 
overnight. Next, the reaction was quenched with NaOH. The mixture was filtered to remove 
the aluminum salts. The THF was removed under reduced pressure, the deep yellow solution 
was dissolved in Et2O and the residual water was dried over Na2SO4. The crude product was 
used for the next step.  
 
[(η5-Me4Cp(CH2)2NH3)RhCl2]2Cl2 (22)
[161] 
 
2-(2,3,4,5-tetramethylcyclopentadienyl)ethyl-amine 21 (tautomer mixture, 500 mg, 3.03 
mmol) was dissolved in Et2O (10 mL) and treated with HCl (1.78 mL, 5.95 mmol, 4 M in 
dioxane). Hexane (20 mL) was added to this solution until a white precipitate formed, which 
was filtered off and washed twice with hexane. The white solid was dissolved in EtOH (50 
mL) and RhCl3•nH2O (186 mg, 0.705 mmol) was added. The reaction mixture was refluxed 
for 4 days and thereafter stored at -20°C overnight. The precipitate was filtered off and 
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washed with hexane, Et2O and cold EtOH to yield the pure product as an orange powder 
(214 mg, 90% yield). 
1H NMR (400 MHz, DMSO-d6): δ 8.02 (br s, 6H, H
1), 2.95-2.85 (m, 4H, H2), 2.46-2.42 (m, 4H, 
H3), 1.71/1.62 (s, 24H, H4, H5, H6, H7). 13C NMR (101 MHz, DMSO-d6) δ 97.35, 92.51, 86.23, 
37.10, 22.33, 9.23 (2C), 9.11 (2C) HR-MS (ESI-MS, pos): m/z = 639.0058 [M-Cl]+, calcd. for 
C22H36Cl4N2Rh2, 673.9742. 
 
[(η5-Me4Cp(CH2)2-N-Biot)RhCl2]2 (17) 
 
[(η5-Me4Cp(CH2)2NH3)RhCl2]2Cl2  22 (100 mg, 0.148 mmol) was suspended in DMF (10 mL) 
and biotin N-hydroxysuccinimide (151 mg, 0.444 mmol) and Et3N (0.416 mL, 2.96 mmol) 
were added. The reaction mixture was left to stir at RT overnight. The solvent was removed 
under reduced pressure and the brown solid was resuspended in CH2Cl2. The solid was 
filtered and washed with CH2Cl2. Then the solid was resuspended in a minimum amount of 
DMF, stirred for few minutes and finally filtered to yield a brown-red powder (125 mg, 75% 
yield). 
1H NMR (500 MHz, DMSO-d6) δ 10.55 (s, 1H, COOH-biotin), 7.97 (t, J = 6.0 Hz, 2H, H
9), 
6.44 (s, 2H, H1’), 6.37 (s, 2H, H1), 4.35-4.27 (m, 2H, H2), 4.15-4.09 (m, 2H, H2’), 3.22 (dt, J = 
13.4, 6.9 Hz, 4H, H10), 3.11-3.09 (m, 2H, H4), 2.83 (dd, J = 12.4, 5.0 Hz, 2H, H3’), 2.59 (d, J = 
12.4 Hz, 2H, H3), 2.27 (t, J = 6.9 Hz, 4H, H11), 2.21 (t, J = 7.4 Hz, 1H, biotin), 2.03 (t, J = 7.4 
Hz, 4H, H8), 1.68/1.64 (s, 24H, H12, H13, H14, H15), 1.80-1.21 (m, 12H, H5, H6, H7). 
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Remark: Presence of residual biotin can be highlighted by the presence of a triplet at 2.21 
ppm as well as the proton from the carboxylic group at 10.55 ppm. 
 
Alternative synthesis of [(η5-Me4Cp(CH2)2-N-Biot)RhCl2]2 (17) 
 
[(η5-Me4Cp(CH2)2NH3)RhCl2]2Cl2  22 (200 mg, 0.296 mmol) was suspended in DMF (20 mL)  
and biotin pentafluorophenyl ester (231 mg, 0.562 mmol) and Et3N (0.831 mL, 5.920 mmol) 
were added. The compound rapidly dissolved to give a dark red solution and was stirred at 
RT overnight. The solvent was removed and the reddish solid was suspended in hexane. 
The solid was filtered and washed with hexane (3x15 mL) then with CH2Cl2 (4x15 mL) to 
afford 284 mg of brown-red powder (85% yield). 
1H NMR (500 MHz, DMSO-d6) δ 7.97 (t, J = 6.0 Hz, 2H, H
9), 6.44 (s, 2H, H1’), 6.37 (s, 2H, 
H1), 4.35-4.27 (m, 2H, H2), 4.15-4.09 (m, 2H, H2’), 3.22 (dt, J = 13.4, 6.9 Hz, 4H, H10), 3.11-
3.09 (m, 2H, H4), 2.83 (dd, J = 12.4, 5.0 Hz, 2H, H3’), 2.59 (d, J = 12.4 Hz, 2H, H3), 2.27 (t, J 
= 6.9 Hz, 4H, H11), 2.03 (t, J = 7.4 Hz, 4H, H8), 1.68/1.64 (s, 24H, H12, H13, H14, H15), 1.80-
1.21 (m, 12H, H5, H6, H7). 13C NMR (126 MHz, DMSO-d6) δ 172.05 (2C), 162.68 (2C), 100.40 
(4C), 99.04 (4C), 96.78 (2C), 61.01 (2C), 59.15 (2C), 55.37 (2C), 54.89 (2C), 35.65 (2C), 
35.05 (2C), 28.19 (2C), 28.00 (2C), 25.07 (2C), 24.13 (2C), 8.70 (4C), 8.59 (4C). HR-MS 
(ESI-MS, pos): m/z = 1093.1555 [M-Cl]+; calcd. for C42H64Cl4N6O4Rh2S2, 1126.1451 
(additional peaks: 492.12 [(M-2Cl)/2]2+, 528.10 [(M-Cl)/2]+). See appendix. 
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[(η5-Me4Cp(CH2)2NH3)IrCl2]2Cl2 (23)  
 
2-(2,3,4,5-tetramethylcyclopentadienyl)ethyl amine 21 (tautomer mixture, 91.1 mg, 0.551 
mmol) was dissolved in Et2O (2 mL) and treated with HCl (0.272 mL, 1.09 mmol, 4 M in 
dioxane). Hexane (4 mL) was added to this solution until a white precipitate formed, which 
was filtered and washed twice with hexane. The white solid was dissolved in MeOH (5 mL) 
and introduced into a 10 mL Schlenk tube. Then, [Ir(COD)Cl]2 (100 mg, 0.149 mmol) and a 
solution of concentrated HCl (0.8 mL of 37% solution in water) was added. This mixture was 
refluxed under nitrogen; after 30 min the initial orange-red suspension turned to a clear 
orange solution. A few minutes later, orange crystals began to precipitate and the reaction 
mixture was refluxed overnight. The compound was filtered off, washed with MeOH and dried 
to yield a bright orange powder (116.8 mg, 60% yield). 
1H NMR (400 MHz, DMSO-d6) δ 8.23 (br s, 6H, H
1), 2.95-2.84 (m, 4H, H2), 2.43-2.39 (m, 4H, 
H3), 1.74/1.64 (s, 24H, H4, H5, H6, H7). 13C NMR (101 MHz, DMSO-d6) δ 97.34, 92.50, 86.22, 
37.10, 22.32, 9.23 (2C), 9.11 (2C). HR-MS (ESI-MS, pos): m/z = 819.1130 [M-Cl]+; calcd. for 
C22H36Cl4N2Rh2, 854.0891 (additional peak: 642.22 [(M-Cl)/2]
+). See appendix. 
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[(η5-Me4Cp(CH2)2-N-Biot)IrCl2]2 (18)  
 
[(η5-Me4Cp(CH2)2NH3)IrCl2]2(Cl)2 23 (200 mg, 0.234 mmol) was suspended in DMF (20 mL) 
and biotin pentafluorophenyl ester (182 mg, 0.445 mmol) and Et3N (0.658 μL, 4.68 mmol) 
was added. The compounds rapidly dissolved to give a clear yellow solution. It was left to stir 
at RT overnight. The solvent was removed and the brown solid was suspended in hexane. 
The solid was filtered and washed with hexane (3x15 mL) then with CH2Cl2 (4x15 mL) to 
afford a pale yellow powder (66 mg, 80% yield). 
1H NMR (400 MHz, DMSO-d6) δ 7.94 (t, J = 5.9 Hz, 2H, H
9), 6.41 (s, 2H, H1’), 6.35 (s, 2H, 
H1), 4.32-4.24 (m, 2H, H2), 4.11-4.09 (m, 2H, H2’), 3.19 (dt, J = 13.2, 6.9 Hz, 4H, H10), 3.14-
3.02 (m, 2H, H4), 2.80 (dd, J = 12.5, 5.0 Hz, 2H, H3’), 2.55 (d, J = 12.5 Hz, 2H, H3), 2.15 (t, J 
= 6.9 Hz, 4H, H11), 2.02 (t, J = 7.4 Hz, 4H, H8), 1.67/1.61 (s, 24H, H12, H13, H14, H15), 1.73-
1.20 (m, 12H, H5, H6, H7). 13C NMR (126 MHz, DMSO-d6) δ 171.99 (2C), 162.76 (2C), 94.45 
(4C), 92.12 (4C), 88.99 (2C), 61.01 (2C), 59.15 (2C), 55.59 (2C), 39.61 (2C), 35.91 (2C), 
35.14 (2C), 28.15 (2C), 27.93 (2C), 25.25 (2C), 23.95 (2C), 8.36 (4C), 8.24 (4C). HR-MS 
(ESI-MS, pos): m/z = 1271.2703 [M-Cl]+, 618.1216 [M/2-Cl]+; calcd. for C42H64Cl4Ir2N6O4S2, 
1306.2443. See appendix. 
 
The biotinylated diimine complexes were synthesized following the procedure of Freedman 
et al..[167] 
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[(η5-Me4Cp(CH2)2-N-Biot)Rh(bpy)Cl]Cl (24)  
 
[(η5-Me4Cp(CH2)2-N-Biot)RhCl2]2Cl2 17 (20 mg, 0.0177 mmol) and 2,2'-bipyridine (4.4 mg, 
0.0282 mmol) were added to ACN (5 mL, HPLC grade, used without further purification). The 
resulting slurry was purged with nitrogen for 20 min and then refluxed for 4h. The precipitate 
was filtered and washed with ACN to yield a brownish powder (13.5 mg, 70% yield). 
1H NMR (400 MHz, DMSO-d6) δ 8.99 (d, J = 5.0 Hz, 2H, H
19, H19’), 8.72 (d, J = 8.1 Hz, 2H, 
H16, H16’), 8.35 (td, J = 8.0, 1.3 Hz, 2H, H18, H18’), 8.11 (t, J = 6.0 Hz, 1H, H9), 7.93-7.85 (m, 
2H, H17, H17’), 6.42 (s, 1H, H1’), 6.38 (s, 1H, H1), 4.35-4.27 (m, 1H, H2), 4.19-4.08 (m, 1H, 
H2’), 3.27-3.17 (m, 2H, H10), 3.13-3.05 (m, 1H, H4), 2.82 (dd, J = 12.4, 5.1 Hz, 1H, H3’), 2.58 
(d, J = 12.4 Hz, 2H, H3), 2.30 (t, J = 6.7 Hz, 2H, H11), 2.04 (t, J = 7.4 Hz, 2H, H8), 1.69/1.67 
(s, 12H, H12, H13, H14, H15), 1.76-1.19 (m, 6H, H5, H6, H7). 13C NMR (101 MHz, DMSO-d6) δ 
172.18, 162.67, 153.93 (2C), 152.37 (2C), 140.37 (2C), 128.41 (2C), 123.83 (2C), 98.71 
(2C), 97.00 (2C), 95.11, 61.01, 59.17, 55.37, 55.33, 35.53, 34.87, 28.19, 28.02, 25.05, 23.56, 
8.59 (2C), 8.45 (2C). HR-MS (ESI-MS, pos): m/z = 684.1643 [M]+; calcd. for 
C31H40ClN5O2RhS, 684.1646; (additional peak: 528.10 corresponding to traces of dimer 17). 
See appendix. 
 
  
Experimental Part             136 
[(η5-Me4Cp(CH2)2-N-Biot)Ir(bpy)Cl]Cl (25) 
 
[(η5-Me4Cp(CH2)2-N-Biot)IrCl2]2Cl2 23 (50 mg, 0.0382 mmol) and 2,2'-bipyridine (13.1 mg, 
0.0841 mmol) were added to ACN (10 mL, HPLC grade, used without further purification). 
The resulting slurry was purged with nitrogen for 20 min and then refluxed for 4h. The 
precipitate was filtered and washed with ACN to yield a brownish powder (24.7 mg, 80% 
yield). 
1H NMR (400 MHz, DMSO-d6) δ 8.99 (d, J = 5.3 Hz, 2H, H
19, H19’), 8.80 (d, J = 8.0 Hz, 2H, 
H16, H16’), 8.34 (td, J = 7.9, 1.4 Hz, 2H, H18, H18’), 8.05 (t, J = 5.9 Hz, 1H, H9), 7.90-7.84 (m, 
2H, H17, H17’), 6.42 (s, 1H, H1’), 6.38 (s, 1H, H1), 4.32 (m, 1H, H2), 4.13 (m, 1H, H2’), 3.23 (dt, 
J = 12.6, 6.4 Hz, 1H, H10), 3.12-3.05 (m, 1H, H4), 2.82 (dd, J = 12.4, 5.1 Hz, 1H, H3’), 2.58 (d, 
J = 12.4 Hz, 1H, H3), 2.23 (t, J = 6.4 Hz, 2H, H11), 2.05 (t, J = 7.3 Hz, 2H, H8), 1.70/1.67 (s, 
12H, H12, H13, H14, H15), 1.73-1.26 (m, 6H, H5, H6, H7). 13C NMR (101 MHz, DMSO-d6) δ 
172.09, 162.47, 154.86 (2C), 152.13 (2C), 140.38 (2C), 128.97 (2C), 124.13 (2C), 91.55 
(2C), 88.93 (2C), 85.84, 61.01 (2C), 55.37 (2C), 35.02, 28.20, 28.02, 26.38, 25.28, 25.01, 
8.26 (2C), 8.12 (2C). HR-MS (ESI-MS, pos): m/z = 774.2175 [M]+; calcd. for 
C31H40ClN5O2IrS, 774.2220. See appendix. 
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[(η5-Me4CpCH2)2-N-Biot)Rh(4,4’-diMeObpy)Cl]Cl (26) 
 
[(η5-Me4Cp(CH2)2-N-Biot)RhCl2]2Cl2 17 (20 mg, 0.0177 mmol) and 4,4'-dimethoxy-2,2'-
bipyridine (7.05 mg, 0.0354 mmol) were added to ACN (5 mL, HPLC grade, used without 
further purification). The resulting slurry was purged with nitrogen for 20 min and then 
refluxed for 4h. The precipitate was filtered and washed with ACN yield a bright orange 
powder (22.4 mg, 85% yield). 
1H NMR (400 MHz, MeOD) δ 8.71 (d, J = 6.5 Hz, 2H, H16, H16’), 8.10 (d, J = 2.7 Hz, 2H, H18, 
H18’), 7.39 (dd, J = 6.5, 2.7 Hz, 2H, H17, H17’), 4.48 (dd, J = 7.7, 5.0 Hz, 1H, H2), 4.33-4.23 (m, 
1H, H2’), 4.09 (s, 6H, H19, H19’), 3.37 (t, J = 7.0 Hz, 2H, H10), 3.20 (dt, J = 10.2, 5.7 Hz, 1H, 
H4), 2.93 (dd, J = 12.7, 4.8 Hz, 1H, H3’), 2.70 (d, J = 12.7 Hz, 1H, H3), 2.40 (t, J = 6.9 Hz, 2H, 
H11), 2.18 (t, J = 7.6 Hz, 2H, H8), 1.75/1.72 (s, 12H, H12, H13, H14, H15), 1.81-1.35 (m, 6H, H5, 
H6, H7). 13C NMR (101 MHz, MeOD) δ 172.80, 168.00, 162.74 (2C), 155.38 (2C), 153.02 
(2C), 114.25 (2C), 110.34 (2C), 99.49 (2C), 98.56 (2C), 95.34, 61.03, 59.18, 57.01 (2C), 
55.37, 48.55, 45.35, 34.96, 28.18, 27.99, 25.17, 25.02, 8.56 (2C), 8.41 (2C). MS (ESI-MS, 
pos): m/z = 707.7374 [M-Cl]+, 742.6812 [M]+; calcd. for C33H44ClN5O4RhS, 742.1857. See 
appendix. 
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[(η5-Me4Cp(CH2)2-N-Biot)Ir(4,4’-diMeObpy)Cl]Cl (27) 
 
[(η5-C5Me4(CH2)2-N-Biot)IrCl2]2Cl2 18 (20 mg, 0.0153 mmol) and 4,4'-dimethoxy-2,2'-
bipyridine (6.62 mg, 0.0306 mmol) were added to ACN (5 mL HPLC grade, used without 
further purification). The resulting slurry was purged with nitrogen for 20 min and then 
refluxed for 4h. The precipitate was filtered and washed with ACN yield a bright orange 
powder (20.4 mg, 80% yield). 
1H NMR (400 MHz, MeOD) δ 8.73 (d, J = 6.6 Hz, 2H, H16, H16’), 8.19 (d, J = 2.7 Hz, 2H, H18, 
H18’), 7.39 (dd, J = 6.6, 2.7 Hz, 2H, H17, H17’), 4.49 (dd, J = 7.9, 5.0 Hz, 1H, H2), 4.33-4.31 (m, 
1H, H2’), 4.14 (s, 1H, H19, H19’), 3.40 (t, J = 6.9 Hz, 2H, H10), 3.19 (dt, J = 10.1, 5.7 Hz, 1H, 
H4), 2.94 (dd, J = 12.7, 4.9 Hz, 1H, H3’), 2.72 (d, J = 12.8 Hz, 1H, H3), 2.32 (t, J = 6.9 Hz, 2H, 
H11), 2.29 (t, J = 7.6 Hz, 2H, H8), 1.77/1.73 (s, 12H, H12, H13, H14, H15), 1.81-1.35 (m, 6H, H5, 
H6, H7).13C NMR (101 MHz, MeOD) δ 170.16, 161.67, 158.37 (2C), 153.89 (2C), 151.20 
(2C), 115.90 (2C), 111.57 (2C), 101.36 (2C), 92.62 (2C), 86.92, 66.92, 61.65, 57.71 (2C), 
57.03, 47.71, 41.13, 36.68, 29.73, 26.68, 25.35, 25.10, 9.00 (2C), 8.63 (2C). HR-MS (ESI-
MS, pos): m/z = 834.2418 [M]+; calcd. for C33H44ClN5O4IrS, 834.2431. See appendix. 
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[(η5-Me4Cp(CH2)2-N-Biot)Rh(Phen)Cl]Cl (28) 
 
[(η5-Me4Cp(CH2)2-N-Biot)RhCl2]2Cl2 17 (50 mg, 0.0443 mmol) and 1,10-phenanthroline 
monohydrate (14.1 mg, 0.0704 mmol) were added to ACN (10 mL, HPLC grade, used 
without further  purification). The resulting slurry was purged with nitrogen for 20 min and 
then refluxed for 4h. The precipitate was filtered and washed with ACN to yield a bright 
orange powder (31mg, 62% yield). 
1H NMR (400 MHz, MeOD) δ 9.38 (dd, J = 5.2, 1.1 Hz, 2H, H16, H16’), 8.86 (dd, J = 8.2, 1.2 
Hz, 2H, H18, H18’), 8.22 (s, 2H, H19, H19’), 8.18 (dd, J = 8.2, 5.2 Hz, 2H, H17, H17’), 4.48 (dd, J = 
7.9, 4.7 Hz, 1H, H2), 4.28 (dd, J = 7.9, 4.6 Hz, 1H, H2’), 3.42 (t, J = 6.9 Hz, 1H, H10), 3.19 (dt, 
J = 9.9, 4.5 Hz, 1H, H4), 2.90 (dd, J = 12.7, 5.0 Hz, 1H, H3’), 2.70 (d, J = 12.7 Hz, 1H, H3), 
2.51 (t, J = 6.8 Hz, 2H, H11), 2.19 (t, J = 7.3 Hz, 2H, H8), 1.85/1.82 (s, 12H, H12, H13, H14, H15), 
1.89-1.34 (m, 6H, H5, H6, H7). 13C NMR (101 MHz, MeOD) δ 172.26, 163.43, 152.56 (2C), 
145.73 (2C), 139.51 (2C), 131.23 (2C), 127.97 (2C), 127.15 (2C), 93.70 (2C), 88.66 (2C), 
84.20, 62.38, 60.61, 56.00, 40.03, 36.45, 35.60, 28.48, 25.63, 25.28, 24.38, 8.40 (2C), 8.06 
(2C). HR-MS (ESI-MS, pos): m/z = 708.1635 [M]+; calcd. for C33H40ClN5O2RhS, 708.1646; 
(additional peak: 528.10 corresponding to traces of dimer 17). See appendix. 
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[(η5-Me4Cp(CH2)2-N-Biot)Rh(4,7-diOHPhen)Cl]Cl (29) 
 
[(η5-Me4Cp(CH2)2-N-Biot)RhCl2]2Cl2 17 (30 mg, 26.2 μmol), and 8.97 mg of 4,7-dihydroxy-
1,10-phenanthroline (42.3 μmol) were added to anhydrous ACN (6 mL, degassed for 20 
min). The mixture was refluxed for 4h. The precipitate was filtered and washed with ACN to 
yield a brownish powder (17.6 mg, 56.1 % yield). 
1H NMR (400 MHz, DMSO-d6) δ 12.25 (s, 1H, H
19’), 11.83 (s, 1H, H19), 8.71 (d, J = 4.9 Hz, 
1H, H16), 8.06-8.04 (m, 1H, H16’), 7.97 (t, J = 6.0 Hz, 1H, H9), 7.92-7.89 (m, 2H, H18, H18’), 
7.11 (d, J = 5.0 Hz, 1H, H17’), 6.43 (s, 1H, H1’), 6.37 (s, 1H, H1’), 6.26 (d, J = 7.3 Hz, 1H), 
4.33-4.27 (m, 1H, H2), 4.15-4.09 (m, 1H, H2’), 3.21 (dd, J = 13.5, 6.9 Hz, 2H, H10), 3.09 (dt, J 
= 8.7, 6.2 Hz, 1H, H4), 2.82 (dd, J = 12.4, 5.1 Hz, 1H, H3’), 2.58 (d, J = 12.4 Hz, 1H, H3), 2.26 
(t, J = 6.9 Hz, 2H, H11), 2.03 (t, J = 7.4 Hz, 2H, H8), 1.68/1.63 (s, 12H, H12, H13, H14, H15), 
1.72-1.21 (m, 6H, H5, H6, H7). HR-MS (ESI-MS, pos): m/z = 740.1536 [M]+; calcd. for 
C33H40ClN5O4RhS, 740.1544. 
The carbon 13C NMR could not be obtained since not enough material was available See 
appendix. 
 
7.2. DNA 
 
Oligonucleotides (desalted) were purchased from Microsynth (Switzerland). DNA stocks 
were dissolved in water and carefully quantified spectrophotometrically at 260 nm. The DNA 
was then prepared for experiments by heat denaturation at 95°C for 10 minutes, in 375 mM 
MOPS buffer with KOH (50 mM) at pH 6.5 and allowed to cool down to room temperature. 
G4A oligonucleotide:[142a] catggtggtttgggttagggttagggttagggttaccac; dsDNA: 
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ctagctacagagaaatctcga and complementary strand (this dsDNA contained the common Braf 
V599E oncogenic mutation);[195] trinucleotide: ggg; ss12mer: gag gag aga aga; scrambled 
G4A (scG4A): gtgagtgttgctgtgtaggtgtagtacgtgtggagtcac. 
7.3. Isothermal Titration Calorimetry (ITC).  
 
7.3. Isothermal Titration Calorimetry (ITC). 
 
To study the interaction of 6 embedded in tetrameric Sav with G-quadruplex telomeric DNA 
(G4A) experiments were carried out at 25°C with in 75 mM MOPS buffer with KOH (10 mM) 
at pH 6.5 using a VP-ITC titration calorimetry (MicroCal, Northampton, MA, USA). At least 
two titration experiments were performed for each sample set to evaluate reproducibility. All 
solutions were thoroughly degassed before use titrations. Before each experiment, the ITC 
sample cell was washed several times with MOPS buffer solution (containing KOH). The 
sample cell was loaded with 1.5 ml of G4A solution (25 μM) and the reference cell contained 
MOPS solution (containing KOH). The titration was carried out using a 300 μL syringe filled 
with the 6 ⊂ Sav solution or Sav solution, with stirring at 300rpm. The solution 6 ⊂ Sav was 
made by mixing two equivalents of complex 6 with one equivalent of tetrameric Sav. 
Injections were started after baseline stability had been achieved. A titration experiment 
consisted of 50 consecutive injections of 5 μl volume and 10 s duration each, with a 10 min 
interval between each injection. The titration was carried out with a 6 ⊂ Sav concentration of 
0.375 mM or Sav concentration of 0.375 mM. Heats of dilution of 6 ⊂ Sav solution into the 
buffer alone were used to adjust total observed heats of binding, although the heat released 
by dilution of 6 ⊂ Sav in MOPS was negligible. Heats of dilution of the complex/protein were 
determined by injecting 6 ⊂ Sav solution or SAV alone into the buffer and the total observed 
heats of binding were corrected for the heat of dilution. The resulting data were fitted using 
MicroCal ORIGIN software supplied with the instrument. 
 
  
Experimental Part             142 
7.4. Electrophoretic Mobility Shift Assays (Work Carried Out by Alessia Sardo) 
 
EMSA were carried out on 1.2 % agarose gels containing ethidium bromide (5 μg per 100 ml 
of gel) in standard Tris-Borate-EDTA (TBE) buffer. Five hundred nanograms (500 ng) of 
DNA, previously refolded after heat denaturation, were incubated at 37 °C for 30 min with the 
desired amount of protein and metal complex mixture to give a final concentration of 3.3 μM 
oligonucleotide and 75 mM MOPS buffer with KOH (10 mM) at pH 6.5. The protein and metal 
complex mixtures were prepared by mixing two equivalents of metal complex with one 
equivalent of tetrameric Sav. After incubation, loading buffer consisting only of 40 % sucrose 
was added to a final 1/6 of total volume before charging the gels. Electrophoresis was 
typically carried out at 45 V for 20-30 min. A DNA marker with blue dye (DNA Molecular 
Weight Marker X, 0.07-12.2 Kb.p., Roche) was used solely for the purpose of confirming 
similar running conditions between gels. Binding constants were estimated from EMSA by 
using the concentrations of incubation at which the DNA migrated approximately equally-
distributed between the slow mobility (ternary complex) and high mobility (free DNA) species 
in titration experiments, according to simple visual inspection. One major shifted species was 
always observed by EMSA, with only small amounts of slower mobility species under specific 
experimental conditions (i.e. when scDNA was used as target; in fully-loaded 6 ⊂ Sav, with 
four Ru per tetramer; in the presence of competing ssDNA). Values estimated assume in all 
cases a 1 : 1 stoichiometry. Gels were repeated three times to ensure reproducibility of 
EMSA titrations. According to the observed single-site binding stoichiometry : 
 
Kd = [Sav]0 – 
 
 
 [DNA]0 
 
Where [Sav]0 and [DNA]0 correspond to the initial concentration of Sav and DNA in which 
DNA was seen to migrate approximately equally-distributed between the slow mobility and 
fast mobility species. In the case of 6 ⊂ Sav binding to G4A, a 1 : 1 stoichiometry of 6 ⊂ Sav 
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to DNA target was observed and only an upper estimate of Kd could be determined by 
EMSA. 
 
7.5. Protein Expression and Purification 
 
7.5.1. Protein Expression and Purification for ATH of Imines (Work Carried Out by 
Alessia Sardo) 
 
Site-directed mutagenesis was carried out using the Quick-Change mutagenesis kit 
(Stratagene) on the pET11b-Sav plasmid.[113] Recombinant T7-tagged streptavidin, was 
expressed in the cytoplasm of Escherichia coli BL21(DE3)pLysS grown in a 10 L fermentor 
and the protein purified as previously described.[113] 
 
7.5.2. Protein Expression and Purification for Reductive Amination of α-Keto Acids 
(Work Carried Out by Livia Knörr and Elisa Nogueira) 
 
7.5.2.1. Production and Purification of Recombinant Sav for Pure Proteins 
 
Expressions and purification of Sav mutants as described in Humbert et al.[196] and Klein et 
al.[197] 
 
7.5.2.2. Sav Protein Purification in SSP (Work Carried Out by Elisa Nogueira) 
 
The pellet (∼3 g from a 50 mL culture) was thawed and resuspended in distilled H2O (3x wet 
cell weight). 1 μL of 10 mg/mL DNase I (Roche Diagnostics, Switzerland) and 1 mM 
phenylmethylsulfonyl fluoride (Applichem, Switzerland) were added and the resuspended 
cells were incubated first at 37°C for 2 h and then at RT under vigorous shaking until total 
degradation of nucleic acids. The proteic extract was centrifuged (18 000 x g, 30 min, 4°C) to 
remove cell debris. The pH was adjusted to 9.8 by addition of 5 M Na2CO3, pH 9.8 to prepare 
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the proteic extract for affinity chromatography. A suspension of 2-iminobiotin sepharose (0.5 
mL, Affiland, Belgium) which was equilibrated at pH 9.8 (50 mM Na2CO3, 0.5 M NaCl), was 
added to the extract (1.5 mL). Pure streptavidin was eluted with 1 % v/v formic acid. The 
eluted protein was immediately brought to pH 8.0 using NH3 (32 %). The purified protein was 
quantified by Nanodrop (ε = 41.490 M-1 cm-1, MWmonomer = 16,430 Da), and shock frozen 
using liquid nitrogen, lyophilized, and stored at 4°C until use.  
The protein was resuspended in NH4COOH and the concentration was confirmed by 
Nanodrop. 
 
7.6. VMD Docking Studies (Work Carried Out by Maurus Schmid) 
 
The structure of the ligand was optimized with Density Functional Theory (DFT)[198] using 
Gaussian[199] and the hybrid B3LYP functional.[200] The atomic basis sets consisted of an 
effective core potential (LanL2DZ)[201] for the metal and the explicit 6-31G(d,p) basis for all 
remaining atoms. 
The optimized structure of the ligand was docked into the protein (PDB code 1MK5) using 
Autodock Vina. The structure with the best docking score was used subsequently. 
Simulations were performed in NAMD[202] using the CHARMM27 force-field with custom 
parameters developed previously (paper in preparation). The metal was treated with a simple 
bonded model. For the metal binding η5-carbons, only a bond was assumed, no angular or 
dihedral parameters were considered. Charges (Mulliken charges) were taken from the DFT 
calculation above. The system was set using VMD. The protein was mutated to the 
respective mutant. An additional bond from the metal to the histidine nitrogen Nε was 
introduced to mimic the histidine bound metal complex. Simulation was carried out using the 
interactive molecular dynamics plugin (AutoIMD) of VMD. Only the complex and residues 
within 5 Angstrom were free to move during the simulation. The rest of the atoms were fixed. 
Interactive molecular dynamics simulations were performed.[203] As a final step, the structure 
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was minimized. The resulting structure was considered as the docked structure of the 
complex. 
 
7.7. Catalysis Experiments 
 
All experiments were carried out using standard Schlenk techniques, with thoroughly 
degassed solutions (nitrogen-flushed). 
 
7.7.1. Preparation of Stock Solutions 
 
Sodium formate (3.4 g, 0.05 mol, 4 M) and MOPS (8.37 g, 0.04 mol, 3.2 M) were dissolved in 
milli-Q water (12.5 mL) and the pH was adjusted to 5.0 using concentrated HCOOH solution. 
The isolated biotinylated complexes and the dimeric metal complex 17 and 18 were 
dissolved in DMSO (0.05 M) and stored under air at 4°C prior to use. For in situ complexes, 
stock solutions of bidentate ligands were prepared in DMSO (0.05 M). A stock solution of the 
substrate was prepared dissolving 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline in milli-Q 
water to a final concentration of 2 M. 
 
7.7.2. Procedure for the Synthesis of Salsolidine 5 by ATH 
 
7.7.2.1. General Procedure for ATH Performed with Isolated Biotinylated Piano Stool 
Complexes and in situ prepared to be Embedded within Sav Isoforms at pH 5 
 
Streptavidin was directly weighed into the reaction tubes (0.916 mM final biotin binding site 
concentration). A solution of formate/MOPS (193 µL) from the stock solution was added. The 
mixture was stirred for 5-10 min until the protein was completely dissolved. The biotinylated 
complex from the stock solution (2.74 µL, final metal concentration 680 μM; 0.75 equivalents 
[M] vs. Sav free binding sites) was added and the mixture was stirred for 15 min. Finally, the 
substrate stock solution was added (6.8 μL, final concentration, 68 mM). The test tubes were 
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placed in a magnetically stirred multireactor (RR 98072, Radleys Discovery Technologies) 
which was purged three times with nitrogen heated to the appropriate temperature and time. 
 
7.7.2.2. General Procedure for ATH Performed with Hybrid Catalysts 17  Sav Isoforms 
and 18  Sav Isoforms 
 
Streptavidin was directly weighed into the reaction tubes (0.916 mM final biotin binding site 
concentration). A solution of formate/MOPS (192 µL) from the stock solution was added. The 
mixture was stirred for 5-10 min until the protein was completely dissolved. The dimer 
precursor complex from the stock solution (1.37 µL, final metal concentration 680 µM; 0.75 
equivalents [M] vs. Sav free binding sites) was added and the mixture was stirred for 15 min. 
Finally, the substrate stock solution was added (6.8 µL, final concentration, 68 mM). The test 
tubes were placed in a magnetically stirred multireactor (RR 98072, Radleys Discovery 
Technologies) which was purged three times with nitrogen heated to the appropriate 
temperature and time. 
 
7.7.2.3. General Procedure ATH Performed with In situ Complexes to be Embedded 
within Sav Isoforms at pH 6.5 
 
Streptavidin was directly weighed into the reaction tubes, (0.916 mM final biotin binding site 
concentration). A solution of formate/MOPS (193 µL) from the stock solution was added. The 
mixture was stirred for 5-10 min until the protein was completely dissolved. The dimer 
precursor complex from the stock solution (1.37 μL, final metal concentration, 680 μM; 0.75 
equivalents [M] vs. Sav free binding sites) was premixed with the bidentate ligand from the 
stock solution (3.6 µL, final concentration, 900 μM; 1.3 equivalent excess vs. metal) The 
mixture was stirred for 30 min at RT. This premix was then added to the protein solution and 
stirred for 15 min. Finally, the substrate stock solution was added (6.8 μL, final concentration, 
68 mM). The test tubes were placed in a magnetically stirred multireactor (RR 98072, 
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Radleys Discovery Technologies) which was purged three times with nitrogen heated to the 
appropriate temperature and time. 
 
7.7.2.4. General Procedure for ATH Performed with 17’  S112H and 17’  K121H 
(Optimized Conditions) 
 
Streptavidin was directly weighed into the reaction tubes, (0.916 mM final biotin binding site 
concentration). A solution of formate/MOPS (193 µL) from the stock solution was added. The 
mixture was stirred for 5-10 min until the protein was completely dissolved. The dimer 
precursor complex from the stock solution was added: For reactions carried out with 17’  
S112H (1.37 μL, final metal concentration, 680 μM; 0.75 equivalents [Rh] vs. Sav free 
binding sites). Alternatively, reactions carried out with 17’  K121H (0.92 μL, final metal 
concentration, 458 μM; 0.5 equivalents [Rh] vs. Sav free binding sites). The reaction mixture 
was stirred for 15 min. Finally, the substrate stock solution was added: For catalysis 
experiments performed with 17’  S112H (6.8 µL, final concentration, 68 mM) and for 
catalysis experiments performed with 17’  K121 (4.58 µL, final concentration, 45.8 mM). 
The test tubes were placed in a magnetically stirred multireactor (RR 98072, Radleys 
Discovery Technologies) which was purged three times with nitrogen heated to the 
appropriate temperature and time.  
 
7.7.2.5. Sample Workup 
 
After reaction completion, milli-Q water (0.5 mL) and NaOH (60 µL of 20 %) were added to 
the reaction mixture, which was then extracted 3 times with CH2Cl2 (2 mL). The organic 
phase was dried over Na2SO4, filtered with a syringe filter and subjected to HPLC analysis. 
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7.7.2.6. Analytical Data 
 
The conversion and the ee of the reduction products were determined by chiral HPLC using 
a Chiralpak IC column (20 μm, 250 x 4.5 mm, Daicel Chemical Industries, Tokyo) with 
CH2Cl2/iPrOH/DEA 98:2:0.1 as an eluent at 1 mL/min (UV-detection at 280 nm). The 
absolute configurations were assigned by comparison with commercial enantiopure samples 
of (rac)-salsolidine 5:  
(R)-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline, t = 10.19 min 
(S)-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline, t = 6.86 min 
6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline, t = 8.37 min 
 
The conversion was determined thanks to the response factor (1.946) reported in previous 
work carried out by Dr. Thibaud Rossel.[160] 
 
7.7.3. Procedure for the Synthesis of α-Amino Acids by Reductive Amination of α-Keto 
Acids 
 
7.7.3.1. Preparation of Stock Solutions 
 
Ammonium formate (6.3 g, 0.1 mol, 5 M) were dissolved in milli-Q water (20 mL) and the pH 
was adjusted to 8.0 using a concentrated ammonia solution (18 M). From the stock solution, 
the dimer metal complex [η5-Me4Cp-(CH2)2-N-Biot)RhCl2]2 17 was dissolved in DMSO (0.05 
M) and stored under air at 4°C prior to use. For preformed and in situ complexes, stock 
solutions of bidentate ligands were prepared in DMSO (0.05 M).  
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7.7.3.2. General Procedure for Reductive Amination Performed with 17’  S112H and 
17’  K121H 
 
Streptavidin was directly weighed into the reaction tubes, (0.916 mM final biotin binding site 
concentration). A solution of NH4COOH (194.5 μL) from the stock was added. The mixture 
was stirred for 5-10 min until the protein was completely dissolved. The metal complex stock 
solution was added: for reactions carried out with 17’  K121H, 0.92 μL of dimer precursor 
complex stock solution was added (final metal concentration, 458 μM; 0.5 equivalents [Rh] 
vs. Sav free binding sites); respectively reactions carried out with 17’  S112H, 1.37 μL of 
dimer precursor complex stock solution was added (final metal concentration, 680 μM; 0.75 
equivalents [Rh] vs. Sav free binding sites). Finally, the substrate solution* was added (4.58 
μL, final concentration 45.8 mM). The test tubes were placed in a magnetically stirred 
multireactor (RR 98072, Radleys Discovery Technologies) which was purged three times 
with nitrogen heated to the appropriate temperature and time. 
*The substrate solution was prepared dissolving α-keto acid in NH4COOH solution to a final 
concentration of 2 M and let to stir 1h in order to favor the imine formation. 
 
7.7.3.3. General Procedure for Reductive Amination Performed with In situ Prepared 
Rhodium and Iridium Complexes Embedded Within Sav Isoforms 
 
Streptavidin was directly weighed into the reaction tubes (0.916 mM final biotin binding site 
concentration). A solution of NH4COOH (194.5 μL) from the stock was added. The mixture 
was stirred for 5-10 min until the protein was completely dissolved. The metal complex stock 
solution was added: 0.92 μL of dimer precursor complex stock solution (final metal 
concentration, 458 μM; 0.5 equivalents [M] vs. Sav free binding sites) was premixed with 3.6 
μL bidentate ligand stock solution (final concentration, 900 μM; 1.3 equivalent excess vs. 
metal). The mixture was stirred for 30 min at RT. This premix was then added to the protein 
solution and stirred for 15 min. Finally, the substrate solution* was added (4.58 μL, final 
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concentration 45.8 mM). The test tubes were placed in a magnetically stirred multireactor 
(RR 98072, Radleys Discovery Technologies) which was purged three times with nitrogen 
heated to the appropriate temperature and time. 
 
7.7.3.4. Sample Workup 
 
After completion, 1.2 mL of MeOH was added to the reaction mixture. The resulting 
suspension was stirred for 15 min. The mixture was centrifugated and 600 μL of the 
supernatant was dissolved in a 1:1 ratio with an aqueous solution containing CuSO4 (2mM). 
The resulting solution was subjected to HPLC analysis. 
 
7.7.3.5. Analytical Data 
 
The conversion, selectivity and the ee of the reduction products were determined by chiral 
HPLC using a Chirex 3126 (D)-penicillamine LC Column (5 μm, 50 x 4.6 mm, Phenomenex) 
with different eluents depending on the α-keto acid. The yield was calculated by multiplying 
the selectivity by the conversion. 
 
7.7.3.5.1. Phenylalanine 
 
HPLC method (see Table 21: Line A (MeOH/H2O/CuSO4: 80/20/2mM) and in Line B 
(H2O/CuSO4, 2mM). A gradient method allowed separation of (rac)-phenylalanine 34, 
phenylpyruvic acid 36 and (rac)-phenyllactic acid 35 at 1.25 mL/min with a column heated at 
40°C (UV-detection at 247 nm). 
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Table 21 HPLC method for the reductive amination of phenylpyruvic acid 36. 
Time (min) Line A (%) Line B (%) 
0.00 22 78 
12.00 22 78 
14.00 37 63 
40.00 37 63 
The absolute configurations were assigned by comparison with commercial enantiopure 
samples: 
-(S)-phenylalanine t = 7.51 min 
-(R)-phenylalanine t = 10.11 min 
-phenylpyruvic acid t = 5.93 min 
-(S)-phenyllactic acid t = 27.79 min 
-(R)-phenyllactic acid t = 33.58 min 
 
Calibration curve: to determine the conversion, a response factor was determined, taking into 
account the different UV responses of the α-keto acids and the amino acids. Therefore; 3 mg 
of phenylpyruvic acid 36 and 3 mg of (rac)-phenylalanine 34 were dissolved in 3 mL of an 
aqueous solution containing CuSO4 (2mM). Different molar ratios of keto acid and amino acid 
were prepared and subjected to HPLC analysis. The ratio of the peak areas keto acid/amino 
acid was plotted against the molar ratio keto acid/amino acid. The slope of the regression 
line allows the determination of the response factor. 
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Table 22 Conditions used to determine the response factor between phenylpyruvic acid 36 
and (rac)-phenylalanine 34. 
Area of 36 Area of 34 Concentration of 36 (mM) Concentration of 34 (mM) 
2671 529 3.04 0.37 
1212 1050 1.52 0.75 
550 1930 0.76 1.51 
369 3549 0.38 3.02 
Response factor for phenylalanine at 247 nm: 1.6021. 
 
The same procedure was applied to the keto acid and the (rac)-hydroxy acid. Therefore, 3 
mg of phenylpyruvic acid 36 and (rac)-phenyllactic acid 35 were dissolved in 3 mL of an 
aqueous solution containing CuSO4 (2 mM). Different molar ratios of keto acid and amino 
acid were prepared and subjected to HPLC analysis. The ratio of the peak areas hydroxy 
acid/keto acid was plotted against the molar ratio hydroxy acid/keto acid. The slope of the 
regression line allows determining the response factor. 
 
Table 23 Conditions used to determine the response factor between phenylpyruvic acid 36 
and (rac)-phenyllactic acid 35. 
Area of 36 Area of 35 Concentration of 36 (mM) Concentration of 35 (mM) 
2671 743 3.05 0.38 
1212 1423 1.52 0.75 
550 2727 0.76 1.50 
369 4888 0.38 3.01 
Response factor for phenyllactic acid at 247 nm: 2.2601. 
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7.7.3.5.2. Phenylglycine 
 
HPLC method (see Table 24): Line A (MeOH/H2O/CuSO4: 80/20/2mM) and in Line B 
(H2O/CuSO4, 2 mM). A gradient method allowed separation of (rac)-phenylglycine 37, 
benzoylformic acid 36 and (rac)-mandelic acid 38 at 1.25 mL/min with a column heated at 
40°C (UV-detection at 247 nm). 
 
Table 24 HPLC method for the reductive amination of benzoylformic acid 36. 
Time (min) Line A (%) Line B (%) 
0.00 22 78 
12.00 22 78 
15.00 37 63 
25.00 37 63 
The absolute configurations were assigned by comparison with commercial enantiopure 
samples: 
 
(S)-phenylglycine t = 2.90 min 
(R)-phenylglycine t = 4.44 min 
benzoylformic acid t = 7.71 min 
(S)- mandelic acid t = 18.57 min 
(R)-mandelic acid t = 23.36 min 
Undetermined impurity t = 11.02 min 
 
Calibration curve: to determine the conversion, a response factor was determined, taking into 
account the different UV responses for the keto acid and the amino acid. Therefore, 3.2 mg 
of benzoylformic acid 36 were dissolved in 3.2 mL of an aqueous solution containing CuSO4 
(2 mM) and 3 mg of (rac)-phenylglycine 37 were dissolved in 13 mL of an aqueous solution 
containing CuSO4 (2 mM). Different molar ratios of keto acid and amino acid were prepared 
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and subjected to HPLC analysis. The ratio of the peak areas hydroxy acid/keto acid was 
plotted against the molar ratio hydroxy acid/keto acid. The slope of the regression line allows 
the determination of the response factor. 
 
Table 25 Conditions used to determine the response factor between benzoylformic acid 36 
and (rac)-phenylglycine 37. 
Area of 36 Area of 37 Concentration of 36 (mM) Concentration of 37 (mM) 
97322 618 6.66 0.19 
51583 1203 3.33 0.38 
25985 2441 1.67 0.76 
8678 4868 0.83 1.53 
Response factor for phenylglycine at 247 nm: 0.2222. 
 
To determine the selectivity, a response factor was determined, taking into account the 
different UV responses for the keto acid and the (rac)-hydroxy acid. Therefore, 3.2 mg of 
benzoylformic acid 36 were dissolved in 3.2 mL of an aqueous solution containing CuSO4 (2 
mM) and 2.5 mg of (rac)-mandelic acid 38 were dissolved in 2.5 mL of an aqueous solution 
containing CuSO4 (2 mM). Different molar ratios of keto acid and (rac)-hydroxy acid were 
prepared and subjected to HPLC analysis. The ratio of the peak areas hydroxy acid/keto acid 
was plotted against the molar ratio hydroxy acid/keto acid. The slope of the regression line 
allowed the determination of the response factor. 
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Table 26 Conditions used to determine the response factor between phenylpyruvic acid 36 
and (rac)-mandelic acid 38. 
Area of 36 Area of 38 Concentration of 36 (mM) Concentration of 38 (mM) 
97323 2171 6.66 0.82 
51583 4359 3.33 1.64 
25985 8793 1.67 3.29 
8678 17476 0.83 6.57 
Response factor for mandelic acid at 247 nm: 0.1810. 
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CV 
 
Professional Experience 
 
PhD thesis in Chemistry, University of Basel (CH)    2007 – 2012 
Artificial Metalloenzymes Laboratory (AMEL)  
 
Objective: Engineering artificial metalloenzymes based on biotin-streptavidin technology for 
DNA recognition and Asymmetric Transfer Hydrogenation catalysis. 
Supervisor: Prof T. R. Ward 
Summary: I synthesized various biotinylated metal complexes for incorporation into a host 
protein (Streptavidin) to create artificial metalloenzymes able to perform specific DNA 
targeting in vitro and enantioselective catalysis in water. 
 
Master thesis in Novartis Pharma, Basel (CH)            February/August 2007 
Department of Chemical and Analytical Development  
 
Objective: Development of a robust and practical process for the Darzens condensation and 
α,β-epoxide rearrangement: Scope and limitations of the methodology. 
Supervisor: Dr. F. Gallou 
Summary: I developed a practical and robust process for a fast oxazole and thiazoles 
synthesis. I studied the electronic effects of the Darzens condensation and subsequent 
rearrangement. The process developed is both amenable to large scale and parallel 
synthesis. 
 
Training course in organic synthesis, Montpellier (F)    March/August 2006 
Co-operative Laboratory Servier CNRS UM-Center of Structural  
Biochemistry CNRS UMR 5048-UM1-INSERM UMR 554.  
 
Objective: Synthesis and biological evaluation of new inhibitors of human Cyclophilin A. 
Supervisor: Pr. J. F Guichou and Pr. A. Chavanieu 
Summary: I synthesized various organic compounds related to Medicinal Chemistry and I 
tested them using enzymatic assays followed by UV spectroscopy. 
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Education 
 
MSc in Professional Chemistry, University Montpellier 2 (F)                          2007 
Specialized in Organic Chemistry, Biomolecules, Conception, Separation and Screening.  
 
BSc in Chemical Engineering, University Montpellier 2 (F)     2005 
 
 
Publications 
 
«Development of a robust and practical process for the Darzens condensation and 
α,β-epoxide rearrangement: scope and limitations of the methodology», J. M. Zimbron, 
M.Seeger-Weibel, H. Hirt, F. Gallou, Synthesis 2008, 8, 1221 - 1226. 
 
«Chemo-genetic optimization of DNA recognition by metallodrugs using a presenter 
protein strategy» J. M. Zimbron, A. Sardo, T. Heinisch, T. Wohlschlager, J. Gradinaru, C. 
Massa, T. Schirmer, M. Creus, T. R.Ward, Chem. Eur. J. 2010, 16, 12883 - 12889. 
 
« Artificial Transfer Hydrogenases for the Enantioselective Reduction of Cyclic 
Imines» M. Dürrenberger, T. Heinisch, T. Rossel, A. Mutschler, K. Kersten, J. M. Zimbron, J. 
Pierron, T. Schirmer and T. R. Angew. Chem. Int. Ed. Engl. 2011, 50, 3026 - 3029 and 
selected as “hot paper”. 
 
«A dual anchoring strategy for the localization and activation of artificial 
metalloenzymes based on the biotin-streptavidin technology» In preparation 
 
 
Award 
 
Poster prize in the 29th REGIO-Symposium, Rheinfelden (D)              2009 
Topic: Organic and Bioorganic Chemistry 
Poster: «Chemo-genetic optimization of DNA recognition by metallodrugs using a presenter 
protein strategy» 
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Conferences  
 
Invited speaker 
5th International Symposium on Bioorganometallic Chemistry, Bochum (D) 
  
       July 2010 
Oral presentation: «Chemo-genetic optimization of DNA recognition by metallodrugs using a 
presenter protein strategy» 
 
Poster presentation 
31th REGIO-Symposium on Bioorganic Chemistry, Mittelwhir (F)                              2009, 2010, 2011 
Swiss Chemical Society Fall meeting, Lausanne (CH)                                                       September 2009 
Biotrans, Bern (CH)                                                                                                                                   July 2009
 
 
Technical skills 
 
Synthesis: multi-step synthesis, work under controlled atmosphere (Schlenk techniques) 
Catalysis: asymmetric homogeneous organometallic catalysis, parallel catalyst screening 
using a multireactor 
Purifications: flash chromatography, preparative HPLC, Kugelrohr distillation 
Characterisation: NMR, MS, UV-Vis, HPLC and GC 
Biology: Protein production and characterisation, EMSA gels 
Instruments: Responsible for the measurements using 500Hz NMR, ESI, MALDI and 
Isothermal Titration Calorimetry. 
 
 
Skills  
 
Courses attended 
“Chemistry and Biology of Natural products” by the Prof. Dr. Karl Gademann 
 
Languages:  
French: mother tongue 
Spanish: native language 
English: fluent 
German: basics 
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Teaching: 
Supervisor of an undergraduate student during 4 weeks  
Supervisor of two Master students during 6 months  
Teaching Assistant (3 years) – Analytical Chemistry for 1st year students in Biology and 
Pharmacy 
 
Informatics: 
Scientific software: Scifinder, Reaxys, Chemdraw, Isisdraw, VMD, MestReNova, Inventory 
Office software: Word, Excel, Powerpoint, EndNote 
 
 
Activities and interests 
 
President of the Chemistry Student Union I.U.P for two years                 2003/2005  
Captain of the SOC football team (F) 
I like to visit different cultures and learn about their local history 
 
 
 
 
 
